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Background: People with Parkinson’s disease are twice as likely to experience a fall as a healthy older
person, often leading to debilitating effects on confidence, activity levels and quality of life.
Objective: To estimate the effect of a physiotherapy programme for fall prevention among people with
Parkinson’s disease.
Design: A multicentre, pragmatic, investigator-masked, individually randomised controlled trial (RCT) with
prespecified subgroup analyses.
Setting: Recruitment from NHS hospitals and clinics and community and social services in eight English
regions with home-based interventions.
Participants: A total of 474 people with Parkinson’s disease (i.e. Hoehn and Yahr scale stages 1–4) were
recruited: 238 were assigned to a physiotherapy programme and 236 were assigned to usual care.
Random allocation was 50 : 50.
Interventions: All participants received routine care; the usual-care group received an information digital
versatile disc (DVD) and a single advice session at trial completion. The intervention group had an
individually tailored, progressive, home-based fall avoidance strategy training programme with balance and
strengthening exercises: PDSAFE.
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Main outcome measures: The primary outcome was the risk of repeat falling, collected by self-report
monthly diaries between 0 and 6 months after randomisation. Secondary outcomes included near-falls,
falls efficacy, freezing of gait (FoG), health-related quality of life, and measurements taken using the
Mini-Balance Evaluation Systems Test (Mini-BESTest), the Chair Stand Test (CST), the Geriatric Depression
Scale, the Physical Activity Scale for the Elderly and the Parkinson’s Disease Questionnaire.
Results: PDSAFE is the largest RCT of falls management among people with Parkinson’s disease: 541 patients
were screened for eligibility. The average age was 72 years, and 266 out of 474 (56%) participants were
men. Of the 474 randomised participants, 238 were randomised to the intervention group and 236 were
randomised to the control group. No difference in repeat falling within 6 months of randomisation was found
[PDSAFE group to control group odds ratio (OR) 1.21, 95% confidence interval (CI) 0.74 to 1.98; p = 0.447].
An analysis of secondary outcomes demonstrated better balance (Mini-BESTest: mean difference 0.95,
95% CI 0.24 to 1.67; p = 0.009), functional strength (CST: p = 0.041) and falls efficacy (Falls Efficacy Scale –
International: mean difference 1.6, 95% CI –3.0 to –0.19; p = 0.026) with near-falling significantly reduced
with PDSAFE (OR 0.67, 95% CI 0.53 to 0.86; p = 0.001) at 6 months. Prespecified subgroup analysis (i.e.
disease severity and FoG) revealed a PDSAFE differing effect; the intervention may be of benefit for people with
moderate disease but may increase falling for those in the more severe category, especially those with FoG.
Limitations: All participants were assessed at primary outcome; only 73% were assessed at 12 months
owing to restricted funding.
Conclusions: PDSAFE was not effective in reducing repeat falling across the range of people with Parkinson’s
disease in the trial. Secondary analysis demonstrated that other functional tasks and self-efficacy improved
and demonstrated differential patterns of intervention impact in accordance with disease severity and FoG,
which supports previous secondary research findings and merits further primary evaluation.
Future work: Further trials of falls prevention on targeted groups of people with Parkinson’s disease are
recommended.
Trial registration: Current Controlled Trials ISRCTN48152791.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 36.
See the NIHR Journals Library website for further project information. Sarah E Lamb is funded by the
NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) at Oxford Health NHS
Foundation Trust, the NIHR Oxford Biomedical Research Centre at the Oxford University Hospitals NHS
Foundation Trust and CLAHRC Oxford. Victoria A Goodwin is supported by the NIHR Collaborations for
Leadership in Applied Health Research and Care in the South West Peninsula (PenCLAHRC). Lynn Rochester is
supported by the NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS
Foundation Trust and Newcastle University. The research was also supported by the NIHR Newcastle Clinical
Research Facility Infrastructure funding. Helen C Roberts is supported by CLAHRC Wessex and the NIHR
Southampton Biomedical Research Centre.
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Catechol-O-methyltransferase inhibitor A drug that inhibits the action of catechol-O-methyltransferase.
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Plain English summary
People with Parkinson’s disease fall often. Falls are scary and make moving about harder. The PDSAFEtrial tested a new ‘home physiotherapy’ programme for reducing falls. People with Parkinson’s disease
were allocated to one of two groups by chance: they either received the PDSAFE exercises or just normal
care. The costs were looked at and people were asked for their views of the PDSAFE exercises.
To take part, people had to have Parkinson’s disease, live in their own home, be able to walk, have had at
least one fall in the previous year and pass a memory test. PDSAFE was taught by physiotherapists and
included exercises and fall avoidance strategies. Everyone had to record falls on a monthly calendar, and
balance, strength and walking were tested.
To our knowledge, this was the largest falls trial looking at people with Parkinson’s disease in the world:
541 people took part. The number of falls an individual reported differed a lot between people. When
all people with Parkinson’s disease in the trial were considered, the physiotherapy programme did not
reduce falls in the first 6 months. However, it was found that some people had fewer falls after taking
part in the exercises, whereas others did not. Those with more severe Parkinson’s disease (i.e. problems
with movement, memory and freezing of gait) fell more often after the PDSAFE intervention, even though
their balance and confidence improved. Those with good memory, moderate disease and two or three
falls in the previous year reacted well to PDSAFE and had fewer falls. It was found that PDSAFE reduced
near-falls (about to fall but managed to save themselves) and improved balance and confidence. The
physiotherapists and those who took part liked the programme and felt that it helped, but it was
expensive to run.
In conclusion, a falls prevention programme should be based on each person’s needs and a different
treatment should be used for those with more severe Parkinson’s disease.
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Scientific summary
Background
People with Parkinson’s disease are twice as likely to fall as the healthy older population. In those with
Parkinson’s disease, falling is associated with a host of risk factors, including disease severity, duration of
disease, self-reported disability and impaired mobility. The strongest predictor of falling, identified from
meta-analysis, is having had a previous fall. Evidence suggests that an exercise-based intervention might
reduce fall risk, although published research findings are inconclusive.
Objective
The primary aim was to examine the clinical effectiveness and cost-effectiveness of an exercise- and
strategy-based intervention (known as PDSAFE) for fall reduction.
Method
This two-group multicentre, single-blinded, randomised (50 : 50) controlled clinical trial of people with
Parkinson’s disease at risk of falls also comprised a 3-month pre-randomisation monitoring of falls,
an economic evaluation and a nested qualitative study of the views of participants.
Participants
Eligibility criteria were as follows: a consultant’s diagnosis of Parkinson’s disease; living in their own home;
independently mobile; experienced at least one fall in the previous 12 months; scored ≥ 24 on the Mini-
Mental State Examination (MMSE); had the cognitive ability to give informed consent; able to understand
and follow commands; and able to complete a guided personalised exercise and strategy programme.
Outcomes
The primary outcome was risk of repeat falling between 0 and 6 months post randomisation with the
fall rate ratio during the same period as a secondary analysis. Data on falls were collected via monthly
self-completed diaries. A fall was defined as an event that resulted in a person coming to rest unintentionally
on the ground or lower level; a near-fall was an event in which the person would have landed on the
ground or lower level if saving reactions, such as stepping or reaching, had not taken place.
Secondary outcomes were balance [measured by the Mini-Balance Evaluation Systems Test (Mini-BESTest)];
functional strength (measured by the Chair Stand Test); falls efficacy [measured by the Falls Efficacy Scale –
International (FES-I)]; near-falls, an event in which the person would have landed on the ground or lower
level if saving reactions, such as stepping or reaching, had not taken place; freezing of gait (FoG)
(measured by the new freezing of gait questionnaire); and the results of the Geriatric Depression Scale
(GDS) (15-question version); the 39-item Parkinson’s Disease Questionnaire (PDQ-39), a quality-of-life
measure designed specifically for people with Parkinson’s disease; the EuroQol-5 Dimensions (EQ-5D),
a measure of health-related quality of life; and the Physical Activity Scale for the Elderly (PASE). Disease
severity was recorded using the International Parkinson and Movement Disorder Society – Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) and cognitive ability was measured using the Montreal
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Cognitive Assessment (MoCA). Outcomes were assessed before randomisation and at 6 and 12 months
after randomisation. Owing to restricted funding, the last 132 participants recruited were followed to
6 months (primary outcome only).
Pre-stated analysis
The primary outcome was risk of repeat falling between 0 and 6 months post randomisation using self-
completed monthly falls diaries with falls rate ratio (incidence rate of falls in time period) and prespecified
subgroups as secondary analysis plus secondary outcomes. Outcomes were assessed before randomisation
and at 6 and 12 months post randomisation.
Results
A total of 541 people with Parkinson’s disease were screened for eligibility and pre-randomisation fall
monitoring by a trial assessor in their own home. Of these, 67 were excluded at this time [reasons for not
being randomised included being medically unfit (n = 24), inadequate completion of falls diaries (n = 6),
no longer met eligibility criteria (n = 12), or changed their mind or did not like the sound of intervention
(n = 18)]. The remaining 474 participants completed a baseline assessment and were randomised into one
of two groups: control (n = 236) or PDSAFE intervention (n = 238). Males constituted 56% of the trial
participants, the mean age was 72 years and the Hoehn and Yahr scale ranges were 1–4 stage.
Loss to follow-up
Sixty-six participants did not engage with the intervention for a number of reasons, such as admission to a
care home, deteriorating health, a change of mind about participation, reluctance to commit to the therapy
or assessment procedures, and death. Some participants did not provide a reason for non-engagement.
A further 20 participants withdrew from the control group.
Therapy content
The PDSAFE intervention, delivered by a physiotherapist, was individually tailored and structured around
fall avoidance strategies and balance and strengthening exercises, selected from a menu with six levels of
progression. The median number of therapy sessions was 12 (interquartile range 11–12 sessions) and the
mean was 11 sessions (standard deviation 2.4 sessions).
Effectiveness
No difference in repeat falling within 6 months of randomisation was found [PDSAFE to control odds ratio (OR)
1.21, 95% confidence interval (CI) 0.74 to 1.98; p = 0.447]. Analysis of secondary outcomes demonstrated
better balance (Mini-BESTest: mean difference 0.95, 95% CI 0.24 to 1.67; p = 0.009) and falls efficacy (FES-I:
mean difference –1.6, 95% CI –3.0 to –0.19; p = 0.026), with near-falling significantly reduced with PDSAFE
(OR 0.67, 95% CI 0.53 to 0.86; p = 0.001) at 6 months. Prespecified subgroup analysis (disease severity and
FoG) revealed a PDSAFE differing effect. A decrease in falling among those in the moderate group classified by
disease (interaction p = 0.009) and retrospective falling at entry to the trial (interaction p = 0.050). Increased
repeat falling following PDSAFE between 0 and 6 months was found among those at the severe end of the
disease spectrum and FoG (interaction p = 0.025) with a trend of increasing falls among those with cognitive
impairment (interaction p = 0.088).
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Participant views
Most people enjoyed participating in the therapy and reported benefits, although they had mixed views
about equipment. The biggest barriers were time and motivation, whereas social support facilitated
participation. In order to optimise the benefits of the therapy, people with Parkinson’s disease need help
for them to mobilise sustained support and encouragement from social support networks.
Economic evaluation
The results showed that the PDSAFE intervention was not likely to be cost-effective for the overall Parkinson’s
disease population for the NHS perspective over the 6-month time horizon. Compared with the control
group, the PDSAFE intervention group had an incremental cost of £925 (95% CI £428 to £1422) and an
incremental quality-adjusted life-year (QALY) gain of 0.008 (95% CI 0.006 to 0.021), generating an
incremental cost-effectiveness ratio (ICER) of £120,659 per QALY. Although this ICER would not be deemed
to be within the realms of what is considered cost-effective, sensitivity analyses reveal cost-effective
scenarios.
Conclusions
The physiotherapy programme PDSAFE was not effective in reducing repeat falling across a heterogeneous
sample of people with Parkinson’s disease. However, fall risk, balance, functional strength, self-efficacy
and near-falls improved. Secondary analysis also showed diverse responses to PDSAFE falls management
according to FoG and disease severity. A negative effect was found among those participants at the worse
end of the spectrum and a positive effect was found among those participants with moderate disease.
Trial registration
This trial is registered as ISRCTN48152791.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). Sarah E Lamb is funded by the NIHR Collaboration for Leadership
in Applied Health Research and Care at Oxford Health NHS Foundation Trust and the NIHR Oxford
Biomedical Research Centre at the Oxford University Hospitals NHS Foundation Trust. Victoria A Goodwin
is supported by the NIHR Collaborations for Leadership in Applied Health Research and Care in the South
West Peninsula (PenCLAHRC). Lynn Rochester is supported by the NIHR Newcastle Biomedical Research
Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The research
was also supported by the NIHR Newcastle Clinical Research Facility Infrastructure funding. Helen C Roberts
is supported by CLAHRC Wessex and Sarah E Lamb by CLAHRC Oxford.
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Chapter 1 Background
Introduction
Parkinson’s disease
Parkinson’s disease (hereafter referred to as Parkinson’s) is a progressive neurological condition
characterised by impairments of movement and postural control (balance) and non-motor deficits.1 There
are estimated to be around 127,000 people with Parkinson’s in the UK.2 The prevalence of Parkinson’s
increases steadily with age.2
Falls in Parkinson’s
Falls among people with Parkinson’s are both common and disabling.3,4 Approximately 40–70% of people
with Parkinson’s fall each year, and one-third fall repeatedly.5 Overall, people with Parkinson’s are twice as
likely to experience falls as a healthy elderly population.6 There is evidence to show that falls have a major
impact on the lives of people with Parkinson’s, including debilitating effects on confidence,7 decreased
activities levels8,9 and reduced quality of life.10 Such falls are financially costly for individuals and health-care
systems. Repeat falls are a risk factor for further falls and carry devastating consequences, such as fractures,
immobility and fear of falling leading to dependency and social isolation.4 Although the incidence of falling
increases with disease severity, falls are common even in the early stages of the condition.11
Falling among those with Parkinson’s is associated with a host of risk factors, including disease severity,
duration of disease,12,13 self-reported disability12 and impaired mobility,11 as confirmed by Canning et al.6
The strongest predictor of falling, identified from meta-analysis, is having had a previous fall.4,6 Loss of
motor control [e.g. anticipatory and reactive postural control, reduced leg muscle strength, proprioception
and gait speed, increased gait variability and freezing of gait (FoG)] have also been shown to be associated
with, and predictors of, falls.14,15 In addition to the motor symptoms, impaired cognition and orientation,14
as well as misjudgement and distraction,16 have also shown significant association with falling.
Falls prevention
Drugs are the main treatment used to manage the symptoms of Parkinson’s, while research into finding a
cure continues. However, reduced postural control and falls do not respond to medication.3 It has long
been accepted that exercise is a fundamental component of treatment for people with Parkinson’s,
alongside medical and surgical management, and its positive effects on symptoms are well supported in
the literature. There is substantial evidence showing that regular exercise can be particularly beneficial for
people with Parkinson’s to maintain postural control, mobility, daily living activities and general symptom
management.17,18 At the conception of this trial, there was no definitive evidence that an exercise
programme would be as effective in the population of people with Parkinson’s as it is in the general
population. Research has also shown that selecting and targeting each of the symptoms independently
may not be enough to influence the falls rate. Instead, a multidimensional model that combines functional
exercises with behavioural strategies is likely to provide a greater influence on reducing falls.19
PDSAFE is an example of a multidimensional programme.19 It is an individualised, home-based,
physiotherapist-delivered, personalised treatment programme of exercises and strategies to help prevent
falls in Parkinson’s. The novelty lies in both the content (i.e. disease-specific exercises and strategies for
instability, use of motor relearning and cognitive awareness) and delivery [i.e. personalised feedback using
a digital versatile disc (DVD) for adherence and self-management]. The programme comprises (1) exercises
for postural control, gait and muscle weakness; (2) strategies for reducing freezing and encouraging
stability and gait efficacy; and (3) a feedback model to promote learning and adherence. Frequency of
intervention sessions is faded over time, 1 hour twice a week for 1 month, then once a week for a further
2 months, then once a month for another 3 months.
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Primary aim of the PDSAFE trial
The primary aim of this trial was to determine the clinical effectiveness and cost-effectiveness of a novel
personalised exercise and strategy intervention (PDSAFE) as a supplement to usual health-care
management in people with Parkinson’s.
Research questions
l Do fallers with Parkinson’s who undertake PDSAFE with usual care have fewer falls than those who do
not undertake the treatment programme during months 0–6 after randomisation?
l Do fallers with Parkinson’s who undertake PDSAFE with usual care have fewer falls than those who do
not undertake the treatment programme during months 6–12 after randomisation?
l Do fallers with Parkinson’s who undertake PDSAFE have better balance, mobility and quality of life than
those who do not undertake the treatment programme?
l Is the PDSAFE intervention cost-effective, compared with usual care for people with Parkinson’s, from
an NHS perspective?
l What are the personal insights of those who participate in the intervention?
Pilot study
Aims and objectives
Prior to the main trial, a small pilot study was conducted as part of the protocol development work.
The aims of the PDSAFE pilot study were to confirm the:
l content and delivery of the novel intervention
l implementation of procedures for recording and checking treatment fidelity
l battery of assessments to be administered at the baseline and follow-up visits.
The objectives of the PDSAFE pilot study were to:
l recruit a sample of up to 20 people with Parkinson’s: up to 10 in Southampton and up to 10
in Newcastle
l take informed consent from up to 20 people with Parkinson’s
l complete screening measures on up to 20 people with Parkinson’s
l test the collection of falls data through the use of diaries with up to 20 people with Parkinson’s
l complete baseline assessments with up to 20 people with Parkinson’s
l assess the time taken to complete assessments
l determine the feasibility of assessments
l determine the acceptability to participants of assessments
l deliver the PDSAFE intervention to up to 20 people with Parkinson’s.
Procedure
Ethics approval was given by the South Central – Hampshire B National Research Ethics Service (reference
number 13/SC/0538). Sixteen participants were recruited [six from Newcastle and 10 from Southampton,
including one patient and public involvement (PPI) representative]. All participants completed all screening
measures [i.e. Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Hoehn and
Yahr (H&Y) scale and falls characteristics]. Six participants from each site completed baseline assessments,
participated in the intervention for 1 month and completed the battery of assessments post intervention.
The remaining four participants in Southampton provided falls diaries only, to test the diary completion
required prior to randomisation in the main trial.
BACKGROUND
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Two patterns of treatment delivery were tested to establish the most appropriate way of providing the
intensity of treatment in the early stages. In Newcastle, participants had the intervention for two sessions a
week for 3 weeks, then once a week for 1 week. In Southampton, participants had treatment for two
sessions a week for 2 weeks and then once a week for 2 weeks.
Outcome
Overall, the participants enjoyed the treatment. Participants’ comments included ‘very pleased he
participated – he has found it very beneficial and continues to use several strategies’, ‘Doing all home
exercises and feels his balance is getting better’ and ‘have enjoyed the exercises and have learned a lot
about keeping active’.
The therapists were enthusiastic about the programme and recognised the importance of mapping the
house for problem mobility areas and integrating the exercises with video strategies appropriate for each
individual. They commented that there was a lot to do in the initial stages around planning the strategies
and fitting the weighted vests, so the pattern of treatment of two sessions a week for 3 weeks may be
more valuable than two sessions a week for 2 weeks. However, it was agreed that this may not be
appropriate for each person and that some flexibility in the way the sessions are delivered should remain.
Training was recognised as very important. Some people found the weighted vests difficult to put on and
required help from their partner; most people could tolerate only a small percentage of body weight in the
vests, yet most people viewed them positively.
The outcomes of the pilot study were discussed at a face-to-face meeting of the grant holders, which
was also attended by three PPI members; adjustments to the protocol were suggested and implemented.
The pilot study confirmed the content and delivery of the novel intervention for the main trial (including
printed versions of the exercises and strategies, video vignettes for play on a tablet or DVD and the use of
weighted vests for strengthening exercises). Procedures for recording and checking treatment fidelity were
also established, including weekly telephone and Skype™ (Microsoft Corporation, Redmond, WA, USA)
consultations with the physiotherapists. As a result of the pilot, the assessment time was shortened and
procedures tightened. For example, the handgrip strength measurement test20 was dropped from the main
study, but retained as a substudy in the Portsmouth area; and the shorter (15- instead of 30-question)
version of Geriatric Depression Scale (GDS) was used.
DOI: 10.3310/hta23360 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 36
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ashburn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Methods
Material in this chapter has been adapted from the trial protocol by Goodwin et al.21 © Goodwinet al.;21 licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available
in this article, unless otherwise stated.
Trial design
The PDSAFE trial was a UK, multicentre, community-based, single-blind, randomised controlled trial (RCT)
with a 12-month follow-up, with nested economic evaluation and qualitative studies. Ethics approval was
given by the South Central – Hampshire B National Research Ethics Service (reference number 14/SC/0039).
Local research and development approval was obtained at each participating centre. Figure 1 shows how
people with Parkinson’s progressed through the trial.
Initially, four recruitment centres were identified: Southampton, Portsmouth, Bournemouth and Poole, and
Exeter. The aim was for each of these to recruit 150 people with Parkinson’s to the trial over a 16-month
period. Unfortunately, there were several delays in site set-up, and several sites found that they did not
have as many people with Parkinson’s as anticipated. Four additional sites were opened: Newcastle,
Winchester and Basingstoke, Plymouth and Truro. These centres represent a range of socioeconomic
environments. Unfortunately, it was not possible to secure additional funding to follow up participants
recruited in these new centres beyond the primary outcome measure at 6 months. Therefore, only
participants randomised before 1 May 2016 had a final 12-month assessment.
Participants
Inclusion criteria were broad to allow inclusion of a wide spectrum of Parkinson’s patients in order to
provide a generalisable result. Participants were eligible to be included to the trial if they met the following
criteria:
l had a confirmed consultant’s diagnosis of Parkinson’s
l lived at home
l had experienced at least one fall in the previous 12 months
l were able to give informed consent
l were able to understand and follow commands
l were able to complete a programme of exercises
l scored ≥ 24 on the MMSE
l were willing to participate.
Participants were not eligible to be included in the trial if they:
l lived in a care home with or without nursing
l required assistance from another person to walk indoors
l were wheelchair bound or bedridden unless aided, as defined by H&Y scale stage 5.
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Recruitment and selection
Recruitment ran from July 2014 to August 2016. Trial participants were recruited through hospital clinics
and Parkinson’s services, through local Parkinson’s UK groups and websites and through word of mouth/the
trial website. Research packs comprising an invitation (see Appendix 1), the participant information sheet
(see Appendix 2), a response slip (see Appendix 3) and a Freepost pre-addressed envelope were distributed.
Once response slips were received by the trial office, trained trial assessors visited potential participants in their
own homes to complete consent and screening assessments. The screening assessments included MoCA,22
the MMSE, 23 the H&Y scale,24 demographic information and medical history. Participants were asked to
retrospectively recall the number of falls that they had experienced in the previous 12 months. The screening
visit was followed by a prospective falls monitoring period of at least 13 weeks.
Three months after a screening visit, the assessor returned to carry out the baseline assessment (October
2014 to November 2016). The assessor checked that the participant was willing to participate in the trial
and that they met the criteria to enable them to proceed to the next stage of the trial; the assessor then
Enrolment
Consent to
screen
Self-recording of falls
using monthly diaries
for 3 months
Randomisation and
allocation of participants
to either intervention or
control 
Baseline assessment
(see Table 1)
Intervention group
Fall avoidance strategies
with exercises at home.
Twelve supervised session
plus individual practice.
Usual care (see Chapter 3)
Control group
DVD only on Parkinson’s.
Usual care (see Chapter 3)
6-month assessment 
(see Table 1)
12-month assessment
(see Table 1)
Primary outcome fall frequency:
recorded using monthly
self-reported diaries for 6 months
Secondary outcome: fall frequency
recorded using monthly self-reported
diaries from 6 to 12 months
Control group
One sessions, advice on fall
avoidance at trial exit 
FIGURE 1 Diagram showing trial plan.
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conducted the baseline assessments with people with Parkinson’s and initiated the randomisation procedure
but was blinded to the group allocation. Blinded assessments were repeated 3, 6 and 12 months following
randomisation (up to November 2016). Participants recruited during the extension period (those randomised
after 1 May 2016) were followed to the primary outcome (6 months) only because of restricted funding.
Randomisation and therapy allocation
Patients were randomised (50 : 50) to receive PDSAFE (intervention group) or usual care plus provision of a
Parkinson’s information DVD (control group), using an online randomisation service at the Oxford Clinical
Trials Research Unit, University of Oxford. Random allocations were computer-generated, stratified by
centre and allocated in blocks with a random size of two, four, six or eight participants. This ensured that
the allocated groups within centres were as evenly distributed as possible, while maintaining a system in
which allocations were unlikely to be deduced by those needing to remain blinded. The randomisation
outcome was e-mailed to the trial co-ordinating centre via the PDSAFE e-mail address and forwarded to
the therapy team. The assigned therapist contacted participants within 2 days to inform them of the
randomisation outcome and arrange the first visit with them (within 2 weeks for those in the intervention
group and within 4 weeks for those in the control group). The same therapist at each site saw control and
intervention participants.
Participants in the control group continued to receive their usual care. In addition, they were given a DVD,
produced by Parkinson’s UK, containing information about living with Parkinson’s (this was not falls-
specific information). A physiotherapist visited the control group participants after randomisation to explain
their allocation and the importance of the control group; at the end of the trial, once their final follow-up
assessments had been completed, control group participants received guidance on physical activities and
strategies for postural control and safety in accordance with their profile of fall events.
For a full description of the PDSAFE intervention refer to Chapter 3.
Outcome measures
The outcome measures are summarised in Table 1. The primary outcome was risk of repeat falling in the
first 6 months after randomisation. A fall was defined as an event that resulted in a person coming to rest
on the ground or other lower level not as a result of a major intrinsic event or overwhelming hazard.25
A near-fall was deemed to have occurred when an individual felt that they were going to fall but managed
to prevent themselves from doing so.26 Fall events (falls and near-falls) were recorded using monthly self-
completed diaries, which have been used successfully in other studies.16 Diaries were given to participants
by assessors during the visits to conduct screening, baseline and follow-up assessments. The assessors
explained to participants how the diaries should be completed and left writing instructions. Participants
were asked to return diaries by post each month in a Freepost envelope provided. See Appendix 4 for
copies of falls diaries and instructions.
Secondary analysis of the primary outcome measure included rates of falling between 0 and 6 months.
Secondary outcomes included risk of repeat falling between 6 and 12 months; rates of falling between
6 and 12 months post randomisation; the Mini-Balance Evaluation Systems Test (Mini-BESTest), a test
of balance control;27 the Chair Stand Test (CST); the new freezing of gait test, a questionnaire on FoG;28
the 39-item Parkinson’s Disease Questionnaire (PDQ-39), a quality-of-life measure designed specifically
for people with Parkinson’s;29 the short, generic quality-of-life measure known as EuroQol-5 Dimensions
(EQ-5D) for economic evaluation;30 the Geriatric Depression Scale (GDS), 15-question version;31 the Falls
Efficacy Scale – International (FES-I);32 and the Physical Activity Scale for the Elderly (PASE).33 The
International Parkinson and Movement Disorder Society – Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) – motor section,34 MoCA,22 data on medications, use of professionals and exercise activity
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TABLE 1 Summary table of screening instruments and outcome measures
Screening measure Source Time point
MoCA Assessor Screening visit
Retrospective recall of falls over the previous
12 months
MMSE
H&Y scale
Demographic information and medical history
Primary measure
Fall events 0–6 months (falls) Monthly self-report diaries Completed from screening visit
to end of participation in trial
(maximum of 15 months)
Measures
Fall events 0–6 months (near-falls and fractures) Monthly self-report diaries Completed from screening visit
to end of participation in trial
(maximum of 15 months)Fall events 6–12 months (falls, near-falls and fractures) Monthly self-report diaries
Mini-BESTest (a test of postural control/balance control) Assessor Completed at baseline and at
each follow-up assessment
(at 3, 6 and 12 months)Timed CST
Handgrip strength test (substudy in one area only)
PASE
PDQ-39 (a quality-of-life measure designed specifically
for people with Parkinson’s)
GDS – 15-question version Self-report
FES-I
NFoG test [a questionnaire on FoG (freezing is closely
linked to falling)]
Medication use
MDS-UPDRS – motor section
Health professionals and exercise
Economic measures (people with Parkinson’s)
Health and social care resource use sheet Assessor Completed at baseline and at
each follow-up assessment
(at 3, 6 and 12 months)EQ-5D Self-report
Economic Measures (carer)
Carer demographic information and caring role Self-report Completed at baseline and at
each follow-up assessment
(at 3, 6 and 12 months)CES Self-report
CSI Self-report
CES, Carer Experience Scale; CSI, Caregiver Strain Index; CST, Chair Stand Test; EQ-5D, EuroQol-5 Dimensions; FES-I, Falls
Efficacy Scale – International; MDS-UPDRS, International Parkinson and Movement Disorder Society – Unified Parkinson’s
Disease Rating Scale; Mini-BESTest, Mini-Balance Evaluation Systems Test; NFoG, new freezing of gait; PASE, Physical
Activity Scale for the Elderly; PDQ-39, 39-item Parkinson’s Disease Questionnaire.
METHODS
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outside the trial were not regarded as outcome measures, but were measured at all time points for
characterisation of the population. The Carer Experience Scale35 and the Caregiver Strain Index36 were
administered to carers at baseline and follow-up time points to capture some broader effects of the
intervention.
Power and sample size
Primary outcome: risk of repeat falling between 0 and 6 months
The power and sample size calculations were based on the findings of a previous trial by Ashburn et al.37
This was a rehabilitation trial similar to PDSAFE in design. In the EXSART trial,37 the risk of repeat falling in
a 6-month period was 68% in the control group and 56% in the exercise group. However, falls risk was
anticipated to be lower in PDSAFE because EXSART was restricted to people who had fallen twice or more
often in the previous year. Therefore, it was assumed that the risk of repeat falling between 0 and 6 months
would be 63% for the control group and 50% for the intervention group. This required 228 participants
per group, with data for analysis of 456 participants in total. Allowing for a 5% drop-out rate between
randomisation and 6 months meant that 480 participants needed to be randomised. Furthermore, allowing
for a 10% drop-out rate between agreeing to the 3 months pre-randomisation falls collection and
randomisation meant that 534 participants needed to be recruited to the pre-randomisation falls collection
period. In total, 541 participants were recruited to the pre-randomisation falls collection period. Power
calculation scenarios are summarised in Appendix 6, Tables 26 and 27.
Power calculations (see Appendix 6) for rates of falling were based on Tango38 and related to the number of
falls during a fixed follow-up period, analysed using negative binomial regression conditioned on baseline
counts: specifically, formula 23 in the paper38 was used, assuming equal rates in the baseline and follow-up
periods in the control group and a follow-up period of twice the length of the baseline. Anticipating a falls
rate ratio (FRR) of 0.8 between 0 and 6 months post randomisation, that is a 20% reduction in the rate of
falling in the intervention group compared with the control group, and based on a rate of 2.5 falls in the
3-month baseline period, 197 participants per group were required at analysis, which led to 488 participants
being recruited to the pre-randomisation falls collection period.
Other scenarios were considered for the differences in risk of repeat falling or for the FRR (see Appendix 6,
Tables 26 and 27) and generally led to recruiting fewer than 600 participants to the pre-randomisation
falls collection period. All the calculations aimed for 80% power in 5% two-sided tests between the
intervention and control groups.
Embedded substudies
Once people with Parkinson’s were consented to take part in the main trial, participants were asked if they
would be willing to take part in the qualitative substudy that ran alongside the main trial. The qualitative
researcher contacted suitable participants on the basis of a theoretical sampling strategy (see Chapter 5).
Forty–two selected participants from the intervention group agreed to partake in qualitative interviews,
before and after receiving treatment (see Chapter 5).
At the point of recruitment, participants were asked if they had a carer. An information sheet was
provided for the carer, along with an invitation letter, response slip and pre-paid Freepost envelope; the
substudy explored carers’ quality of life. If a carer expressed a wish to take part, they were invited to
attend the participant’s (people with Parkinson’s) baseline visit and informed consent was taken from them
at that time. There were 463 participants with a carer; 189 carers agreed to take part.
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Statistical analysis
A statistical analysis plan was finalised before the data set was unblinded. An intention-to-treat (ITT)
approach was used for the main analyses with data analysed on the basis of group allocation. When there
were incomplete diaries, a participant was coded as a repeat faller if they reported two or more falls in
their incomplete diaries or if there was a report of two or more falls from a retrospective recall at the end
of the trial; otherwise, they were included as a non-repeat faller if they had completed ≥ 50% diary days
for the period in question. Participants not reporting two or more falls, completing < 50% of diary days
and with no other indication of repeat falling during a follow-up period were excluded.
Repeat faller status during 0–6 months (primary outcome) and 6–12 months post randomisation was
analysed in logistic regression controlling for site, age, gender, H&Y scale stage as a regressor, the
logarithm of retrospectively collected number of falls in the year prior to screening, repeat fall status prior
to screening and the logarithm of the prospectively collected rate of falling during the 3-month period
prior to randomisation. A small quantity, 0.5, was added to numerators of the rates of falling so that
participants with zero falls during the period were included; the results are not sensitive to the quantity
added.39 These controlling variables were finalised in a blind analysis without access to the group indicator,
as specified in the analysis plan, and were included in all regression models. Rates of falling during the
periods 0–6 months and 6–12 months post randomisation were examined in negative binomial models
fitted with command nbreg in Stata® version 11 (StataCorp LP, College Station, TX, USA). The logarithm
of a participant’s days of diary follow-up was included in nbreg modelling as an offset.
Odds ratios (ORs) and FRRs are presented with 95% confidence intervals (CIs). The geometric means of
individual participant rates (with 0.5 added to the numerator, as before) of falling during 6-month follow-up
periods are presented as rates per 6 months to accommodate the skewed distribution across participants.
Prespecified subgroup analyses for falling between 0 and 6 months post randomisation were undertaken to
identify the differential impact of the intervention according to MoCA status (≤ 25 and ≥ 26) and freezing
status, and removing participants with most severe disease by virtue of the MDS-UPDRS (≥ 58) and H&Y
scale stage (1–3). Differential effects were further explored on the basis of MoCA, MDS-UPDRS and number
of falls in the year prior to screening by creating subgroups defined by tertiles at baseline. All the subgroup
analyses involving tertiles were exploratory, that is they were not pre-stated. Both MoCA and MDS-UPDRS
had been pre-stated but with different cut-off points and had shown some indication of differential effects.
Retrospective falls recall was examined by Canning et al.40 as pre-stated subgroups but with different
cut-off points; we wished to check the statistically significant interactions that they reported. Therefore, the
decision was taken to examine subgroups defined by tertiles, not selected cut-off points. Subgroup analysis
started with likelihood ratio tests for interaction in logistic models and Wald tests for interaction in the
negative binomial models. Within-subgroup intervention effects are presented with 95% CIs. A secondary
per-protocol analysis was carried out, as prespecified, by excluding participants from the PDSAFE group
who received fewer than seven of the planned 12 sessions. A similar approach to analysis was followed for
continuous secondary outcomes, additionally controlling for the outcome assessed at baseline. Analysis
was conducted in SPSS version 24 [(Statistical Product and Service Solutions) SPSS Inc., Chicago, IL, USA]
and Stata.
Safety reporting
Following a full risk assessment, PDSAFE was classified as a low-risk trial and, as such, in agreement with the
ethics committee and sponsors, proportional safety reporting was implemented. Incidents of hospitalisation
and disability, falls or incapacity are expected among this patient population. Therefore, only death, life-
threatening events or new disability leading to prolonged hospitalisation attributed to the trial intervention
were considered to be serious adverse events (SAEs). Similarly, any hospitalisation that was planned prior to
randomisation or that could not be attributed to the PDSAFE intervention or assessments was not recorded
METHODS
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as a SAE. Adverse events, such as hospitalisations, changes in health status and falls, were collected routinely
as part of follow-up assessments and were monitored for potential SAEs. Falls diaries were also reviewed: if a
fall resulting in hospitalisation had happened while someone was participating in the PDSAFE intervention
and trial assessments, it would have been recorded as a SAE, but no one had such an event. All suspected
SAEs were reviewed by Professor Helen Roberts, a medical physician, who adjudicated whether or not they
were related to the trial activity.
An independent Data Monitoring Committee was established. The group met regularly throughout the trial
to undertake interim reviews of the trial’s progress, including the review of updated figures on recruitment,
data quality, adherence to protocol and follow-up, and main outcomes and safety data. Falls rates in
particular were monitored.
Patient and public involvement
Patient and carer involvement was incorporated at all levels of the PDSAFE trial. Several PPI representatives
were involved in the design of the study, including the development of participant information sheets,
consent forms and intervention resources. Mr John Wood acted as PPI representative on the Trial Steering
Committee. The trial was presented to several local Parkinson’s support groups; representatives were
invited to the results launch event in September 2017 and contributed to discussion on the interpretation
of results and key messages. PPI representatives will also be involved with the dissemination of the findings
through existing patient networks, mainly through Parkinson’s UK and its newsletter service.
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Chapter 3 The PDSAFE intervention and its
delivery
This chapter details the PDSAFE intervention and its delivery. Background information is provided tosupport the conceptual development of the intervention, the protocol is presented using the TIDieR
(Template for Intervention Description and Replication)41 and descriptive statistics demonstrate the content
of the intervention delivered over the intervention period.
Background for intervention design
A role for exercise in the treatment of both the physical and cognitive/behavioural symptoms of Parkinson’s
has been advocated and is supported by the European Physiotherapy Guidelines for Parkinson’s Disease.42
In reviewing 70 clinical trials, the guidelines suggest that there is strong evidence that specific physiotherapy
interventions help to improve transfers, balance, gait, physical capacity and movement functions,42 all isolated
falls risk factors. A recent Cochrane review43 stated that the overall aim of physiotherapy intervention is to
optimise independence, safety and well-being, thereby enhancing quality of life; however, the intervention
that is most effective at achieving this remains unclear.
Evidence suggests that a multidimensional intervention to reduce falls, incorporating balance, functional
strength and strategy training, and thus appreciating the need for motor, cognitive and behavioural
training, may be more effective than interventions focusing on independent risk factors such as postural
control and/or functional strength alone.19
The PDSAFE intervention is delivered in the home, tailored to an individual’s specific falls mechanism and
functional presentation and personalised to rehabilitate the primary strategy or strategies that contributed to
the fall(s) (Figure 2). Not only does this allow the protocol to align with all components of the International
Classification of Functioning, Disability and Health (ICF)44 as a person-centred approach, it also follows
the consensus-based clinical practice recommendations for falls management in Parkinson’s.45 From this,
personalised exercise prescription, within a menu of exercises, allows an individualised programme to be
designed specific to the falls-related risk factors (impairments) that contribute to the primary ‘problematic’
strategy (as recommended by the European Physiotherapy Guidelines for Parkinson’s Disease42). The specific
‘impairment’ training enables physiological improvements in Parkinson’s symptoms and deficits, which allow
functional training and strategy task practice in everyday life (see Figure 2). In this way, the rehabilitation of
the falls-related strategy and its contributing falls risk factors not only works towards reducing the risk of
similar falls again, but also embeds the training in everyday function and, therefore, is more likely to have a
greater overall effect across all components of a participant’s life (and, thus, full ICF model).
Intensity is maintained across all aspects of the frequency, intensity, time and type (FITT) principle (as published
in the American College of Sports Medicine guidelines)46 to drive physiological adaptation. ‘Frequency’ is
regulated to a minimum of three times per week, ‘intensity’ must be perceived as ‘moderately hard/hard’
for all activities of the programme, ‘time’ is set to a maximum of 60 minutes and ‘type’ of exercise is tailored
and specific to each individual’s falls mechanism. With the consideration of all factors, it is therefore possible
to design a multidimensional programme that does not lose intensity as a result of its many components.
In addition, the high intensity, continuous progression and titrated support from intensive to independent
practice maintains focus and adherence and encourages personal commitment and investment, as well as
fostering an understanding and empowerment of the rehabilitation process for the individual. The addition
of visual feedback both in therapy time and as a review through personalised DVDs also aids accurate
independent practice and continuation of therapy. Thus, continuous progress and adaption to the
neurodegenerative properties of the condition can be made to maintain safety.
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In appreciation of the mechanisms of neurorehabilitation and exercise prescription, the PDSAFE
intervention protocol is structured in a way that enables intensive, repetitive practice that is salient to an
individual and their specific falls profile, thus meeting their needs for effective neuroplastic change. In
addition, the embedding of the training in strategy task-related practice across all functional activities
enables rehabilitation to take place across all levels of life participation and not just in relation to a specific
task, goal or previous fall behaviour.
As a result of its unique structure and delivery, the PDSAFE intervention (see Figure 2) reflects the evidence
base for falls prevention in Parkinson’s, meets the holistic recommendations of the ICF framework for
practice and facilitates onward progression and independent self-management of the condition by the
individual. The novelty lies in both the content (disease-specific exercises and strategies for instability,
use of motor relearning and cognitive awareness) and delivery (personalised feedback using a DVD for
adherence and self-management).
Intervention protocol
In line with the recommended methods of reporting intervention design, TIDieR41 is detailed in Table 2.
The 12 items detailed in the checklist are an extension of the Consolidated Standards of Reporting
Trials (CONSORT) 2010 statement – item 547 and the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 statement – item 1148 and are intended to improve the reporting of
interventions.
For a visual representation of the intervention, please refer to the film available at: www.youtube.com/
watch?v=emNr0REIm4A&list=PLT3AipgP4l_x7OVNryanVgtcvPZXVJyX1 (accessed 21 February 2019).
Practice
in
function
Continual functional
adaptation and
falls prevention
Progression
Continual, guided to independent
Strategy selection
Selection of strategy(ies) that contributed to the fall(s)
Strategy training Identification of risk factors
(contributing impairments)
Fall(s) mechanism
Established via subjective and functional assessment plus falls
Specific, progressive and
personalised to fall and
contributing strategy
Established through subjective
and objective assessments
Training at different levels
FIGURE 2 Conceptual model of the PDSAFE falls prevention protocol intervention.
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TABLE 2 The PDSAFE protocol description, as per TIDieR guidelines
TIDieR Checklist requirement Protocol description
1 Protocol name PDSAFE: a personalised falls prevention programme of home exercises for postural
control training, muscle strengthening and task-orientated movement strategy
training
2 Protocol rationale and
theory of main elements
l Personalised: the individual programme for each participant is derived from falls
mechanism and underlying disease specific impairments
l Postural control, functional strength and strategy: the programme must include
elements of all exercise prescription from a standardised menu of options
l Intensive, repetitive, progressive: elements of exercise prescription and
neurorehabilitation followed
3 Protocol materials For the participant:
l participant exercise folder (including safety guidelines, daily checklist, personalised
postural control and functional strength exercises, progression guidelines and
intensity guidelines)
l personalised DVD of falls prevention strategy training and exercises or the
Parkinson’s UK DVD, Keeping Active
l Weighted vest (up to 10 kg, if required)
l Foam balance pad (if required)
For the physiotherapist:
l the PDSAFE protocol documentation, including intervention paperwork
l standardised strategy menu and postural control and functional strength
exercise menu
l a tablet to record strategy training and give ‘in-time’ visual feedback
l pre-recorded library of strategy training vignettes
l laptop for burning personalised DVDs and uploading study documentation
4 Procedures of protocol
delivery
l Randomisation to intervention or comparison arm (50 : 50)
l All participants contacted within 48 hours by telephone to inform them of
group allocation
l Intervention participants seen first by week 2 and regularly until month 6
l Comparison participants seen first up to week 6 and second at month 12
5 Protocol providers l All sessions for both groups are delivered by a physiotherapist: advanced clinical
reasoning required to align postural control, functional strength and strategy
components with falls mechanisms
l All therapists complete compulsory 2-day initial training, monthly continuing
professional development, weekly peer-led case discussion and fidelity checks
with lead therapist (once a month for the first 3 months and then 3-monthly for
duration of involvement in trial)
6 Mode of protocol
delivery
l All sessions for both groups are face to face and individualised
l Participants are also left with an individualised exercise folder and DVD for
independent strategy training practice
7 Location of protocol
delivery
l All sessions for both groups are home/community based. This may include regular
visits or previous falls locations, if feasible
l Therapist training sessions take place at trial sites and are available virtually or
by telephone
8 Protocol duration,
intensity and dose
Intervention
Supervised sessions comprise:
l 12 1-hour, physiotherapy sessions progressing from intensive supervision to
independent practice; sessions are twice weekly to begin with (sessions 1–4), then
weekly (sessions 5–7), then monthly (sessions 8–12), followed by 6 months’
independent practice
l From assessment, selection of 1–3 falls mechanism strategies alongside a postural
control, functional strength and strategy exercise programme selected from
standardised menu
continued
DOI: 10.3310/hta23360 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 36
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ashburn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Delivery outcomes
Delivery of the PDSAFE intervention was over 2 years and 4 months. The intervention was delivered in a
total of eight clinical sites across nine NHS trusts.
Therapists
Physiotherapists were recruited by each site. Trial requirements stated that each therapist should have
experience in Parkinson’s or falls rehabilitation. It was initially designed that each site would have one
treating therapist and a trained cover for periods of absence. However, owing to clinical workload
and logistical delivery, a total of 18 therapists were trained over the study period. One lead therapist
co-ordinated the team, delivered the training and development activities, and monitored the fidelity of
intervention delivery.
Training, facilitated by the lead therapist, included attendance at one of the compulsory 2-day training
events held on three separate occasions. In addition, therapists were asked to attend a virtual weekly
meeting by telephone to discuss clinical cases and problem-solve within the boundaries of the intervention
protocol. These sessions were chaired by the lead therapist, with a total of 122 telephone contacts made
available over the intervention period. To maintain a high standard of clinical reasoning throughout the
intervention period, therapists were also asked to attend (either physically or virtually) monthly
‘masterclasses’ on key clinical topics such as cognition and dual tasking, turning, FoG and balance.
Alternating with masterclasses, therapists were asked to present case studies on key topics for team
discussion. Twelve ‘masterclass’ topics (some were repeated for new therapists) and seven case study
reviews were held over the intervention period.
TABLE 2 The PDSAFE protocol description, as per TIDieR guidelines (continued )
TIDieR Checklist requirement Protocol description
l Once the programme is selected, every session includes fall history review, warm-up,
exercise practice and progression, functional task practice with strategy training and
use of video for ‘in-time’ visual feedback and making personalised DVDs
Independent practice:
l Daily (or a minimum of three times weekly) independent practice of the exercise
programme (approximately 30 minutes), including safety review, warm-up,
exercise practice, progression review, functional practice of strategy training
(may include watching the DVD) and compliance monitoring
l Participants are expected to rate their ‘perception of work’, or intensity, as
‘moderate to hard’ or 6 to 10. Therapists’ progress and teach participants how to
independently progress their programme to maintain this level
Comparison group
Supervised sessions comprise:
l Initial visit to participant to provide Parkinson’s UK DVD and reassure them of
their importance in the trial
l Comparison treatment visit (following final trial assessment): a 1-hour session to
advise on personal strategy training and risk factor modification based on fall
mechanisms
9 Protocol personalisation l Detailed neurological physiotherapy assessment, focusing on falls mechanism and
potential underlying impairment, guides individual selection of falls-related strategy
l Strategy training and contributing falls risk impairments inform the selection of
individualised postural control and functional strength exercise programme from a
standardised menu
l All training is progressed at a participant-specific rate to maintain the required intensity
l Daily exercise practice is promoted but a minimum of three times a week is
accepted as necessary to accommodate participants’ requirements
THE PDSAFE INTERVENTION AND ITS DELIVERY
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Fidelity of the intervention was a priority to encourage uniformity of practice. The lead therapist observed
each therapist in a treatment session with a participant, once a month for the first 3 months of delivery
and then once every 3 months for the delivery period. Following the observation, a clinical reasoning
discussion was completed and a report written. Therapists could also request additional joint sessions with
the lead therapist if they had concerns or queries regarding a particular participant. This ensured that the
PDSAFE intervention was uniformly delivered across all sites and by all therapists. A total of 75 fidelity
sessions were held over the intervention period, with all therapists being assessed.
Intervention sessions
A total of 2587 sessions were delivered to the 291 intervention participants, with the majority of participants
receiving the anticipated 12 sessions (mode = 12).
Figure 3 presents the total number of sessions received by participants allocated to the intervention arm of
the trial. The majority of participants, 236 out of 238, received the exercise assessment and at least one
supervised session. Two participants did not start because they had changed their mind and 19 received
fewer than seven sessions; reasons for not fully engaging included admission to a nursing home,
deteriorating health, commitment was too much and caring for others; in some cases, no reason was
given.
All interventions sessions included a brief review of falls; warm-up exercises; review, practice and
progression of a participant’s individual exercise programme; and strategy training in functional scenarios
as a basic structure. Each therapist tailored the strategies treated, exercises prescribed and functional tasks
practised from a menu for each participant.
Selection of strategies
Evidence from the literature and from previous studies of falls among patients with Parkinson’s, as well as
expert opinion, were used to determine the most frequent falls mechanisms in Parkinson’s.19 Eight strategies
were defined: avoiding tripping, dual tasking, freezing cues, moving in tight spaces, picking up an object,
reaching, stepping backwards and turning. As described above, through the process of taking a detailed
falls history, clinical assessment and advanced clinical reasoning, therapists determined the most likely ‘fall
mechanism’ for each participant (levels 1 and 2 in Figure 2). For example, in the case of a participant who
repeatedly reported catching their foot and falling, regardless of the task being undertaken or location,
would be most likely to have a falls mechanism of tripping; thus, the strategy ‘avoiding tripping’ would be
selected by the therapist.
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FIGURE 3 Total number of intervention sessions received by participants.
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Over the 291 participants who received the PDSAFE intervention, strategies were selected a total of
440 times, with a strategy being used in treatment a total of 3447 times over the period. This provides
a large sample to consider the clinical reasoning process of the therapists selecting the strategies.
Figure 4 demonstrates the number of times each strategy was selected as a potential falls mechanism
corresponding to the number of times that strategy was used in a treatment session.
Importantly, this allows description of the strategies selected as primary falls mechanisms and thus treated
for the majority of the intervention period versus strategies that may have been selected as a secondary or
subsequent strategy and thus treated less frequently or for a shorter period of time.
It is apparent that ‘avoiding tripping’ was the most widely used strategy. It was selected following
assessment a total of 116 times, used 1110 times during treatment sessions and accounted for 26% of all
strategies selected. The figures for ‘turning’ are similar [selected 107 times and used 938 times during
treatment (26% of the total)]. ‘Freezing cues’ was also frequently selected as a strategy [selected 79 times
and used 365 times (24% of the total)]. It is clear from Figure 4 that all other strategies were selected and
used in treatment with similar frequencies to each other.
Selection of exercise prescription
Once the strategy or strategies most appropriate for addressing a participant’s falls mechanism had been
selected, therapists used advanced clinical reasoning and assessment skills to determine the physical
impairments and deficits in physical falls risk factors that were most likely to contribute to the fall
mechanism (see Figure 2). For example, the participant described above, who frequently caught their foot
and subsequently fell, was allocated the ‘avoiding tripping’ strategy. The therapist must consider a number
of reasons why the participant has a tendency to catch their foot, such as weakness of the muscles used to
lift the toes, failure to transfer weight onto the supporting leg appropriately because of hip weakness or
reduced limits of postural control stability, or failure to achieve enough clearance from the ground because
of weakness in the hip flexors. Through assessment, the therapist determines the most likely impairment
and designs a functional strength and postural control exercise programme from the available menu that
treats this impairment.
Evidence from the literature and from previous studies of falls among patients with Parkinson’s, as well as
expert opinion, were used to determine what exercises were available on the menu for therapists to select
from.19
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FIGURE 4 Stratification of strategies used in delivery of PDSAFE intervention.
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Table 3 shows the menu of exercises available for the therapist to select from when putting together an
individual participant’s PDSAFE intervention.
Exercises were available on six levels; working through the levels enabled progression (level 4 in Figure 2)
and maintenance of intensity for each exercise. All programmes had to include at least one balance and
one strengthening exercise. A total of 1693 exercises were selected by all therapists over the intervention
period with an average of six (range one to eight) exercises prescribed per participant across the period.
Figure 5 shows a spread of all exercises being used over the intervention period.
Figure 5 demonstrates the predominance of the more dynamic postural control (compensatory step and
lunge and heel/toe walking) and strengthening exercises over other exercises from the menu. The complex
nature of the compensatory step and lunge exercise makes it suitable for the treatment of many of the
falls risk factors associated with Parkinson’s; for example, high dynamic stepping actions help with motor
control, compensatory stepping helps with the regain of an appropriate base of support from a loss of
postural control or a trip by increasing stepping amplitude for those who freeze and expanding limits of
stability for those who fall when reaching. The practice of stepping backwards with appropriate postural
control and weight distribution will assist those who fall stepping backwards. A common symptom of
the Parkinsonian gait is loss of foot clearance, heel strike and step length45 (hence the predominance of
tripping as a falls mechanism); thus, the high frequency of the use of heel/toe walking to improve these
impairments is also unsurprising. As each exercise programme had to include both strengthening and
postural control exercises, the high frequency of selection of strengthening exercises can be attributed to
the fact that the postural control menu contained fewer exercises that could be selected. This is less of a
clinical reasoning observation and more related to the ratio of exercises in the menu.
TABLE 3 Exercise menu for the PDSAFE intervention
Function Exercise
Balance/postural control
Standing Standing balance
Tandem stand
Reaching
Compensatory step and lunge
Walking Heel/toe walking
Toe/heel walking backwards
Tandem walking
‘Figure of 8’ walking
Picking up an object
Stepping over an object
Strengthening Sit to stand
Standing toe and heel raises
Forward stepping up and down
Side stepping up and down
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Summary
The PDSAFE intervention was deeply rooted in evidence from both rehabilitation after falls and exercise
prescription literature. The protocol was a holistic model encompassing all aspects of the ICF and its
design allowed a personalised, sophisticated, complex intervention to be prescribed for each participant.
‘Personalised’, ‘intensive’ and ‘progressive’ were key parameters of the intervention, demanding a high
level of commitment and collaboration between the therapist and the participant. The intervention was
delivered to a high standard. All requirements of fidelity were met and the intervention was comparable
across all sites. Delivery was significantly enhanced by the level of training and support provided to the
delivery team and a high standard of clinical reasoning and protocol delivery was maintained. The majority
of participants received the planned number of sessions. There was a slight rise in the number of
participants receiving only seven or eight sessions as this is the point at which the therapists visited less
frequently and participants were required to complete longer periods of independent practice. It is likely
that this led to some participants withdrawing at this point because of the reduced support/motivation
from the therapist. There was a clear predominance of some strategies, which is likely to reflect the
demographic of the intervention group (i.e. more frequent fallers and people with Parkinson’s who freeze,
plus those who have more advanced disease and thus are more likely to have difficulty turning: with axial
rigidity, poor stepping and impaired cognition). The predominance of ‘avoiding tripping’, ‘turning’ and
‘freezing cues’ is in line with the reasons for falling provided by participants most frequently in the previous
literature.26 The design of strategy selection leading to supported exercises to treat falls risk factors
provided a protocol design that was deliverable, with all participants receiving both strategies and exercises
as planned. Owing to the complexity of the exercises, some exercises are better able to be adapted for
multiple impairments and thus are used more frequently. Previous studies19 have provided the same
intervention for all participants, regardless of fall mechanism. The use of all the strategies and exercises
demonstrates the need for a complex intervention and variability as ‘one size, clearly does not fit all’.
0
50
100
150
200
250
300
N
u
m
b
er
 o
f 
ti
m
es
 e
ac
h
 e
xe
rc
is
e
w
as
 u
se
d
 in
 t
re
at
m
en
t
St
an
di
ng
 b
ala
nc
e
Ta
nd
em
 w
alk
in
g
Re
ac
hi
ng
Co
m
pe
ns
at
or
y s
te
pp
in
g 
an
d 
lu
ng
in
g
He
el/
to
e w
alk
in
g
To
e/h
ee
l w
alk
in
g 
ba
ck
wa
rd
s
Ta
nd
em
 w
alk
in
g
Fig
ur
e o
f 8
Pic
k u
p 
ob
jec
t
St
ep
pi
ng
 o
ve
r o
bj
ec
t
Sit
 to
 st
an
d
St
an
di
ng
 to
e a
nd
 h
ee
l r
ais
es
Fo
rw
ar
d 
ste
pp
in
g 
up
 an
d 
do
wn
Sid
e s
te
pp
in
g 
up
 an
d 
do
wn
Exercise
FIGURE 5 Exercise use frequency across all of the intervention, in all participants.
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Chapter 4 Statistical trial results
Participants
Recruitment of participants ran from July 2014 to August 2016 (see Appendix 5, Figure 14).
Figure 6 provides the CONSORT flow diagram of participants’ assessments. A total of 640 people with
Parkinson’s were invited to participate, but 99 either did not respond or did not meet the eligibility criteria,
which left 541 people for consent and completion of a screening visit with a trial assessor in their own
home. Of these 541 people, seven did not score the minimum score on the MMSE and were excluded.
The remainder went on to complete prospective falls diaries for 3 months (i.e. a minimum of 13 weeks).
A further 60 people were excluded during this time [reasons for not being randomised were as follows:
medically unfit (n = 21), dislike of completing falls diaries (n = 6), no longer met eligibility criteria (n = 12),
reported cognitive issues (n = 2), died (n = 1) or decided not to participate in the trial (n = 18)]. The
remaining 474 (88%) people completed a baseline assessment and were randomised into one of two
groups: control (n = 236) or the PDSAFE intervention (n = 238). Recruitment and randomisation graphs can
be found in the appendices. The groups allocated to PDSAFE and control were similar at baseline (Table 4)
in terms of age, gender, disease severity, disease duration, cognitive ability, freezing, medication and
coexisting conditions and living status. Retrospective recall of falls was also similar between the groups, but
the rate of falling in the 3 months prior to randomisation was greater in those subsequently randomised to
the intervention group.
Delivery of intervention
In the PDSAFE group, 66 participants did not engage with the intervention for a number of reasons,
including admission to a care home, deteriorating health, changing their mind about participation, feeling
the commitment to be too great, or death; in some cases, no reason was given. The therapy aim was
to provide 12 supervised sessions for each participant and, on average, participants had a median of
12 sessions [interquartile range (IQR) 11–12 sessions] or a mean of 11 sessions [standard deviation (SD)
2.4 sessions]. A total of 21 participants received fewer than seven sessions and, along with a further four
participants for whom the number of sessions was not available, were excluded from per-protocol analyses.
Falling outcomes
In Table 5, the prospective completion of diaries is described during the period of baseline diary
completion prior to randomisation, and in the 12-month period of post-randomisation follow-up. The
percentage who returned no diaries was generally low (2–4%) during the period 0 to 6 months; during
the final 6 months the percentage who returned no diaries was higher (1–12%). These percentages
exclude the number who withdrew or died during the respective periods. Among those returning any
diaries for the period in question, the IQR of the numbers of days completed was 90–92 (within target).
The target number of days varied between 89 and 92 days across participants, depending on the calendar
months covered by their 3-month baseline period.
There was a trend towards increased repeat falling during the 6 months following randomisation in the
PDSAFE group compared with the control group (OR 1.21, 95% CI 0.74 to 1.98; p = 0.447). During the
final 6 months of follow-up, there was a trend towards decreased repeat falling (OR 0.86, 95% CI 0.45
to 1.65; p = 0.657). No statistically significant differences between the groups were found (Table 6).
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Consent to screen
(n = 541)
Completed baseline assessment
(n = 474)
Randomised
(n = 474)
Not randomised
(n = 67)
• Ineligible, reason not stated, n = 12
• Cognitive issues, n = 2
• Failed MMSE, n = 7
• Commitment, n = 16
• Falls diaries, n = 6
• Ill health, n = 21
• Intervention unappealing, n = 2
• Died, n = 1
Control
(n = 236)
PDSAFE
(n = 238)
• 0 sessions, n = 2
• 2 sessions, n = 2
• 3 sessions, n = 4
• 4 sessions, n = 3
• 5 sessions, n = 5
• 6 sessions, n = 5
• 7–12 sessions, n = 217
Withdrawn
(n = 49)
Withdrawn
(n = 16)
• Trial too much, n = 10
• Ill health, n = 16
• Back pain, n = 7
• Commitment, n = 5
• Falls, n = 2
• Change in diagnosis, n = 1
• Cognitive issues, n = 2
• Nursing home, n = 3
• Spouse unwell, n = 1
• No reason, n = 2
• Trial too much, n = 2
• Ill health, n =  4
• Commitment, n = 1
• Falls, n = 1
• Spouse unwell, n = 1
• In another trial, n = 2
• Randomisation outcome, n = 2
• No reason, n = 1
• Trial too much, n = 3
• Ill health, n = 3
• Back pain, n = 1
• Commitment, n = 1
• Falls, n = 1
• Change in diagnosis, n = 2
• Nursing home, n = 3
• Moved out of area, n = 1
• No reason, n = 1
• Ill health, n = 2
• Falls, n = 1
• Nursing home, n = 1
• Moved out of area, n = 1
Continued follow-up
(n = 19)
Continued follow-up
(n = 6)
Died
(n = 2)
Died
(n = 2)
Died
(n = 1)
Died
(n = 3)
Lost to follow-up
(n = 30)
Lost to follow-up
(n = 10)
Withdrawn/lost to follow-up
(n = 14)
Withdrawn/lost to follow-up
(n = 5)
• 6 months, n = 206
• With ≥ 1 diary,a n = 231
• Assessment visit, n = 190
• Postal return, n = 176
• 12 months, n = 127
• With ≥ 1 diary,a n = 127
• Assessment visit, n = 121
• Postal return, n = 116
• 12 months, n = 142
• With ≥ 1 diary,a n = 147
• Assessment visit, n = 136
• Postal return, n = 127
• 6 months, n = 219
• With ≥ 1 diary,a n = 230
• Assessment visit, n = 214
• Postal return, n = 196
Those randomised after 1 May 2016
were not followed up after 6 months
(n = 68)
Those randomised after 1 May 2016
were not followed up after 6 months
(n = 69)
Treatment sessions
FIGURE 6 Flow diagram of participants’ progression through the trial. a, Number with any diaries during the preceding
6 months. Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under
CC BY-NC. No commercial re-use. See rights and permissions. Published by the BMJ Publishing Group Ltd. This is an
open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)
license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their
derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any
changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 4 Baseline characteristics in the intervention and control groups
Characteristic
Trial group
PDSAFE (n= 238)a Control (n= 236)b
Gender, n (%)
Male 147 (62) 119 (50)
Female 91 (38) 117 (50)
Age (years)
Mean (SD) 71 (7.7) 73 (7.7)
Minimum, maximum 51, 91 46, 88
Disease duration (years)
Mean (SD) 8 (6.6) 8 (5.8)
Minimum, maximum 0, 36 0, 29
MMSE score
Mean (SD) 28 (1.7) 29 (1.6)
Minimum, maximum 24, 30 24, 30
MoCA score
Mean (SD) 26 (2.9) 26 (3.2)
Minimum, maximum 15, 30 9, 30
≤ 25 (cognitively impaired), n (%) 91 (38) 93 (39)
Living status, n (%)
Lived alone 48 (20) 59 (25)
With a spouse/partner 174 (73) 166 (70)
With a friend/family 15 (6) 10 (4)
H&Y scale stage, n (%)
1 26 (11) 30 (13)
2 78 (33) 56 (24)
3 102 (43) 112 (48)
4 32 (13) 38 (16)
MDS-UPDRS
Mean (SD) 32 (15.2) 33 (17.3)
Minimum, maximum 2, 77 4, 92
Phenotype
TD, n (%) 21 (9) 19 (8)
PIGD, n (%) 194 (83) 206 (88)
Indeterminate, n (%) 20 (8) 10 (4)
continued
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TABLE 4 Baseline characteristics in the intervention and control groups (continued )
Characteristic
Trial group
PDSAFE (n= 238)a Control (n= 236)b
FoG in the past month, n (%) 152 (64) 139 (59)
Number of falls in the 12 months prior to screening
Median (minimum, maximum) 3 (1, 1460) 3 (1, 1095)
Mean (SD) 26 (132.7) 19 (105.4)
Repeat falling in 12 months prior to screening, n (%) 186 (78) 189 (80)
Rate of falls/person/3 months prior to randomisation
Median (minimum, maximum) 1.98 (0, 319) 0.99 (0, 73)
Mean (SD) 5.9 (22.8) 3.0 (7.3)
Rate of near-falls/person/3 months prior to randomisation
Median (minimum, maximum) 4.4 (0 to 440) 4.3 (0 to 601)
Mean (SD) 13.8 (35.8) 15.6 (51.4)
Medications, n (%)
Levodopa 208 (88) 216 (92)
Dopamine agonist 108 (46) 106 (45)
Monoamine oxidase inhibitor 52 (22) 46 (20)
Catechol-O-methyltransferase inhibitors 59 (25) 41 (17)
Other Parkinson’s medication 19 (8) 23 (10)
GDS score at baseline, n (%)
> 5 (suggestive of depression) 147/235 (63) 164/236 (70)
≥ 10 (indicative of depression) 50/235 (21) 49/236 (21)
Coexisting conditions, n (%)
Orthopaedic 109 (46) 129 (54)
Cardiovascular/respiratory 85 (36) 96 (41)
PIGD, Parkinson’s-induced gait deficit; SD, standard deviation; TD, tremor dominant.
a Missing values in the intervention group: living status (n = 1), MDS-UPDRS (n = 1), disease duration (n = 1), FoG (n = 1),
rate of falling in the 3 months prior to randomisation (n = 1), tremor dominant/Parkinson’s-induced gait deficit/
indeterminate phenotype (n = 3).
b Missing values in the control group: living status (n = 1), MDS-UPDRS (n = 1), tremor dominant/Parkinson’s-induced gait
deficit/indeterminate phenotype (n = 1).
Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC. No
commercial re-use. See rights and permissions. Published by the BMJ Publishing Group Ltd. This is an open access article
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TABLE 5 Diary completion during pre randomisation: 0–6 months and 6–12 months post randomisation
Characteristic
Trial group
PDSAFE Control
Randomisation, n 238 236
Baseline
Number with no diaries 1/238 0/236
Number of diary days among those with diaries (n = 237) (n = 236)
Median 92 92
IQR 90–92 90–92
Minimum, maximum 12, 92 26, 92
n/N with complete diaries (%) 196/238 (82) 198/236 (84)
n/N with ≥ 50% diary days (%) 229/238 (96) 226/236 (96)
0–6 months post randomisation
Number entering 0–6 months period 238 236
n/N with no diaries (%) 7/238 (3) 6/236 (3)
n/N in falls rate ratio analysis (%) 231/238 (97) 230/236 (98)
n/N exiting (died or withdrawn from follow-up during 0–6 months) (%) 32/238 (13) 17/236 (7)
n/N exiting with no diaries 2/206 (1) 3/219 (1)
Number of diary days among those not exiting with diary days (n = 204) (n = 216)
Median 182 182
IQR 153–183 174–183
Minimum, maximum 3184 29,184
n/N with complete diaries (%) 130/238 (55) 158/236 (67)
n/N with ≥ 50% diary days (%) 203/238 (85) 211/236 (89)
Number in follow-up at 6 months 206 219
Number in trial follow-up randomised after 1 May 2016
Southampton 5 4
Portsmouth 7 6
Bournemouth 2 2
Newcastle 15 13
Hampshire 13 18
Plymouth 10 11
Cornwall 16 15
Total 68 69
6–12 months post randomisation
Number entering 6–12 months period 138 150
n/N with no diaries (%) 11/138 (8) 3/150 (2)
n/N in falls rate ratio analysis (%) 127/138 (92) 147/150 (98)
n/N exiting (died or withdrawn from follow-up during 6–12 months) (%) 11/138 (8) 7/150 (5)
n/N exiting with no diaries (%) 5/127 (4) 2/143 (1)
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TABLE 5 Diary completion during pre randomisation: 0–6 months and 6–12 months post randomisation
(continued )
Characteristic
Trial group
PDSAFE Control
Number of diary days among those not exiting with diary days (n = 122) (n = 141)
Median 180 180
IQR 151–183 153–183
Minimum, maximum 4184 30,184
n/N with complete diaries (%) 94/138 (68) 112/150 (75)
n/N with ≥ 50% diary days (%) 114/138 (83) 132/150 (8)
Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC.
No commercial re-use. See rights and permissions. Published by the BMJ Publishing Group Ltd. This is an open access article
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non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
TABLE 6 The ITT analysis of falling outcomes: 0–6 and 6–12 months
Period
Trial group
OR (95% CI)a p-valueaPDSAFE Control
Repeat falling restricted to ≥ 50% diaries, n (%)
Baseline 127/231 (55) 92/230 (40)
Baselineb 112/203 (55) 80/211 (38)
0–6 months 125/203 (62) 116/211 (55) 1.21 (0.74 to 1.98) 0.447
Baselineb 55/114 (48) 47/132 (36)
6–12 months 57/114 (50) 71/132 (54) 0.86 (0.45 to 1.65) 0.657
Fall rates Falls/person/6 monthsc FRR (95% CI)
Baseline 4.5 3.3
0–6 months 3.4 2.7 0.98 (0.80 to 1.19) 0.824
6–12 months 2.7 2.8 0.83 (0.62 to 1.11) 0.200
Near-fall rates Near-falls/person/6 monthsc NFRR (95% CI)
Baseline 8.0 8.1
0–6 months 4.7 5.6 0.67 (0.53 to 0.86) 0.001
6–12 months 3.9 3.7 1.01 (0.67 to 1.52) 0.968
NFRR, near-falls rate ratio.
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period and H&Y scale stage (NFRR additionally
controlled for log rate of near-falling in the pre-randomisation falls collection period).
b Baseline repeat falling restricted to participants included in the analyses for 0–6 and 6–12 months.
c Geometric mean of individual fall rates with 0.5 added to all numerators.
Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC.
No commercial re-use. See rights and permissions. Published by the BMJ Publishing Group Ltd. This is an open access article
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These analyses followed the planned treatment for participants with incomplete diaries during a follow-up
period, that is participants were classified as a repeat faller if they reported two or more falls in their
incomplete diaries or if a check of all PDSAFE records indicated two or more falls in that period. They were
classified as a non-repeat faller if fewer than two falls were reported in the incomplete diaries, there was
no indication of repeat falling in the period in the PDSAFE records and ≥ 50% of diary days for the period
had been completed. Otherwise they were excluded. Two sensitivity analyses are shown in Appendix 7,
Table 28, where analysis of repeat falling is also reported, restricted to participants with complete diaries
and including all participants with any diaries during the follow-up period in question. Although there
were no changes in the statistical significance or otherwise depending on these treatments of missing
diaries, there were changes in the magnitude of ORs.
Participants typically reported rates of falling, expressed per 6 months, of between three and five falls
(see Table 6). There was little difference in the rate of falling between the two groups in the first 6 months
of follow-up, indicated by the FRR, and a slightly greater difference, with FRR of 0.83 (95% CI 0.62 to
1.11; p = 0.200), during the following 6 months. The analysis of rates of falling is based on participants
with any amount of diary completion for the follow-up period in question, with only participants returning
no diaries excluded.
Rates of near-falling are also shown in Table 6, expressed per 6-month period. Near-falling was greater in
the period prior to randomisation than subsequently. During the 6 months post randomisation, the ratio
of near-falling rates between the PDSAFE and control groups was significantly reduced (p = 0.001), with
a rate of near-falling in the PDSAFE group of 0.67 (95% CI 0.53 to 0.86) that of the control group. This
reduction in near-falling was not maintained during the following 6 months. Like the analysis of falling
rates, the analysis of near-falling rates also includes participants irrespective of the amount of diary
completion for the period of follow-up in question (as long as any diaries were returned for the period).
In Table 7 a comparison is made between the overall falling (and near-falling) results following the ITT
analysis and a per-protocol analysis (excluding participants in the PDSAFE groups receiving fewer than
seven sessions). This shows the findings to be similar, there being no suggestion of reduced falling in the
PDSAFE group when the analysis is restricted to those receiving seven or more sessions.
TABLE 7 Comparison of ITT and per-protocol analyses of falling and near-falling outcomes: 0–6 and 6–12 months –
whole group
Period
Analysis
ITT Per protocol
OR (95% CI)a p-valuea OR (95% CI)a p-valuea
Repeat falling restricted to ≥ 50% diaries
0–6 months 1.21 (0.74 to 1.98) 0.447 1.16 (0.71 to 1.92) 0.538
6–12 months 0.86 (0.45 to 1.65) 0.657 0.92 (0.47 to 1.77) 0.793
Fall rates FRR (95% CI) p-valuea FRR (95% CI) p-valuea
0–6 months 0.98 (0.80 to 1.19) 0.824 0.99 (0.81 to 1.22) 0.982
6–12 months 0.83 (0.62 to 1.11) 0.200 0.84 (0.63 to 1.13) 0.268
Near-fall rates NFRR (95% CI) p-valuea NFRR (95% CI) p-valuea
0–6 months 0.67 (0.53 to 0.86) 0.001 0.67 (0.53 to 0.86) 0.001
6–12 months 1.01 (0.67 to 1.52) 0.968 1.01 (0.67 to 1.52) 0.963
NFRR, near-falls rate ratio.
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period and H&Y scale stage (NFRR additionally
controlled for log rate of near-falling in the pre-randomisation falls collection period).
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Secondary outcomes
Analysis of the secondary outcomes collected by the assessing therapist during home visits (Mini-BESTest,
FES-I, FoG and MDS-UPDRS) is reported in Table 8, with CST results reported in Tables 9 and 10. At the
6-month visit, the PDSAFE group had improved mean Mini-BESTest score of 0.95 points (95% CI 0.24 to
1.67 points; p = 0.009), controlled for baseline Mini-BESTest score and other covariates (see Table 7); better
falls confidence as assessed by a lower mean FES-I score of 1.60 points (95% CI 3.00 to 0.19 points; p = 0.026),
controlled for similar covariates; and improved balance as assessed by the CST (p = 0.041). There were no
significant differences at 12 months.
TABLE 8 Secondary outcomes at 6 and 12 months
Outcome measure Visit
Trial group, mean (SD), n
Mean difference
(95% CI)a p-valuePDSAFE (N= 238) Control (N= 236)
Mini-BESTest (0–28,
lower values worse)
Baselineb 18.3 (5.7), 183 17.3 (6.1), 211
6 months 19.4 (5.9), 183 17.5 (6.4), 211
6 months – baseline 1.1 (3.8), 183 0.2 (3.8), 211 0.95 (0.24 to 1.67) 0.009
Baselineb 18.5 (5.8), 115 17.5 (6.1), 126
12 months 17.9 (6.5), 115 17.4 (6.7), 126
12 months – baseline –0.7 (4.5), 115 –0.2 (3.8), 126 –0.41 (–1.48 to 0.66) 0.449
FES-I (16–64, higher
values worse)
Baselineb 34.1 (11.0), 189 35.1 (11.5), 211
6 months 33.4 (10.6), 189 36.2 (11.4), 211
6 months – baseline –0.7 (7.9), 189 1.1 (7.2), 211 –1.6 (–3.0 to –0.19) 0.026
Baselineb 33.4 (10.7), 119 33.7 (11.3), 135
12 months 34.8 (11.2), 119 37.2 (11.6), 135
12 months – baseline 1.3 (8.2), 119 3.5 (9.3), 135 –1.4 (–3.41 to 0.66) 0.184
PASE (0–4, lower
values worse)
Baselineb 107.8 (73.5), 153 100.1 (67.1), 177
6 months 110.2 (70.4), 153 100.6 (68.0), 177
6 months – baseline 2.4 (50.8), 153 0.5 (49.5), 177 –1.05 (–11.3 to 9.21) 0.841
Baselineb 108.1 (71.9), 98 98.6 (61.1), 115
12 months 99.4 (72.8), 98 87.6 (62.3), 115
12 months – baseline –8.7 (53.0), 98 –11.0 (48.5), 115 –0.55 (–13.9 to 12.8) 0.935
PDQ-39 (0–100,
higher values worse)
Baselineb 27.4 (14.3), 126 28.7 (15.9), 153
6 months 28.3 (15.0), 126 29.5 (16.5), 153
6 months – baseline 0.8 (8.3), 126 0.9 (9.0), 153 0.12 (–2.0 to 2.28) 0.911
Baselineb 27.2 (13.6), 77 28.9 (15.9), 100
12 months 29.1 (15.4), 77 31.7 (15.5), 100
12 months – baseline 1.9 (8.6), 77 2.8 (11.2), 100 0.48 (–2.53 to 3.49) 0.754
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Analysis is shown in Table 11 of the secondary outcomes self-reported by participants after the 6- and
12-month home visits and returned by post. No statistically significant differences between the groups
overall were found for these outcomes.
Subgroup analysis
In the statistical analysis plan, a subgroup analysis excluding participants with severe disease by virtue of a
MDS-UPDRS score of ≥ 59 or H&Y stage 4 was prespecified. These analyses yielded very similar results to
those shown in Table 6 for the group as a whole.
TABLE 8 Secondary outcomes at 6 and 12 months (continued )
Outcome measure Visit
Trial group, mean (SD), n
Mean difference
(95% CI)a p-valuePDSAFE (N= 238) Control (N= 236)
GDS (0–15, higher
values worse)
Baselineb 7.7 (2.3), 154 7.7 (2.1), 183
6 months 7.8 (2.5), 154 8.0 (2.5), 183
6 months – baseline 0.3 (1.8), 154 0.2 (1.9), 183 –0.02 (–0.42 to 0.39) 0.942
Baselineb 7.7 (2.1), 96 8.0 (2.2), 118
12 months 7.8 (2.5), 96 8.5 (2.4), 118
12 months – baseline 0.2 (2.0), 96 0.4 (1.7), 118 –0.21 (–0.72 to 0.31) 0.421
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period, H&Y scale stage and the outcome in
question assessed at baseline.
b Baseline results restricted to existing participant assessment at 6 months.
Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC.
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TABLE 9 Inability to perform the CST at the 6- and 12-month visits
Period
Trial group, n/N (%)
PDSAFE/control
OR (95% CI) p-valueaPDSAFE Control
Baseline 45/236 (19) 45/235 (19)
Baseline among participants
with a 6-month assessment
29/188 (15) 35/213 (16)
6 months 27/188 (14) 47/213 (22) 0.61 (0.37 to 1.02) 0.076
Baseline among participants
with a 12-month assessment
15/119 (13) 21/134 (16)
12 months 23/119 (19) 38/134 (28) 0.66 (0.37 to 1.17) 0.208
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to
screening, log rate of falling in the pre-randomisation falls collection period, H&Y scale stage and CST ability at baseline.
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In addition, subgroup analyses were prespecified among those with reported freezing of gait or not and
among the cognitively impaired (i.e. MoCA score of ≤ 25) and not impaired (i.e. MoCA score of ≥ 26) at
baseline. The results of these analyses, relating to the period 0–6-months following randomisation in the
case of the falling outcomes, and to the 6-month home visit in the case of the MINI-BESTest and FES-I, are
shown in Figure 7. There was a significant interaction between the PDSAFE intervention effect and freezing
status (p = 0.025). Among those with Parkinson’s who experienced freezing, the OR of repeat falling was
doubled in the PDSAFE group (2.04, 95% CI 1.03 to 2.70; p = 0.042) compared with the control group. With
a p-value for interaction of 0.088, there was a trend of differential PDSAFE effect in relation to the rate of
falling according to the prespecified MoCA subgroups, with a FRR of 1.19 (95% CI 0.88 to 1.61; p = 0.255)
in the cognitively impaired subgroup (i.e. MoCA score of ≤ 25). Subgroup-specific effect sizes and p-values
are given in Appendix 8 (Table 29) and Appendix 9 (Table 30) for the analyses of repeat falling and fall rates,
respectively.
The results of further subgroup analyses exploring the differential effects of PDSAFE on the basis of tertiles
of MDS-UPDRS, MoCA and the retrospective falls question asked at screening are shown in Figure 7.
A further prespecified subgroup analysis excluding the most severe participants according to MDS-UPDRS
(≈10% were excluded) did not show statistically significant PDSAFE-to-control effects for falling outcomes.
In an exploratory subgroup analysis, only the middle tertile showed a PDSAFE reduction in falls, whereas the
most severe tertile showed an increase in falls rate. A similar pattern was found across the tertiles according
to the retrospectively reported number of falls in the year prior to screening, with p-value for interaction of
0.050 and only the middle tertile showing a PDSAFE reduction in falls. The analysis of subgroups defined by
tertiles of MoCA, MDS-UPDRS and the number of falls, retrospectively, reported in the year prior to screening
were not specified in the protocol, but were carried out to explore further the prespecified subgroups in
relation to MoCA, and, because Canning et al.40 report prespecifying subgroup analysis in relation to falls
history, the MDS-UPDRS and cognition.
The same subgroup analyses were also explored with respect to near-falls and other secondary outcomes,
and results for near-falling, Mini-BESTest and the FES-I are also shown in Figure 7. The effect of PDSAFE
did not differ significantly across subgroups for any of these three outcomes, with interaction p-values
> 0.05; in general, the PDSAFE effect can be seen to be more consistent across the various parts of the
participant group. Details of these analyses are shown in Appendices 8–12 (Tables 29–33).
TABLE 10 Change from baseline in CST assessed at the 6- and 12-month visits
Period
Trial group, median (IQR); n
p-valueaPDSAFE Control
Baseline among participants
with 6-month assessment
14 (11–18); 159 14 (11–18); 178
6-month assessment 12 (10–15); 161 13 (10–16); 166 0.041 (n = 401)
Baseline among participants
with 12-month assessment
14 (11–17); 104 14 (12–18); 113
12-month assessment 12 (9–14); 96 13 (11–15); 96 0.163 (n = 253)
a Mann–Whitney U-test incorporating participants unable to perform CST and times from participants able to
perform CST.
Adapted from Chivers Seymour et al.49 © Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC. No
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Appendices 13 and 14 (Tables 34 and 35) repeat the subgroups analyses for the repeat falling and falls rate
outcomes shown in Tables 6 and 7, but include corresponding analyses carried on a per-protocol basis.
Although there are some differences (including changes in p-values around the cut-off point of 0.05),
the overall picture remains similar to that of Figure 7. Appendices 15–17 (Tables 36–39) detail subgroup
analyses for the MDS-UPDRS, PASE, PDQ-39 and GDS and these are displayed graphically in Appendix 18
(Figure 13).
Serious adverse events
As described in Chapter 2, Safety reporting, for this trial a SAE was defined as a death, a life-threatening
event or a new disability leading to prolonged hospitalisation, attributed to the trial intervention. No SAEs
were reported in this trial. From the CONSORT flow diagram (see Figure 6), it can be seen that, in total,
three participants died in the PDSAFE group and five in the control group, from causes unrelated to the
trial protocol.
TABLE 11 Change from baseline in secondary outcomes, returned postally following the 6- and 12-month visits:
PASE, PDQ-39 and GDS – whole group
Assessment and visit
Trial group, mean (SD) Mean difference
(PDSAFE – control)
(95% CI)a p-valueaPDSAFE (N= 238) Control (N= 236)
PASE (0–400, lower values worse)
Baselineb 107.8 (73.5); n = 153 100.1 (67.1); n = 177
6 months 110.2 (70.4); n = 153 100.6 (68.0); n = 177
6 months – baseline 2.4 (50.8); n = 153 0.5 (49.5); n = 177 –1.05 (–11.3 to 9.21) 0.841
Baselinec 108.1 (71.9); n = 98 98.6 (61.1); n = 115
12 months 99.4 (72.8); n = 98 87.6 (62.3); n = 115
12 months – baseline –8.7 (53.0); n = 98 –11.0 (48.5); n = 115 –0.55 (–13.9 to 12.8) 0.935
PDQ-39 (0–100, higher values worse)
Baselineb 27.4 (14.3); n = 126 28.7 (15.9); n = 153
6 months 28.3 (15.0); n = 126 29.5 (16.5); n = 153
6 months – baseline 0.8 (8.3); n = 126 0.9 (9.0); n = 153 0.12 (–2.0 to 2.28) 0.911
Baselinec 27.2 (13.6); n = 77 28.9 (15.9); n = 100
12 months 29.1 (15.4); n = 77 31.7 (15.5); n = 100
12 months – baseline 1.9 (8.6); n = 77 2.8 (11.2); n = 100 0.48 (–2.53 to 3.49) 0.754
GDS (0–15, higher values worse)
Baselineb 7.7 (2.3); n = 154 7.7 (2.1); n = 183
6 months 7.8 (2.5); n = 154 8.0 (2.5); n = 183
6 months – baseline 0.3 (1.8); n = 154 0.2 (1.9); n = 183 –0.02 (–0.42 to 0.39) 0.942
Baselinec 7.7 (2.1); n = 96 8.0 (2.2); n = 118
12 months 7.8 (2.5); n = 96 8.5 (2.4); n = 118
12 months – baseline 0.2 (2.0); n = 96 0.4 (1.7); n = 118 –0.21 (–0.72 to 0.31) 0.421
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period, H&Y scale stage and the covariate value
at baseline.
b Restricted to participants with a 6-month assessment.
c Restricted to participants with a 12-month assessment.
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FIGURE 7 Overall and subgroup analyses of falling and near-falling outcomes during 0–6 months and secondary outcomes at 6 months. a, Test for interaction of PDSAFE
contrast differing across subgroups, controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening,
log rate of falling in the pre-randomisation falls collection period, H&Y scale stage and the outcome in question assessed at baseline. Adapted from Chivers Seymour et al.49
© Author(s) [or their employer(s)] 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by the BMJ Publishing Group Ltd.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is
given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. NFRR= near-falls rate ratio.
STA
TISTICA
L
TRIA
L
RESU
LTS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
32
Information on hospitalisations was self-reported by participants during the baseline, 3-month, 6-month
and 12-month home visits. At each visit, participants were asked about any hospitalisation that occurred
since the previous visit and its duration. In the first 6 months following randomisation, nine PDSAFE and
20 control group participants reported hospitalisations; of these, one PDSAFE participant reported two
stays. During the 6- to 12-month follow-up period, 18 PDSAFE and 21 control group participants reported
hospitalisations; of these, two PDSAFE and four control group participants reported two stays.
Information on fractures was obtained from a variety of sources, including fall-specific information
associated with the falls diaries and from self-reported hospitalisations. In the first 6 months following
randomisation, five fractures were reported by PDSAFE participants and nine by control group participants;
during the period 6–12 months post randomisation, PDSAFE participants reported seven fractures and
control group participants reported three fractures.
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Chapter 5 Qualitative process evaluation: part 1
The next two chapters describe the two-stage qualitative process evaluation. This chapter explores theexpectations and experiences of participants in the PDSAFE intervention in a longitudinal qualitative
study.
Aims
l To explore the expectations of people with Parkinson’s about the intervention.
l To explore the experiences of people with Parkinson’s about participation in the intervention, including
its perceived impact.
l To gain insight into the barriers to and facilitators of participating in the intervention.
Qualitative methods
Design
A longitudinal qualitative study was conducted alongside the main PDSAFE RCT. The qualitative study
drew on the principles of grounded theory50 as follows:
l gathering rich, in-depth data through ‘intensive interviewing’
l conducting detailed analyses, which become increasingly theoretical
l using line-by-line coding to ensure a high level of familiarity with the data
l writing reflective memoranda to assist with data interpretation
l employing theoretical sampling.
Theoretical sampling refers to a strategy that ‘allows the researcher to generate theoretical insights by
drawing on comparisons among samples of data’.51 As per the theoretical sampling strategy, participants
with a range of different characteristics were included, to confirm that the qualitative findings were
broadly applicable to the variety of people with Parkinson’s included in the larger sample. Previous
research has suggested that these key characteristics might affect participants’ experiences of the PDSAFE
intervention.
Longitudinal qualitative studies are comparatively rare in health research, although they have been
identified as particularly useful when exploring conditions of change such as might occur in those with
long-term and progressive illnesses, as in this study.52
Methods and data collection tools
Qualitative semistructured interviews were conducted to explore the experiences of participants in the
intervention arm of the PDSAFE trial; they were chosen for their capacity to generate rich, in-depth data
about the social realities of participants, in context.53
Two qualitative interviews were carried out with people from a subset of those who participated in the
PDSAFE intervention arm of the trial (see the following section). The initial interview took place after
randomisation [time 1 (T1)], but prior to commencement of the intervention. It focused on the impact of
Parkinson’s and the participants’ expectations of the intervention. The second interview was carried out
6 months later (T2), and elicited information about participation in the intervention arm of the trial (Table 12).
Because the focus was on exploring participants’ experiences of the intervention, the control group were not
included in the qualitative substudy.
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Initial interview schedules were informed by scoping the relevant literature, which was carried out by
referring to study protocols for primary questions of interest. Interview schedules were developed
iteratively, in collaboration with the main trial team and stakeholders (including trained physiotherapists,
rehabilitation experts and qualitative researchers), other clinical and academic experts (i.e. two qualitative
researchers, two social networks experts) and two expert patients. Both interview guides were piloted
with expert patients, to ensure that the questions made sense, and revised as necessary. The qualitative
Research Fellow employed on the PDSAFE trial completed all the interviews at T1 and T2.
Sample and recruitment
Recruitment for the qualitative study took place from only the first four trial sites (Southampton,
Portsmouth, Bournemouth and Poole, and Exeter), so that the qualitative Research Fellow had sufficient
time to carry out both sets of interviews and complete analysis.
Participants who were eligible for the PDSAFE trial (see Chapter 2) were invited to ‘opt in’ to qualitative
interviews at the time of recruitment to the main trial. Only those participants randomised to the
intervention arm were approached to participate.
Theoretical sampling was used to represent the views of participants with a range of characteristics,
and included:
l location (at least 10 people from each site)
l age (at least two people aged < 80 years and two aged > 80 years in each site)
l gender (a minimum of two men and two women per site)
l severity of disease (at least one participant per site with disease severity of H&Y scale stages 1, 2 or 3/4)
l number of falls [at least one person experiencing a single fall in the previous 12 months, one who had
repeat falls (more than one fall and fewer than 10 falls in the last 12 months) and one who had
multiple falls (more than 10 falls in the previous 12 months) per site]
l time since diagnosis [at least one person per site who had been diagnosed for (1) ≤ 5 years,
(2) 6–10 years, (3) 11–15 years and (4) ≥ 16 years]
l living status (at least one person who lived alone per site).
Procedure
During the screening visit for the PDSAFE main trial, assessors asked participants if they would be interested in
participating in the qualitative substudy, and left a qualitative study patient information sheet if participants
expressed an interest. If a participant was randomised to the intervention arm, the qualitative Research Fellow
telephoned them to answer any questions they had and to explore if they were still interested in participating
in the qualitative substudy. Once their participation was confirmed, a convenient time for the first qualitative
interview (before the treatment with the therapist commenced) was identified.
TABLE 12 Content of interview guides
Content of interview guide
T1 (after randomisation
but prior to start of intervention) T2 (6 months after initial interview)
l Introduction and impact of Parkinson’s
l Typical day
l Managing movement and stability
l Experiences of previous therapy and expectations about treatment
l Perceived benefits and challenges of treatment
l Looking forward to/not looking forward to treatment
l Anything else
l Introduction and changes
l Experience of the intervention
l Facilitators of and barriers to participation
l Perception of falls and mobility since T1
l Expectations vs. experiences
l Anything else
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The Research Fellow then scheduled a second follow-up interview 6 months later. Just prior to the
scheduled second interview, the researcher checked with the trial manager and administrator that the
participant had not withdrawn from the trial for any reason and then telephoned the patient to confirm
that the second scheduled interview was still convenient.
Ethics
Ethics approval and relevant NHS trust governance approvals to carry out this qualitative study were
covered within the main trial approvals processes. All data were anonymised, and information about
participants was kept separate from the data in locked filing cabinets. The qualitative Research Fellow did
not contact potential participants until they had expressed an interest in taking part, and participants also
had the opportunity to clarify any queries before confirming participation. Written informed consent was
taken immediately before each interview.
Qualitative analysis
Interviews were transcribed verbatim and then checked for accuracy by a member of the research team
who had carried out the data collection. Analysis of interview transcripts was carried out using inductive
thematic analysis, in which dominant themes were identified through close examination of the data.54,55
Interview transcripts were read and re-read to ensure a high level of familiarity with the data before
line-by-line coding. A coding manual was then created to define emerging codes and themes for initial
interviews at T1 and T2, and these codes were then applied to the remaining transcripts. The coding
manual was developed iteratively and revised throughout the coding process to ensure that the codes
adequately reflected the data. The coding manual was discussed and agreed by core members of the
research team at various stages of the coding process.
All interviews were transcribed and analysed by the qualitative Research Fellow. In addition, two T1 and
three T2 interview transcripts were independently coded by the senior investigator with qualitative
expertise, and discussed with the Research Fellow to promote thorough, careful and reflexive practice in
the development of the coding framework.53
Findings
Participant characteristics
Forty-two participants were recruited at T1. Of these, 37 were interviewed at T2, although two of these
participants had withdrawn from the main RCT. Consequently, 35 participants remained in the trial, and
completed interviews at T1 and T2. Their demographic characteristics are shown in Table 13.
Participant characteristics in the qualitative sample were comparable to the overall trial sample, with the
exception of time since diagnosis (the mean was slightly higher in the qualitative sample), number of falls
in the previous 12 months (again, the mean was slightly higher in the qualitative sample) and living status
(with slightly more participants in the qualitative sample living alone). The higher numbers of people
within the last two categories reflect the theoretical sampling, in which we deliberately sampled for these
characteristics. All transcripts were included in the thematic analysis.
Findings from the thematic analysis
The transcripts were analysed in two tranches: first, those from the first set of interviews at T1, followed by
the second set of interviews at T2.
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TABLE 13 Characteristics of participants in the qualitative substudy
Characteristic
Interview
at T1 only
(n= 42)
Interviewed at T1 and
T2 and remained in
trial and qualitative
study (n= 35)
Interviewed at
T1 and T2, but
withdrawn from
trial (n= 2)
Interviewed
at T1 and T2
(n= 37)
Gender, n (%)
Male 24 (57) 18 (51) 2 (100) 20 (54)
Female 18 (43) 17 (49) 0 (0) 17 (46)
Age range (years) 57–84 57–84 68–79 57–84
Age group (years), n (%)
≤ 59 2 (5) 2 (6) 0 (0) 2 (5)
60–69 15 (36) 11 (31) 1 (50) 12 (32)
70–79 20 (47) 17 (49) 1 (50) 18 (49)
≥ 80 5 (12) 5 (14) 0 (0) 5 (14)
Mean age (years) 71 71 70 71
H&Y scale stage, n (%)
1 4 (10) 4 (11) 0 (0) 4 (11)
2 12 (28) 10 (29) 1 (50) 10 (27)
3 23 (55) 20 (50) 1 (50) 21 (57)
4 3 (7) 1 (3) 0 (0) 2 (5)
Time since diagnosis (years), n (%)
< 5 15 (36) 15 (36) 0 (0) 14 (38)
6–10 7 (17) 7 (17) 0 (0) 5 (14)
11–15 13 (31) 13 (31) 1 (50) 12 (32)
≥ 16 8 (19) 8 (19) 1 (50) 6 (16)
Time since diagnosis (years) (range) 1–35 1.5–21 13–35 1.5–25
Mean time since diagnosis (years) 10 9.2 24 10.4
Falls in previous 12 months, n (%)
1 11 (26) 10 (29) 1 (50) 11 (31)
2–10 24 (57) 19 (54) 1 (50) 20 (57)
> 10 3 (7) 2 (6) 0 (0) 2 (6)
> 100 4 (10) 4 (11) 0 (0) 4 (11)
Range of falls in the previous
12 months by groups
1 to ≥ 200 1 to ≥ 200 1 to 4 1 to ≥ 200
Mean number of falls in the
previous 12 months
32.5 37.5 2.5 35.7
Living status, n (%)
Lives alone 13 (32) 10 (29) 2 (100) 12 (33)
Living with partner 27 (64) 23 (66) 0 (0) 23 (62)
Living with relative 1 (2) 1 (2.5) 0 (0) 1 (2.5)
Living with carer 1 (2) 1 (2.5) 0 (0) 1 (2.5)
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For the first set of interviews, 13 main themes were generated, including 40 subthemes and 104 codes.
The 13 main themes were:
1. Parkinson’s diagnosis
2. Parkinson’s symptoms and experience of Parkinson’s
3. reflections on the forthcoming PDSAFE intervention/therapy
4. previous experience of rehabilitation therapies
5. effect of Parkinson’s on day-to-day routines and life
6. effect of Parkinson’s on mobility
7. losses attributed to Parkinson’s
8. adaptation
9. falls and risk
10. well-being and Parkinson’s
11. other health and social issues
12. trial and study participation
13. importance of social networks.
The second interviews at T2 generated 17 main themes, which included 33 subthemes and 75 codes.
The 17 main themes comprised:
1. activities
2. after the sessions ended
3. experience of the assessor sessions
4. barriers to the PDSAFE intervention
5. deteriorating mobility
6. equipment and technology
7. experience of physiotherapy and other exercise outside of PDSAFE
8. facilitators of continuing with the PDSAFE intervention
9. falls
10. impact and treatment of Parkinson’s condition
11. impact of health condition
12. impact of condition
13. impact of PDSAFE intervention
14. PDSAFE physiotherapy sessions
15. strategies
16. therapist input
17. other.
These themes and supporting data have been organised in the rest of this chapter to reflect the three main
research aims for the qualitative study. The following four main themes will be discussed below:
1. expectations of participants about the PDSAFE intervention
2. experiences and perceived impact of the PDSAFE intervention for participants
3. barriers to participating in the PDSAFE intervention
4. facilitators of continuing with the PDSAFE intervention.
The following sections include verbatim extracts from interview transcripts. The interviewer was the
qualitative Research Fellow.
Expectations of participants about the PDSAFE intervention
The first interview guide included a question enquiring about previous therapies, rehabilitation and experiences
of exercise, in order to better understand participants’ expectations about the intervention. Almost all of the
participants had experienced some form of physiotherapy in the past, although not necessarily in relation to
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their Parkinson’s. This previous experience of rehabilitation and exercises appeared to influence participants’
expectations about the intervention, with many anticipating that this would involve a programme of exercises:
Well, as I said, hopefully they will come up with a series of exercises that I can do, hopefully every day,
or most days, which will keep me a bit mobile and stop me getting stiff. I dread the thought of being
really really stiff and not being able to move and get around; I don’t want that to happen.
Participant with Parkinson’s (21/057)
(Throughout the report, the numbers at the end of the quotation sources indicate anonymised participant
identifier/anonymised site identifier.) Some participants described in some detail what they expected, which
included tailored exercises, stretching, freezing exercises and exercises for postural control, co-ordination,
stiffness and muscle tone:
I’m hoping that they will give me some useful exercises that will deal with, well, the balance; now
the question in my mind is whether they will go on from that and talk about also posture, which is
something I desperately need and general muscle tone I suppose, so I’m sort of hoping that they will
cover all three things.
Participant with Parkinson’s (43/017)
I anticipate that she will do things like check my balance and um, my mobility and coordination and
give me exercises to help improve my balance.
Participant with Parkinson’s (54/040)
A few participants highlighted everyday tasks that they anticipated the programme might help with,
such as getting dressed, and also wider benefits, such as improvement in confidence and helping to
sustain social contacts:
Yes, so, that’s really why I put my name down [for participating in the trial], because I thought, well
anything that can help me keep going as long as possible, because I have got one daughter in Dubai
and one daughter in Germany, so, and no daughters in England [laughter] and they are not likely to
be coming back, so ah, I want to keep going.
Participant with Parkinson’s (43/058)
Participants appeared to value the fact that the intervention was to be delivered at home, citing reasons
such as convenience, problems travelling because of poor mobility and relief at not having to visit hospital
or clinic sites, or park a car. One person highlighted that, although they were happy for the PDSAFE
intervention to take place at home, they felt that appointments outside the home were important to fulfil
the need to ‘broaden outlook’ on life.
Most participants talked about anticipated benefits of the PDSAFE intervention. These included general
improved mobility, as well as enhanced functional and physical improvements, for example better postural
control, stability, posture, co-ordination, muscle tone and pain control, help with FoG, maintenance or
improvement of mobility and walking with more confidence:
Well, as I said, hopefully they will come up with a series of exercises that I can do, hopefully every day,
or most days which will keep me a bit mobile and stop me getting stiff. I dread the thought of being
really really stiff and not being able to move and get around; I don’t want that to happen.
Participant with Parkinson’s (21/057)
Interviewer: Is there anything that you are hoping that you might achieve from the therapy sessions?
Participant with Parkinson’s (21/053): Well, maybe that I can walk without, walk with more confidence
possibly, and also I have tried using a stick before and I don’t like using a stick because I don’t think
it helps your posture. My posture at the moment is pretty good and I’ve seen so many people with
sticks, really bent over and I’d like to be taught how to use, if need be, a stick properly.
QUALITATIVE PROCESS EVALUATION: PART 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
A few participants highlighted more general, functional tasks and a desire that partaking in the
intervention would maintain or improve their general independence. The wish to help others by taking
part in a trial was also another major motivator for participation in the study:
Interviewer: Anything that you are hoping it might help with?
Participant with Parkinson’s (32/061): Mainly co-ordination and manipulation of such things as my
buttons. If I can remain independent so much the better.
Interviewer: OK, so is there anything you think it might help you achieve?
Participant with Parkinson’s: Helping others with Parkinson’s, if they can learn something about
physio[therapy] and how it can help people, so that it helps others in the future.
Interviewer: OK, that’s important, anything you would like to achieve personally?
Spouse: Cure Parkinson’s! I’m joking.
Participant with Parkinson’s (32/023): But it can’t do that, can it?! I hope it will help give me my
independence back a bit, or some independence, some mobility, I miss my independence. Parkinson’s
is so frustrating.
A small minority of people expressed feelings of anxiety or nervousness about the initial therapy sessions;
some of this was related to perceived expectations about what it might involve and the intensity of the
sessions. Others voiced that they had not previously had success with physiotherapy and so wondered how
beneficial it might be:
I will be a bit nervous until I know quite the intensity of it, everybody’s a little bit aware you know
that, I mean, what does intense mean?
Participant with Parkinson’s (21/049)
Perceived challenges or barriers to participation included concern about having a ‘bad day’ or an ‘off day’,
including anxieties about medication:
I suppose one thing that might be worrying is if the physio[therapist] comes round to do some
exercises and I am having an off spell ‘cause I have, you know, sometimes I’ve got a day that’s like
that and it makes a difference; sometimes the drugs haven’t kicked in properly for whatever reason
and it might be a down spell, an off spell, and I might sort of have to, you know, that might have to
be taken into account.
Participant with Parkinson’s (21/039)
Some also had concerns about the time commitment, and expressed ambivalence about or dislike of
physical activity:
I mean the thought of doing it every day for 6 months is a bit daunting and I said at the time, I am
not absolutely sure I can promise that every day.
Participant with Parkinson’s (21/057)
Interviewer: And anything you’re not looking forward to at all?
Participant with Parkinson’s (21/026): Well, the, the further drain on my time and, you know, doing
physical exercise is not my favourite thing.
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At the time of the second interview, participants were asked if their expectations about the intervention
had been fulfilled. The majority were not surprised by what they had been asked to do, and were pleased
with the content of the PDSAFE intervention. Those few with unrealistic or inappropriate expectations
acknowledged this at the second interview:
Interviewer: Did the physiotherapy meet your expectations, was it what you thought it would be?
Participant with Parkinson’s (43/034): Yes, I suppose generally there was not much else she could do
really to make sure that everything I did was done correctly and that I understand what it was doing
and why it helped.
I knew it would be personal to me but I didn’t expect it to be so personal, I know that sounds a bit
ambiguous but she almost assessed how I was doing each time and geared it specifically to what I
could and couldn’t do.
Participant with Parkinson’s (54/040)
A number of participants suggested that they had not fully appreciated the time and commitment the
intervention programme would take, sometimes suggesting that the programme was onerous or a ‘bind’.
This reflected anxieties and concerns from the first interviews about being able to find time in already busy
schedules to complete the programme daily:
Interviewer: So it was not quite what you thought it was going to be . . .
Participant with Parkinson’s (32/008): No. It was alright in the winter when you, when I have got
nothing to do, but when the vegetables started to come, it became a bit of a bind trying to find time
to do it, and I wanted to pack it in.
The experiences and perceived impact of the PDSAFE intervention for participants
During follow-up interviews, participants were asked to describe the content of the PDSAFE intervention.
All of the participants spoke about the exercises and strategies that they were encouraged to use. Most
participants were able to describe these in detail, and described a range of exercises.
Most people found the level of the programme acceptable and usually recognised the progressive nature
of the exercises over time:
They got harder [laughs] . . . The expectations were greater, um, for example I could just about put
one foot in front of the other and walk the line, like you do if you are drunk, if I did it quickly; so then
the next stage was to do it slowly and it is much more difficult and so it was graded.
Participant with Parkinson’s (43/058)
Participants also described a variety of strategies that they had been taught as part of the intervention,
including swaying from side to side to promote motion, not cutting corners, walking with one foot in front
of the other, using wider steps so as not to shuffle, having feet further apart to prevent falling and picking
up feet.
Interviewer: Did the physio[therapist] give you any sort of strategies to use or hints?
Participant with Parkinson’s (54/069): Well, if I ground to a halt, because I have been freezing a little
bit, just to psych meself up and to count from one to four and then I could go [i.e. move] on the four.
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Most participants commented on the expectation that they would engage with the programme daily, or as
close to this as possible, and tried to conform to this, although this appeared to be challenging for some,
particularly if they had other commitments on the same day:
The idea is to do the exercises every day, she said, if you could do them three or four times a week
that would be sufficient, not ideal, but it would be sufficient, so I did try.
Participant with Parkinson’s (21/057)
The PDSAFE intervention involved the use of a range of equipment, including a weighted vest or jacket,
the step, the exercise folder and log, a metronome and/or a DVD. Some recognised that the intensity
of the exercises increased with the use of equipment:
I would do the exercise, I’d be out the garden doing it out there during the summer and using the
step for the legs . . . there in the sunshine, and then I got a weighted jacket, which was harder,
more challenging.
Participant with Parkinson’s (21/039)
Experiences of using the equipment were mixed, with many participants commenting particularly on the
weighted vest:
I was doing stepping on that [i.e. the step] and that was fine, um, and then she put little feet on it to
make it harder, but every time she came, she made it a little bit more difficult and the real shock was
when she came with the weighted vest. Have you seen the weighted vest? It’s a torture chamber,
honestly, so I picked it up and I said ‘Am I supposed to be wearing this? . . . I can hardly lift it’ and it
actually weighed 14 pounds and I had to really sort of struggle to get it on and then do it up and I
had to do the stepping with this vest on. Well, I couldn’t believe it, I said ‘Are you sure this is doing
me good?’ and she said ‘Yes, [laughter] it definitely is’ and then after I had done that for a few weeks
she wanted to put some more weights in it. I said ‘Look I am sorry, but this is really as much as I can
cope with’.
Participant with Parkinson’s (21/057)
Although views about use of the equipment were mixed, a small number of participants were disappointed
that the vests, steps and folders had to be returned once the physiotherapy visits ceased.
Several people mentioned that the filming and resulting DVD helped them to understand issues with their
gait or posture:
There was one of me, my posture, which was, I did not mean to be alarmed because I knew my
posture was awful. I did try, as it is one of the things she has helped me with quite a lot actually is the
posture and, erm, I suppose it has improved a bit. Well anyway, the DVD was helpful in seeing how
awful it was.
Participant with Parkinson’s (21/026)
However, more commonly, participants disliked, or experienced problems with the technology. Some felt
that the DVD/metronome was unnecessary or did not help them, some did not use it and some preferred
to do exercises to counting or using the beat of music. Some participants described technical problems
with the DVD or would have preferred to see the programme on a portable device such as a tablet.
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Follow-up interviews also explored the perceived impact and benefits of the PDSAFE intervention for those
taking part. The majority of participants felt that they had made some progress in terms of mobility
(including improved posture, postural control, functional strength, walking better, falling less frequently
and/or enhanced control of freezing symptoms). Some also described improvements in functional activities:
[Laughs] I thought ‘what have I let myself in for?’ initially, but once you start doing the exercises and
you know you can do them, you know, like putting my socks on was very difficult and that’s better
now, stretching, that helped a lot.
Participant with Parkinson’s (54/074)
In follow-up interviews, over one-third of participants reflected that either their falls had reduced or they
were better able to recognise falls triggers since embarking on the PDSAFE intervention:
I think they [i.e. falls] are less frequent because I am thinking in my mind all the time, walk sensibly,
open this door sensibly, do this sensibly, because otherwise you are going to fall.
Participant with Parkinson’s (32/014)
Other perceived benefits of the PDSAFE intervention included increased awareness of limitations, for
example recognising the need to plan things carefully, increased awareness of safety and recognising poor
posture. Linked to this was enhanced recognition of the need to ‘slow down’ and ‘not rush(ing) around’:
I think the most useful thing, probably, is that I have had to learn [pause], to slow down, . . . I mean
before I would just dash everywhere, not run I don’t mean, but you know just sort of walk and then
I would get my feet in a muddle and you know all that sort of stuff and I think that is probably the
thing I have learned most, to control that so that, you know, if I am in a hurry I can still function
without fear of tripping.
Participant with Parkinson’s (43/050)
Around half the participants interviewed at T2 also spoke of increased confidence, independence and
general well-being:
It made you feel you could do it independent. It was a good help.
Participant with Parkinson’s (32/054)
I feel more confident.
Participant with Parkinson’s (43/027)
Although most participants interviewed at follow-up perceived some improvements, physically,
functionally, in falls reduction or more generally (as described above), a small number felt that they had
not experienced any benefit from participation in the PDSAFE intervention. Several of these participants
simply questioned whether or not the intervention could make any difference to them in the face of a
deteriorating condition, even if they felt that the programme was, in itself, good.
Barriers to participating in the PDSAFE intervention
During the follow-up interviews at T2, participants were asked for their views about the barriers to and
facilitators of taking part in the PDSAFE intervention. The time commitment to complete the exercise
programme was identified as one of the major barriers to continued participation, particularly towards
the end of the programme and beyond. Participants often described the programme as being fairly
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time-consuming or requiring a big commitment. Although for some this was not an problem, others found
this challenging, particularly if they already led busy lives, which seemed to be a particular issue for those
whose Parkinson’s was not so advanced:
There was nothing difficult about it; the only difficulty about it was me staying on target with the
exercises between the visits. I found, because I lead a fairly active life anyhow, I couldn’t always find
the time to get to do the regular exercises.
Participant with Parkinson’s (43/055)
A lack of motivation was also commonly offered as the reason for giving up the exercise programme,
particularly when visits from the treating physiotherapist became less frequent or stopped altogether:
It would be trying to do it every day [is the most difficult part]. But that day, I know that if I do it I
would be better and more flexible and more co-ordinated but it is just motivating myself to do it
sometimes. It’s the hardest, that’s . . . it’s the hardest thing to do.
Participant with Parkinson’s (54/040)
However, not all participants ceased the programme at the end of the visits from the physiotherapists
(see the following section). Another common barrier alluded to previously, was use of the programme
equipment or technology. The two items most often mentioned as problematic were the weighted vest
and the DVD with metronome.
For some people, illness, injury and other life events, such as a family death, prevented them from
participating fully or at all in the programme. Illnesses and injuries mentioned during the interviews as
barriers included problems with knee and shoulder, heart attack, shingles, pain, cancer and high blood
pressure. Difficult life events included bereavements and family illness:
I had one week off in March when I was away for the week and then in the beginning of June my
husband died and that threw us all out completely.
Participant with Parkinson’s (32/014)
Participants also described their experience of ‘off’ or ‘bad’ days as another barrier. These days were
characterised by difficulty in engaging with the programme, particularly at times when medication was not
optimised, participants felt particularly ill or symptoms were at their worst:
And sometimes, you know, with Parkinson’s you have your off periods where your drugs haven’t
kicked in and there are times when I am having an off evening and I try and do my exercises, but the
off spell seemed to be longer than normal, so I might have to miss it then, so it’s just choosing the
time of day.
Participant with Parkinson’s (21/039)
Finally, a couple of barriers mentioned by just a few people included fear and forgetting to engage with
the programme.
Facilitators of continuing with the PDSAFE intervention
In the same way that a reduction in and eventual cessation of visits from the treating physiotherapist acted
as a barrier to continued participation in the programme, the knowledge that the physiotherapist would be
visiting again acted as a facilitator of participation for participants. Interviewees commented that they tried
harder when they knew that the physiotherapist would be returning and expressed the view that they did
not want to disappoint her. Some mentioned the importance of reinforcement for their efforts provided by
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the therapist, and looked forward to her visits. A few suggested that they engaged in the exercises only
when the therapist was present. Even the occasional participant who did not feel that they gained a lot
from the programme appeared to value the therapist’s presence:
Also, having the physiotherapist visiting regularly, that gives you something to aim for, like, when you
know that she is coming next week and you want to make sure that everything is up to date and
that you are doing the exercises properly, so having that sort of check and balance if you like helps
to keep . . . and it ran very smoothly.
Carer (21/056)
Support and encouragement from one’s partner, spouse or carer was another important facilitator.
This could take several forms, for example the partner or carer completing the exercises alongside the
participant, or reminding the participant to complete them:
And it was nice as well because she included me, it was really nice because obviously I would do the
exercises with him, but she didn’t make me feel that I shouldn’t be there and she included me, which I
thought was really nice. I thought at first did she just want me to go out of the way and think I was
interfering, but no she was really good. Obviously, I like to know what is happening, because when I
do them with him I would like to know what she is doing. That is quite good.
Spouse (43/059)
Another facilitator mentioned by participants was the written information about the PDSAFE programme
provided in a blue folder to those taking part in the intervention arm of the trial:
Well, on every session, whenever she came, we started straight away with the list of exercises which
she gave me, which she showed me . . . I had a list, a chart that she gave me, so I could tick off each
one as I did it.
Participant with Parkinson’s (43/050)
For some, particularly those with already busy lives, the intervention was easier to engage with if
integrated into their daily lives. Participants found novel ways of building the exercises into their daily
routines, for example doing them while completing chores, gardening or while in the kitchen. Others
would integrate exercises, for example walking or stepping exercises, into leisure activities such as dog
walking, playing golf or simply walking into town, or adapted exercises to their environment:
I did them in the morning. I did them while the kettle was boiling. Once you knew what to do it was
quite simplistic so I would do my marching you know, and then I would go and put the kettle on and
I would do this bit and that and by the time I went out in the morning it had all been done.
Participant with Parkinson’s (43/058)
Other facilitators of the PDSAFE intervention included seeing direct improvements or feeling a sense of
progress.
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Chapter 6 Qualitative process evaluation: part 2
This second qualitative process evaluation chapter reports on the expectations and experiences of thephysiotherapists who delivered the PDSAFE intervention, which were explored using a series of
individual interviews.
Overview
The second stage of the qualitative process evaluations involved conducting in-depth, semistructured
interviews with a group of the treating therapists. Six of the treating therapists (not those trained to
provide cover) were interviewed by an independent researcher. Data were managed and analysed using
framework analysis56 and five themes emerged:
1. views on the PDSAFE concept and therapist involvement
2. benefits and limitations of the PDSAFE intervention
3. influences on intervention success
4. perceptions of patients’ experiences and engagement
5. PDSAFE intervention usability and transferability.
Theme 1: views on the PDSAFE concept and therapist involvement
This theme describes therapists’ thoughts on the concept of PDSAFE, their involvement in delivering the
programme and the challenges they faced.
Views on the PDSAFE concept and study involvement
On a conceptual basis, therapists responded positively towards PDSAFE; the intervention was described as
being holistic, comprehensive and inherently relevant to an individual’s problems and environment. The
approach focusing on strategies to enable functional activity was seen as differing from the prevalent
approach used in usual practice/the NHS, which was described as being exercise driven:
I thought it was very good, it takes a slightly different tack than a traditional NHS assessment because
it’s sort of strategy driven rather than exercise driven so it’s potentially looking at a person at a
functional level, trying to kind of really drill down when they are falling and why they are falling but at
a much more of a global level and trying to really focus in on that, not address that problem through
the provision of exercises but more actually looking at practising functional activities that are linking in
with the falls.
Therapist 6
Having PDSAFE in the individual’s environment, ‘where the falls happen’, was seen by all the therapists
as the ideal. Being in the person’s home, setting their environment and situation was considered to give
much better insight into how to tailor treatment:
It had relevance to them, [. . .] and their problems, they demonstrated their problems by when you
look at them and you map the house and you have a really good look at them. So the relevance for
them is excellent, so they know that this is their problem and you start working towards trying to solve
that problem or a couple of problems that they do have with stuff that is functional, that they need to
do for their everyday lives.
Therapist 1
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All therapists reported enjoying the experience. One therapist commented that the PDSAFE approach was
so different that working with it was initially difficult. Another therapist noted at times feeling constrained/
unsupported when patients were unwell and the links back to clinical services seemed less apparent:
I suppose initially actually not approaching it from a training base but approaching it from a strategy
training in a functional side was quite hard to embrace to start with but now I’ve got the hang of it,
I absolutely love it and I think it’s a really ingenuitive different way of actually looking at how
therapists approach the treatments to their patients. I’ve really, really enjoyed it.
Therapist 3
Intervention challenges
There was a consensus that working with patients who had cognitive issues and/or dyskinesia was the
most challenging aspect of the delivery of the PDSAFE intervention. This group were noted as challenging
to support in usual practice, and one therapist noted needing to seek support during the intervention from
a colleague to help their patient progress. This difficulty was attributed to patients with cognitive issues
being unable to retain an understanding of the PDSAFE structure, rationale and content covered. Some
therapists felt that this group required different support to PDSAFE. Others consider PDSAFE to be capable
of helping this group if they had support from a significant other or carer:
We had a fair few that did pass the cognitive screens to be part of the trial but then it is very different
to pass a screen like that and then actually be able to participate in the trial, [. . .] It was fine if they
had a partner or someone that they were living with to support them, but if they didn’t, that was
really hard and we had to use so many different strategies and took lots of our time to try and get
them on board and get them familiar with the programme and sometimes it still wouldn’t really work.
Therapist 5
Promoting exercises was seen as more challenging among patients who were unused to exercise/deconditioned,
were less physically able and were unwilling to change their routines/habits. There was also comment that many
patients struggled to grasp how to progress their exercises:
I think it’s very easy to follow the sort of structured exercises and things but that carry-over into
function is the biggest, I found the biggest hurdle and was starting to say to patients at the start of
my treatment. I said you know there’s gonna be exercises which support the use of a strategy and the
crux of it for you I felt was to have that transferred into function and you know and that’s where the
real hard work is for you is to try and change habits, things that you do on a daily basis without really
thinking. So I try and sort of prep them, yeah, there was resistance to that I think.
Therapist 2
More individually raised challenges included working with patients who had overly protective spouses/
partners and fitting the required number of sessions in around seasonable periods/patients’ busy
schedules:
With the higher-level people, only that they had busy lives and getting a schedule to fit in. [. . .] and
several of them had really active social lives and travelled and went away and went to rugby matches
and so fitting in all the appointments at the appropriate times was difficult.
Therapist 1
Theme 2: benefits and limitations of the PDSAFE intervention
This theme outlines the benefits and limitations attributed to the PDSAFE intervention by therapists.
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Ingredients of intervention success
Most therapists associated having minimal/no cognitive difficulties as a key element for intervention
success. Cognitive issues were explained as potentially reducing motivation (owing to reduced
understanding of intervention intent) and preventing carryover from treatment:
I think the whole thing worked very well as long as they had the cognitive capacity to understand how
it all knitted together, which aided their motivation.
Therapist 4
This issue then limited a patient’s ability to progress. However, the belief that cognitive acuity was
important for intervention effectiveness was not universal; Therapist 1 did not feel that any group
benefited more than any other and reported that all of her patients progressed, including those with
cognitive issues:
Everybody progressed, everybody really enjoyed it, all the people I had, even the ones with cognitive
impairment were very compliant [. . .] whoever benefits are the ones that are motivated to exercise and
I have to say that every participant I saw, mine and (two other therapists) were all motivated. I can’t
say that anyone benefited more than anybody else.
Therapist 1
Those described as ‘motivated’ to exercise and to integrate PDSAFE into their routines were thought more
likely to derive benefit. Those with mild to moderate Parkinson’s, who were functionally independent,
were seen by some as ideal candidates in terms of potential to benefit. Finally, being concerned over one’s
personal risk of falls was discussed explicitly by one therapist as important for facilitating the required
lifestyle changes:
I think people who have had a significant enough experience of a fall to see why they would want to
work on it, so I think sometimes when patients maybe in the trial had had one fall a very long time
ago or whose symptoms were so mild that they couldn’t really engage so much with changing their
daily habits to prevent them falling, the problem wasn’t really significant enough I suppose.
Therapist 2
Factors associated with reducing intervention effectiveness
In line with therapist comments on the limitations of the PDSAFE intervention, cognitive impairment and/or
dyskinesia were noted as limiting intervention success:
There were issues regarding patients with cognitive impairment which made it that much more
difficult. [. . .] Patients with dyskinesia which made it again very difficult for anyone who wasn’t really
used to cope with some of those issues but I think for the . . . mainly for the person who isn’t that
severely affected, I think it had a better outcome.
Therapist 4
One therapist commented that PDSAFE could then become a burden to the patients who, on being given a
programme to work on, could not obtain sufficient benefit. Support was noted as a key issue, particularly
for those with cognitive problems; patients with no support reportedly struggled to complete all exercises
and, as a result, could only partially engage in PDSAFE. The time since a patient’s last fall/the significance
of the last fall to the patient was suggested as influencing intervention effectiveness. As PDSAFE was
recognised as requiring changes to routines, some therapists commented that, if falling was not a big
concern, patients may be less likely to alter these routines.
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The extent to which a patient felt able to cope with new commitments was also identified as influential;
those with multiple conditions and accompanying appointments, or busy lives generally, were noted as
being more likely to withdraw from the treatment because of an inability to take on the substantial
commitment posed by PDSAFE:
Where people haven’t progressed is where you’ve got some underlying cognition problems, whether
they forget the appointments, where you turn up and they are out and where they just don’t get the
intensity, you can’t build them up to that intensity and they have to commit like 6 days or up to
6 days, 5–6 days they have to be doing this for half an hour, so that is quite a commitment to them
and so you need to be motivated, you need to be knowing what you’re doing, why you’re doing it and
what benefit you are going to get from it and if you haven’t got that type of person, it’s a hard slog.
Therapist 6
Those patients that are so severe that they’ve got so much going on in their life and they’ve got
different appointments to attend, they’ve got sort of other illnesses, they’re so tired, they are falling
quite frequently and for want of a better phrase ‘in a pickle’ basically. The patients who have got so
much on, the idea of doing these, you know, looking at this blue folder and using the blue folder to
do anything extra on top of everything else that is going on is just too much for them really. It was
quite a struggle and you would go and you would feel like it was just one thing too many at
that time.
Therapist 2
Other factors reported as reducing intervention effectiveness included the following:
l patient attitude/motivation (patients who embraced illness and inactivity were seen as less likely to
engage/benefit from PDSAFE)
l physical ability (e.g. those with walking aids participated at a lower level, which limited the benefit they
could achieve)
l medication (side effects in some in cases hindered participation).
Theme 3: influences on intervention success
This theme highlights the factors and patient characteristics perceived to improve or reduce the likely
success of PDSAFE at an individual level.
Strengths associated with the PDSAFE intervention
Several strengths were attributed to the PDSAFE intervention. The focus of PDSAFE on an individual’s
functional problems and issues, in their own environment, was seen as a core strength of the programme.
One therapist overtly related this patient-centred focus and approach to building patients’ confidence in
their functional abilities:
It boosts a lot of people’s confidence, especially the fact that you can take them anywhere, take them
outside, [. . .] I did get someone on the beach [. . .] she said to me that her friends had commented
periodically, how much better her gait pattern was and how much more confident she was and she
felt more confident.
Therapist 1
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A number of therapists commented on how helpful the PDSAFE programme structure was not only for
them, but also for their patients. This structure was described as being extremely clear and different from
usual practice in that there was no ‘wait and see’ element:
The fact that you had very, very clear guidelines to work towards and I thought it was a clear and
easy-to-follow intervention programme, [. . .] you had a clear progression and a clear way to lead
but you also had a huge amount as a therapist of decision-making yourself and using your clinical
reasoning to come to the decisions of what strategy you chose or exercises you chose, so again,
it didn’t dumb you down.
Therapist 3
The opportunity afforded by PDSAFE to reinforce functional strategies was reportedly appreciated by
therapists. The range of strategies available was also considered to be particularly good; this was seen as
giving therapists the ability to respond flexibly and creatively to their patients’ individual needs:
It was a good variety and, from a strategy point of view, you could really open it up and could treat in
many different sorts of ways out and about and in their own home and doing anything that they find
particularly difficult. So it was quite open at that stage.
Therapist 6
Limitations associated with the PDSAFE intervention
Therapists described a number of limitations associated with the PDSAFE intervention. The three most
commonly discussed related to the following:
1. PDSAFE was seen by a number of therapists as less suited to patients with cognitive issues and/or dyskinesia.
2. Some therapists reported that progressions posed ceiling and/or floor effects on exercises, namely
exercises could not be made simpler than the lowest-level exercise (even though in usual practice it
could be adapted) and, similarly, exercises could not be made more challenging than the uppermost
exercise progression.
3. Therapists also reported that being unable to deviate from the set exercise positions inhibited their
freedom to clinically reason and adapt the exercise to suit an individual, for example if a patient had a
comorbidity, such as knee arthritis, that prevented them from adopting certain positions:
I probably would have treated them in a different position, so somebody for example, if they are, if
they’ve got lots of arthritis or if they’ve got any other comorbidities, it’s difficult to then start loading
joints if they are a bit arthritic in order to then strengthen. Previously, I would have then maybe looked
at strengthening up in lying or on their tummy so I would have done it slightly differently [. . .] rather
than on a protocol. I could only, for example, strengthen people up in, say, standing and obviously if
you’ve got an arthritic knee or hip, it’s actually quite difficult. So there were some limitations with it
but from an exercise point of view.
Therapist 6
Consequently, therapists reported that some patients remained ‘stuck’ at a certain point in the programme.
Both of these issues led to therapists suggesting ways to improve the PDSAFE intervention for future
implementation (see Theme 5: PDSAFE intervention usability and transferability). Other limitations concerned
(1) exercises becoming repetitive for some patients and (2) some progression (specifically involving the
metronome) promoted dual tasking at the expense of movement quality:
I definitely think the exercises, I want to be a bit more sort of creative with the patient and I think
sometimes they potentially started to find things quite repetitive (Interviewer: yeah, yeah) so I probably
would want to involve other exercise ideas, maybe to make them a bit more fun as well. That’s not
necessarily a PDSAFE criticism, it’s a general, a lot of exercises we described are often quite boring.
Therapist 2
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Yeah I think the variety of exercises and the fact that there is a lower limit and an upper limit to what
you can do so you can’t progress further than a certain point. You can’t strip the exercise back past a
certain point as well, I suppose.
Therapist 2
Theme 4: perceptions of patients’ experiences and engagement
This theme describes therapist perceptions of patients’ experiences and their engagement with PDSAFE
during the programme lifetime and beyond.
Perceptions of patient experience
Most therapists perceived that a majority of patients enjoyed the PDSAFE experience, reporting patients to
be engaged and ‘on board with it’. However, one therapist noted occasions when patients had not seemed
to enjoy the overall experience, for example when coexisting musculoskeletal conditions were exacerbated
by PDSAFE activities or when patients were not open to changing their routines:
I think most people were on board with it [. . .] I don’t think I had any dropouts at all or not due to not
wanting to do it. It was they were withdrawn because their diagnosis changed but most people were
on board with the programme and wanted to do it and wanted to be part of the trial so that
went well.
Therapist 5
There are a couple of patients who had musculoskeletal problems and had problems with pain who
probably didn’t enjoy it as much just because they associated movement with discomfort.
Therapist 2
Therapists described a number of particular elements of PDSAFE that they believed patients to have most
enjoyed. Three of the most commonly discussed of these were (1) the focus of the programme being
on issues most relevant to the individual patient, (2) the clear structure attributed to the programme and
(3) the intensity and level of input/contact with therapists to support activity. Other features reported as
being positively received by patients related to the novel focus on strategy training, the chance to exercise,
the opportunity to use equipment and the confidence regarding managing a fall and the resultant feeling
of increased safety developed within the programme:
I think it’s having somebody supervise them, I think it’s somebody coming in and they are not being
left with a piece of paper, doing a list of exercises, they are actually having somebody come in and
teach them something that they can relate to and for us it was falling but it might have also been
getting up out of a chair, rolling over in bed, getting their food out of the boot of the car from
shopping, you know.
Therapist 6
The intensity of the programme, that it was centred around them as an individual and the strategy
training practice which was different to what they had received before.
Therapist 3
Aspects of the programme that were least enjoyed included (1) completing paperwork, for example falls
diaries (although it is worth noting that these were a product of the research trial rather than the
intervention itself), (2) reduced contact in later stages of the programme, 3) changing habits/the home
environment and (4) exercise. Regarding falls diaries, some therapists attribute this to the tedium of
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completing paperwork whereas others felt that embarrassment was a factor. Regarding exercise, for some
this was due to the difficulty of the exercises whereas for others, more physically able, exercises might
become a bore:
It’s always about the documentation, the tick sheets – it’s always a recurring issue so we got to the
6 months’ point and the majority, the ones that had done well without any cognitive impairment,
didn’t need the tick sheets, they think ‘I do this every day’ or ‘Monday, Wednesday, Friday is my days’,
I’ve got a reference for the exercises and they were glad to see the back of that. Although it’s just a
tick sheet and doesn’t take long, it becomes a bit of a nuisance doing it so that’s the thing that I
found people moaned about more than anything else.
Therapist 4
I think they probably found it difficult when it went down to monthly and they were used to seeing
you more regularly than that and I think probably filling in their forms, none of them liked filling in
their fall forms [laughter] and I can understand why because you are focusing in on your . . . falling is
. . . whenever I fall over, which thank god is not very often, but if I fall over in the street or trip over
the dogs fairly frequently, it’s embarrassing, isn’t it? I really don’t want to dwell on that and I cover up
my grazes and I kick my dog out of the way and I carry on my way that nobody sees. If you ask
somebody constantly to write down their falls and reminisce about them, I think people found
that difficult.
Therapist 1
Patient engagement in the PDSAFE intervention
Therapists perceived most patients to be motivated during the most intensely delivered points of PDSAFE.
Patient engagement following intervention tapering was described as variable; some therapists perceived
patient engagement to reduce when contact changed to monthly visits, others felt that their patients
continued to engage through to programme completion. All therapists raised uncertainty and/or concern
regarding the likelihood of their patients continuing the exercise programme. There was a feeling that
some would continue, many would ‘ease off’ in terms of intensity/frequency of exercise and some would
not continue. Although it was recognised that therapy contact could not continue indefinitely, it was
considered that there was a need for some form of follow-on programme/group. Therapist reports of
patient feedback support this also:
I did find that a few people, quite a few, lost motivation towards the end. So they started off quite
motivated and then towards the end they would lose it so when I was seeing them at a less intense
level, they definitely lost motivation and a few of them, I would say to them at the end, will you
continue they would say – probably not just doing it themselves and be more likely to go to a group,
some of them do tai chi and other exercise classes that are Parkinson’s related or non-Parkinson’s
related and they would continue with that.
Therapist 5
They all said ‘is that it?’ so I think my feeling is that with exercise-based programmes you’ve just got to
keep seeing people or move them on to something else.
Therapist 1
Theme 5: PDSAFE intervention usability and transferability
This theme discusses therapists’ perceptions of the usability of PDSAFE tools, the training they received,
ways to enhance the original programme and its transferability to clinical practice.
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Evaluations of therapist training
Training was highly praised, the knowledge of staff was commended and, for the most part, therapists
reported feeling supported:
Absolutely fantastic, loved every second of it, comprehensive. I don’t think anything could train
you for the completely different way, obviously [name] did the training and then we did the case
studies to make us try and think strategy based and I think until you are actually out there and
actually doing it, the training couldn’t have been any better and the early fidelity checks were
paramount, I think.
Therapist 3
The one instance in which a therapist felt unsupported initially related to part-time working patterns and
difficulty synchronising schedules to arrange a telephone conversation. The monthly group discussions
and masterclasses were valued as very supportive, inspirational and good sources of continuing
professional development. The peer support/double visits were particularly valued as learning and support
opportunities. Some therapists noted that although the training in class was good, much learning occurred
when implementing the programme, and peer support/double visits were vital to this. There were few
negative comments; one therapist reported experiencing a large gap between receiving training and
beginning the intervention, which resulted in the therapist struggling/feeling less confident when initially
commencing treatment. Another comment was made regarding time spent working through paperwork
(e.g. the treatment protocol, which detailed the treatment structure) during initial training, reducing time
for practical learning:
The training was delivered and I then had a very long wait before I got my first participant. I can’t
remember how long but I can’t remember if I’m honest, but it could have been over a month and I
couldn’t . . . it was then difficult to really feel confident with delivering the protocol because you are
new, you can’t totally remember, you read the paperwork and you read what’s given to you and
you’ve got a reasonable idea but it’s all the conversations, it’s all the scenarios that was discussed so
whether somebody could have come and did one . . . our first visit, a few of our first assessments,
then that might have worked.
Therapist 6
Tool utility
Therapists commented on the utility of various tools, equipment and documentation used in the PDSAFE
intervention. Some of these resources were praised by all participants as exceedingly useful. The use of
one-to-one videos, whereby the therapist recorded a patient’s movement and then talked them through
an assessment of this, was considered a very useful facility that was, for the most part, appreciated by a
majority of patients. There were some therapists who noted some patients struggling to focus on the
recorded movement, instead attending to their appearance:
The one thing I did find really useful was when you are doing a strategy with someone and you’ve got
them doing a functional task and you video them and then give them immediate feedback, they can
see themselves.
Therapist 1
The weighted jacket and the metronome received a more mixed review. The participants reportedly found
it very difficult to put on the weighted jacket themselves; some patients found this a considerable struggle
and required assistance. Concern was raised regarding being able to use the jacket if people did not have
significant others/carers to help. The weighted jacket was also seen as (1) having potential to aggravate
musculoskeletal issues and (2) being intimidating/off-putting, especially for those who were unused to
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exercise/weight training. It was not only patients, but sometimes also partners/spouses, who were
intimidated by the jacket:
I would say there was an element of them trying to protect their partner a little bit and not want them
to do too much, so things like the weighted vest, even if the participant themselves were quite keen
on using it, their wives were not.
Therapist 5
However, some therapists reported that with practice donning the jacket became easier, and some
patients responded well/enjoyed wearing it:
I think sometimes with the strengthening part of the programme they may have been quite daunted by
the thought of wearing a vest, especially some of the females. The actual, the realisation that they could
actually do far more than they ever thought that they were capable of that was really encouraging.
Therapist 4
The metronome was seen as being disliked by many patients because of the associated difficulty of dual
tasking, although some therapists reported patients enjoying working with this. There was some
suggestion that trying to maintain speed could reduce quality of movement (see Theme 2: benefits and
limitations of the PDSAFE intervention).
The pre-recorded DVDs were unanimously reported to be used infrequently by patients. A number of
therapists noted technical difficulties associated with this, and reasoned that the effort of setting up the
DVD was not justified by the benefit patients derived from watching it. Another explanation was that
some patients did not feel the need to remind themselves how to perform the exercises. Therapists noted
being surprised by this finding.
Suggestions for improving the PDSAFE intervention
Increasing the number of exercises in the exercise library was a common suggestion/request, as was
allowing more flexibility in modifying exercise progressions and postural sets to aid clinical reasoning and
individual intervention tailoring. Other suggested improvements included the following:
l Increase the choice of functional activities and strategies.
l Allow a more flexible blue folder composition so that it can be simplified for people with cognitive
issues. Remove old cards when new ones are issued to reduce confusion.
l Emphasise video feedback one-to-one sessions with patients and therapists over DVD usage.
l For exercises, consider having A4 laminated sheets with pictures and few words that can be put up on
a patient’s wall.
l Consider spreading the first two sessions over four sessions, as there is a lot to assimilate.
l Make computer versions of paperwork more readily available for patients who struggle to complete
forms in hardcopy.
l Add patient demo to PDSAFE training to help therapists understand the flexibility of the programme
and how things may be adapted if initial choices fail.
l Potentially encourage more ‘double’/fidelity sessions and sooner in the programme as these are valuable
learning opportunities.
Feasibility and desirability of integrating the PDSAFE in clinical practice
Therapists felt that PDSAFE could be delivered in the community. Although it was recognised that aspects
of the programme would work in a hospital setting (e.g. exercises) and that group exercise particularly
could be motivational, devoid of vital context, hospital delivery was still seen as a less desirable setting.
The need for context in order for patients to learn strategies and attain carry-over was stressed by all.
For some, delivering the programme in a hospital, divorced of this context, was possible but less optimal/
effective, whereas others considered it infeasible.
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There was recognition that PDSAFE, as delivered, amounted to double the therapy sessions usually
delivered as part of routine care. This led to therapist uncertainty regarding whether or not PDSAFE would
be funded adequately in the current climate; as a result, this issue was noted as being decisive when
evaluating the feasibility of delivery of PDSAFE in clinical practice:
I guess it comes down to funding anyway, if the funding is there to deliver it as it is, then yes I
imagine that it would be hard to get, just because of the time involved and it’s not just even the
intensity of the programme, it’s all that extra stuff in terms of the admin[istration] and the [tele]phone
calls to arrange the appointments and things and the yeah, whether it was put into a community
service for people with Parkinson’s as a – you are seeing them anyway but we want you to deliver it
like this rather than what you would normally do, then yes, I guess, but you would have to have that
funding there.
Therapist 5
There was discussion regarding who should be involved in the delivery of PDSAFE; there was a feeling that
a qualified physiotherapist would be needed to assess, develop the treatment programme and progress
patients, but that therapy assistants could take on some sessions to check in and support patients when
they were implementing their personal programmes.
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Chapter 7 Economic evaluation
Overview
The cost-effectiveness analysis (CEA) of the PDSAFE physiotherapy intervention compared with usual care
in people with Parkinson’s is presented in this chapter. Cost-effectiveness was estimated using a ‘within-
trial’ analysis, based on health-care resource use and health-related quality of life (HRQoL) utility data
collected over the 12-month trial period. Results are presented using an incremental cost-effectiveness
ratio (ICER), estimated by dividing the difference in mean costs between arms by the difference in mean
quality-adjusted life-years (QALYs) between arms. ICER estimates were compared with a £20,000- and
£30,000-per-QALY threshold applied by the National Institute for Health and Care Excellence (NICE).57
Methods
Resource use
In line with NICE economic evaluation recommendations, this CEA adopted an NHS and Personal Social
Services (PSS) perspective.58 Data for CEA were collected at baseline and at 3, 6 and 12 months. Costs
were evaluated in Great British pounds using a 2016 base year. All analyses were undertaken according
to the principle of ITT and in Stata/SE version 12.0. Costs included intervention costs (apportioned per
participant) and NHS and social care resource use costs. Intervention costs were collected directly from trial
records. For resource use costs, unit costs were obtained from national sources: the Personal Social Services
Research Unit’s (PSSRU’s) Unit Costs of Health and Social Care59,60 and NHS Reference Costs 2015 to 2016.61
Quantities were collected from the trial participants. The resource use questionnaire collected information
on (1) primary care services provided in the NHS system [e.g. general practitioner (GP) visits, physiotherapy,
occupational therapy], (2) secondary care services provided in the NHS system [e.g. ambulance call outs,
accident and emergency (A&E) attendances, hospital stay] and (3) social care services (e.g. home care visits,
meals on wheels). Medication use was collected separately. All resource use data were originally collected
from participants by interview with an assessor. This was revised after identifying a risk of unblinding of
assessors during the interview by the question asking participants how many times they saw a physiotherapist.
Therefore, the whole section containing the number of times a physiotherapist was seen was then collected
via postal questionnaire, which was completed by participants. Questions on fall-related A&E attendances
and hospitalisation admissions were also embedded into the falls diaries for validity checks. Unit costs in the
financial year 2015/16 published by the PSSRU59 and NHS Reference Costs 2015 to 2016,61 when information
was not available from the PSSRU, were attached to each item of resource use. Table 14 shows the unit
costs applied to each resource use item and Table 15 shows details of assumptions varied in each sensitivity
analysis.
Cost of personalised home-based physiotherapy
The cost of implementing the PDSAFE intervention was collected from the trial co-ordinator and lead
therapist. The analysis followed an ITT principle; therefore, only the participants allocated to the intervention
arm were assumed to incur the cost of treatment and any research-only cost was excluded. This ensures the
relevance of the cost estimates if the programme were to be ‘rolled out’ to larger numbers of people.
Therapy session costs included the personnel costs (i.e. salary) of the therapist, travel costs, equipment costs
and consumables. The salary cost of the therapist was calculated based on NHS band 6 full-time equivalent
(£41,005.91) taken from the 2016 Health Service pay scale.66 A 2-day training course was carried out with
the involved therapists to train them in delivering the home-based personalised physiotherapy intervention.
Cost of training included time spent by the trainer (lead therapist), room hire and training materials. During
the delivery of the therapy sessions, all participants were provided with printed materials and compact discs
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TABLE 14 Unit costs for health-care resource use
Resource use item
(unit used in the source) Unit cost (£) Source
NHS resource use
GP (per contact) 36.00 PSSRU 2015/16.59 Per-patient contact lasting 9.22 minutes,
with qualifications
Practice nurse (per hour) 43.00 (11.11 per contact) l PSSRU 2015/1659 Nursing average cost per hour,
with qualifications
l Duration of contact per patient is 15.5 minutes
(PSSRU 2014/15,62 based on the 2006/7 UK general
practice survey63)
Parkinson’s nurse (per hour) 75.00 (19.63 per contact
after inflation)a
l PSSRU 2014/15.62 Cost per hour of patient-related
work as a nurse specialist (community) with
qualifications
l Duration of contact per patient is 15.5 minutes
(PSSRU 2014/15,62 based on the 2006/7 UK general
practice survey63)
Health visitor (per contact) 54 (54.72 after inflation)a PSSRU 2014/15.62 Cost per face-to-face contact in
health visiting services
Social worker (per hour) 79.00 PSSRU 2015/16.59 Cost per hour of client-related work
with qualification. Assume average contact is one hour
NHS physiotherapist (per contact) 49.00 NHS Reference Costs 2015 to 2016.61 Allied health
professionals, physiotherapist, adult, one to one
(A08A1). National average unit cost
Occupational therapist (per contact) 79.00 NHS Reference Costs 2015 to 2016.61 Allied health
professionals, occupational therapist, adult, one to one
(A06A1). National average unit cost
Speech or language therapist
(per contact)
88.00 NHS Reference Costs 2015 to 2016.61 Allied health
professionals, speech and language therapist, adult,
one to one (A13A1). National average unit cost
A day case at hospital (per case) 733.00 NHS Reference Costs 2015 to 2016.61 Table 15: unit
costs by point of delivery, 2013–14 to 2015–16. Unit
costs per finished consultant episode (time a patient
spends in the care of one consultant) for a day case
Hospital outpatient attendance
(per attendance)
117.00 NHS Reference Costs 2015 to 2016.61 Table 15: unit
costs by point of delivery, 2013/14 to 2015/16. Unit
cost per outpatient attendance
A&E by ambulance (per incidence) 236.00 NHS Reference Costs 2015 to 2016.61 Table 15: costs
by currency for ambulance services between 2013/14
and 2015/16. Unit cost per ‘see and treat and convey’
Ambulance followed by emergency
care only (i.e. paramedics, but not
conveyed to hospital) (per incidence)
181.00 NHS Reference Costs 2015 to 2016.61 Table 15: costs
by currency for ambulance services between 2013/14
and 2015/16. Unit cost per ‘see and treat or refer’
A&E by own/public transport
(per incidence)
138.00 NHS Reference Costs 2015 to 2016.61 Table 15: unit
costs by point of delivery, 2013/14 to 2015/16. Unit
cost per A&E attendance
Hospital stay for treatment (per day) 373.00 NHS Reference Costs 2015 to 2016 main schedule.61
Average of cost per elective and non-elective inpatient
excess bed-days across all currency codes. Elective
inpatient excess bed-days, average across all currency
codes: £395. Non-elective inpatient excess bed-days,
average across all currency codes: £351
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TABLE 14 Unit costs for health-care resource use (continued )
Resource use item
(unit used in the source) Unit cost (£) Source
Respite care at hospital (per day) 264.75 NHS Reference Costs 2015 to 2016 main schedule.61
Estimated from the day cost for respite care with
length of stay of 4 days or fewer (£1059/4 = £264.75)
Social care resource use
Home care/home help (per hour) 30.75 (15.37 per contact) PSSRU 2015/16.59 1.5 Home care for older people.
Average standard hourly rate for services provided
in-house. Assumed 30 minutes per contact
Meals on wheels (per time) 3.00 South Lanarkshire Council service, social care and
health, meals at home (meals on wheels)64
Day centre (per attendance) 61.00 PSSRU 2015/16.59 1.4 Local authority own-provision
day care for older people. Unit cost per client
attendance
Lunch club (per time) 3.09 Glasgow City Council, social care and health, adults
and older people, a lunch club65
Sitting service (per hour) 21.00 PSSRU 2015/16.59 6.12 Short-break provision for
disabled children and their families. Unit cost per
family per hour. Assumed 1 hour per contact
Night care (per hour) 31.83 PSSRU 2015/16.59 11.6 Home care worker. Applied
price multipliers for unsocial hours: 1.035 for an
independent sector home care hour. Assumed 1 hour
per contact
a Hospital and Community Health Service inflation factor 1.013 [2014/15 pay and prices index (PPI) 293.1, 2015/16
PPI 297.0].
TABLE 15 Details of assumptions varied in each sensitivity analysis
Scenario Element Position in base-case analysis Variation for the sensitivity analysis
1 Time horizon 6 months, in line with the primary end point of the
trial and the completion of all the therapist sessions
12 months, with non-collected data at
12 months being imputed
2 Cost 12 therapist sessions in total (12 sessions × 1 hour
per session). Intervention cost per person = £649
10 actual sessions conducted.
Intervention cost per person = £546
3 Cost 12 therapist sessions in total (12 sessions × 1 hour
per session). Intervention cost per person = £649
Total therapist sessions reduced to
eight sessions (eight sessions × 1 hour
per session). Intervention cost per
person = £442.80
4 Missing data Missing data assumed to be missing at random and
a mixed strategy of imputation was conducted
Complete-case analysis: missing data
assumed to be missing completely at
random
5 Routine visits of
physiotherapist
NHS routine use of physiotherapists was included
in the total NHS costs
Visits of physiotherapist between
baseline and 6 months was not
included as there might be bias in
the collected data
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(CDs) of the intervention demonstration. In addition, a proportion of participants used assisted equipment
including weighted vests, balance pads and steps. This equipment was kept by the physiotherapists and
could be used with different participants. Annuitisation was carried out to spread the costs over the
anticipated lifespan of this equipment.
Analysis
A cost–utility analysis of the PDSAFE physiotherapy intervention compared with usual care was conducted
after imputation. Differences in costs and QALYs between the two groups were estimated using generalised
linear models (GLMs), which take into account the typically skewed nature of cost and QALY data. Histograms
revealed that the cost data were right-skewed; therefore, gamma distribution was used. For QALYs, as
suggested in a previous National Institute for Health Research Health Technology Assessment report,67
decrement of QALY was originally predicted in the regression using a gamma distribution. Decrement of
QALY was calculated as the difference between the maximum QALYs that could possibly be accrued within
the time frame and the actual QALY gained. However, this analysis cannot proceed with the imputed data;
therefore, a Gaussian family was used instead given that the distribution of QALYs was close to a normal
distribution. Covariates in the GLM were selected based on statistical significance using regressions with
complete cases from the full list of demographics, medical history and screening measures. The chosen
covariates included in the model were age, gender, H&Y scale stage, MoCA score, MMSE score, presence of
diabetes, history of myocardial infarction, history of ischaemic heart disease, history of deep-brain stimulation
and whether or not the participant had an informal carer. Baseline utility score and baseline cost were also
included to adjust for any imbalance of utility between groups.68
Mean costs and QALYs for each group were estimated using the method of recycled predictions. The ICER was
estimated from the difference in cost and QALYs from the GLM regression. A 1000-iteration bootstrapping
was conducted to investigate the uncertainty surrounding the ICER estimate and the probability that the
intervention was cost-effective under a wide range of hypothetical thresholds (£0–200,000). These results were
represented in a cost-effectiveness plane and cost-effectiveness acceptability curve (CEAC), respectively.
Utility and quality-adjusted life-year
Effectiveness was expressed as QALYs. QALYs were estimated by the area-under-the-curve approach using
the utility index values at each data collection time point, which were generated using the EuroQol-5
Dimensions, three-level version (EQ-5D-3L), questionnaire, with preference weights from the UK general
population.69 EQ-5D-3L questionnaires were completed by participants during an interview conducted by
assessors at baseline and at 3, 6 and 12 months. The EQ-5D-3L is a commonly used standardised generic
preference-based quality of life (QoL) measure addressing five domains: (1) mobility, (2) self-care, (3) usual
activities, (4) pain/discomfort and (5) anxiety/depression.70 For each dimension, participants indicate the
level of problems experienced on a three-level scale: (1) no problem, (2) some problems or (3) extreme
problems. These responses were then converted to utility scores using the value set elicited from the UK
general population. The EQ-5D-3L is the preferred measure of HRQoL in adults by NICE technology appraisal.57
Participants who died had their utility score set to zero from the next assessment point after death.
The area-under-the-curve method was then used to estimate the QALY score over the 12-month period,
following the trapezium rule assuming a linear change in utility between each assessment time point.
Missing data and multiple imputation
Data were missing if participants did not return a questionnaire or returned an incomplete questionnaire.
Multiple imputation was conducted at aggregate level for both cost and utility values to avoid convergence
issues of the imputation model (the model becomes very statistically demanding when there are too many
variables with missing data to predict, which usually leads to model convergence failure, meaning that the
model cannot be executed). The EQ-5D-3L scores were imputed as utility values and cost items were
imputed as categories, namely NHS cost excluding hospitalisation, hospitalisation cost and social care cost.
To maximise the use of the completed data, a single item on resource use in both the interview and postal
questionnaire was assumed to indicate that no resource was used for that item during that assessment
period.71 Hospitalisation data in falls diaries were checked and filled up the responses from the resource
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usage questionnaire if the response was missing. The aggregate-level missing data were imputed with
multiple imputation with chained equations and predictive mean matching method for all imputed
variables. The intervention and control groups were imputed separately. The multiple-imputed data sets
were then used to estimate the difference in QALYs and costs, and the ICER.
Sensitivity analyses
A number of sensitivity analyses were undertaken to assess the robustness of the base-case results to
alternative assumptions. These sensitivity analyses are summarised in Table 15.
The time horizon for the base-case analysis was 6 months, as all the participants completed their 6-month
data collection and it was the primary end point. Nonetheless, for half of the participants, 12-month data
were collected and the effect of intervention may last after the trial period; therefore, the time horizon was
varied to 12 months. Sensitivity analyses were carried out on the number of physiotherapy sessions to gain an
insight into the most cost-effective level of provision. Complete-case analysis was conducted assuming that
data were missing completely at random to assess the impact of imputation strategies on the incremental
cost and QALYs. Finally, the participants may have found it difficult to differentiate between the NHS routine
physiotherapist and the trial physiotherapist; thus, the reported number of visits may not be accurate.
Therefore, the use of an NHS physiotherapist between baseline and 6 months was excluded from the total
cost in the sensitivity analysis.
Subgroup analysis
Following on from the statistical analysis plan outlined earlier, three subgroup analyses were undertaken
to identify if the intervention was potentially more or less cost-effective than the overall group. The clinical
effectiveness analysis found that the PDSAFE intervention reduced the number of falls in the participants
who had scored in the middle level of the MDS-UPDRS (i.e. a score of 23–29), were not cognitively impaired
(a score of ≥ 26 in the MoCA), did not have freezing symptoms at baseline and had two or three falls during
the 12-month monitor period prior to recruitment. Therefore, the ICERs were estimated in the subgroups
defined by the above criteria. Interaction variables of the treatment and the group indicator were added
into the regression to obtain the incremental effects without splitting the sample. The incremental effects
were generated using recycled prediction methods to balance the covariates.
Results
Intervention cost
The PDSAFE intervention costs are detailed in Table 16. The cost per patient for each of the breakdown
items is shown in Figure 8. The cost of the intervention was a main cost driver that made up a large
portion of the difference between treatment arms. Within the cost of intervention, the therapist time and
travel expenses account for > 95% of the total cost; thus, assumptions were varied around the number of
sessions.
Missing data
The number and percentage of missing data for each collected cost item and EQ-5D-3L questions at the
four assessment points are shown in Table 17 for the whole sample, and in Table 18 for the intervention
and control (usual-care) groups, respectively. Baseline for the resource use refers to the 3-month monitor
period prior to randomisation. Approximately half of the data were missing (primarily attributed to the
termination of data collection) for the 12-month follow-up for both the resource use and the EQ-5D-3L
data. For the 6-month follow-up, the proportion of data missing for variables collected via postal
questionnaires (i.e. NHS resource use excluding hospitalisation) (≈28%) was almost twice that for variables
collected through the face-to-face interview (≈15%). The proportions of data missing at each assessment
were much higher (≈10% higher for all variables) in the PDSAFE intervention group than in the control
group (see Table 18).
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TABLE 16 The PDSAFE intervention costs
Item Unit cost (£) Quantity (n) Sum (£)
Therapists training
Trainer (lead therapist) 165 per day 1.75 days 288.75
Room hire for 2 days 150 per day 2 days 300.00
Training materials 3.50 per therapist 14 therapists 49.00
Therapy sessions
Therapist time 43.62 per visit 238 participants × 12 124,578.72
Consumables (clinical notes) 1.20 per visit 238 participants × 12 3427.20
Travel expenses 8.00 per visit 238 participants × 12 22,848.00
Patient equipment during the sessions
Printed materials 2.00 per patient 238 participants 476.00
CDs 0.08 per patient 238 participants 19.04
Weighted vests 54.16 each 23.8a 1289.01
Balance pads 19.41 each 59.5b 1154.90
Step 11.99 each (6.31 after annuitisationc) 15.87d 100.14
Total cost (per patient) (£) 649.60
CD, compact disc.
a Approximately 1 in 5 participants used a vest. Each vest can be used for two participants for all the visits.
(238/5)/2 = 23.8.
b Approximately 1 in 2 participants used a balance pad. Each pad can be used for two participants for all the visits.
(238/2)/2 = 59.5.
c Estimated life is 2 years. Annuitisation was applied to estimate the cost of 1 year of use of these steps. Formula:
E = K/{[1 – (1 + r)-n]/r}. K = 11.99, r = 3.5%, n = 2; E = 6.31.
d Approximately 1 in 15 participants used a step count.
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FIGURE 8 Cost of PDSAFE home-based personalised physiotherapy intervention. CD, compact disc.
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Resource use and costs
Table 19 reports the use of each resource item (mean number of visits, SD, median, minimum and
maximum) accrued over the 6-month primary follow-up period in the intervention and the control groups.
The total costs of NHS service use excluding hospitalisation and of hospitalisation and of social care
services are presented in Table 20 (before and after the imputation) and Figure 9. Overall, there was no
difference between the intervention and control groups in the cost of NHS and social care service use.
The total 6-month cost of service use per patient was £3137 (95% CI £2602 to £3673) in the intervention
group and £3069 (95% £2621 to £3518) in the control group. Figure 9 shows that resource use was
TABLE 17 Overall missing data for the cost items and EQ-5D-3L
Data items collected from the trial
Time point, n (%)
Baseline 3 months 6 months 12 months
NHS resource use
GP 51 (10.76) 95 (20.04) 124 (26.16) 238 (50.21)
Practice nurse 53 (11.18) 102 (21.52) 130 (27.43) 240 (50.63)
Parkinson’s nurse 52 (10.97) 98 (20.68) 129 (27.22) 241 (50.84)
Health visitor 52 (10.97) 98 (20.68) 137 (28.90) 245 (51.69)
Social worker 52 (10.97) 100 (21.10) 138 (29.11) 247 (52.11)
NHS physiotherapist 52 (10.97) 99 (20.89) 136 (28.69) 244 (51.48)
Occupational therapist 51 (10.76) 99 (20.89) 140 (29.54) 243 (51.27)
Speech therapist 52 (10.97) 102 (21.52) 139 (29.32) 245 (51.69)
Day hospital 52 (10.97) 96 (20.25) 138 (29.11) 245 (51.69)
Outpatient clinic 51 (10.76) 95 (20.04) 131 (27.64) 241 (50.84)
A&E by ambulance 53 (11.18) 100 (21.10) 138 (29.11) 244 (51.48)
Ambulance with paramedics only 132 (27.85) 124 (26.16) 144 (30.38) 243 (51.27)
A&E by own transport 56 (11.81) 103 (21.73) 142 (29.96) 251 (52.95)
Hospitalisation 1 (0.21) 45 (9.49) 65 (13.71) 209 (44.09)
Social care resource use
Home care help 13 (2.74) 61 (12.87) 79 (16.67) 230 (48.52)
Meals on wheels 1 (0.21) 46 (9.70) 70 (14.77) 217 (45.78)
Day centre 2 (0.42) 47 (9.92) 71 (14.98) 217 (45.78)
Luncheon club 3 (0.63) 47 (9.92) 73 (15.40) 221 (46.62)
Sitting service 2 (0.42) 48 (10.13) 71 (14.98) 217 (45.78)
Night care 1 (0.21) 48 (10.13) 70 (14.77) 217 (45.78)
EQ-5D-3L
Mobility 1 (0.21) 45 (9.49) 71 (14.98) 217 (45.78)
Self-care 1 (0.21) 45 (9.49) 71 (14.98) 217 (45.78)
Usual activities 1 (0.21) 47 (9.92) 72 (15.19) 217 (45.78)
Pain and discomfort 1 (0.21) 45 (9.49) 71 (14.98) 217 (45.78)
Anxiety and depression 4 (0.84) 46 (9.70) 70 (14.77) 217 (45.78)
Visual analogue scale 9 (1.90) 47 (9.92) 73 (15.40) 217 (45.78)
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TABLE 18 Missing data for resource use and EQ-5D-3L QoL in the intervention and control groups
Data items collected from the trial
Trial group, n (%)
PDSAFE (N= 238) Control (N= 236)
Baseline 3 months 6 months 12 months Baseline 3 months 6 months 12 months
NHS resource use
GP 31 (13.03) 59 (24.79) 77 (32.35) 126 (52.94) 20 (8.47) 36 (15.25) 47 (19.92) 112 (47.46)
Practice nurse 31 (13.03) 60 (25.21) 79 (33.19) 126 (52.94) 22 (9.32) 42 (17.80) 51 (21.61) 114 (48.31)
Parkinson’s nurse 31 (13.03) 60 (25.21) 80 (33.61) 127 (53.36) 21 (8.90) 38 (16.10) 49 (20.76) 114 (48.31)
Health visitor 32 (13.45) 58 (24.37) 84 (35.29) 130 (54.62) 20 (8.47) 40 (16.95) 53 (22.46) 115 (48.73)
Social worker 32 (13.45) 60 (25.21) 84 (35.29) 131 (55.04) 20 (8.47) 40 (16.95) 54 (22.88) 116 (49.15)
NHS physiotherapist 30 (12.61) 60 (25.21) 82 (34.45) 130 (54.62) 22 (9.32) 39 (16.53) 54 (22.88) 114 (48.31)
Occupational therapist 31 (13.03) 59 (24.79) 85 (35.71) 127 (53.36) 20 (8.47) 40 (16.95) 55 (23.31) 116 (49.15)
Speech therapist 31 (13.03) 61 (25.63) 84 (35.29) 131 (55.04) 21 (8.90) 41 (17.37) 55 (23.31) 114 (48.31)
Day hospital 30 (12.61) 58 (24.37) 83 (34.87) 131 (55.04) 22 (9.32) 38 (16.10) 55 (23.31) 114 (48.31)
Outpatient clinic 31 (13.03) 59 (24.79) 79 (33.19) 127 (53.36) 20 (8.47) 36 (15.25) 52 (22.03) 114 (48.31)
A&E by ambulance 31 (13.03) 60 (25.21) 82 (34.45) 130 (54.62) 22 (9.32) 40 (16.95) 56 (23.73) 114 (48.31)
Ambulance with paramedics only 72 (30.25) 68 (28.57) 84 (35.29) 129 (54.20) 60 (25.42) 56 (23.73) 60 (25.42) 114 (48.31)
A&E by own transport 33 (13.87) 60 (25.21) 85 (35.71) 134 (56.30) 23 (9.75) 43 (18.22) 57 (24.15) 117 (49.58)
Hospitalisation for treatment 1 (0.42) 27 (11.34) 48 (20.17) 117 (49.16) 0 (0) 18 (7.63) 22 (9.32) 99 (41.95)
Hospitalisation for respite care 1 (0.42) 27 (11.34) 48 (20.17) 117 (49.16) 0 (0) 18 (7.63) 22 (9.32) 100 (42.37)
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Data items collected from the trial
Trial group, n (%)
PDSAFE (N= 238) Control (N= 236)
Baseline 3 months 6 months 12 months Baseline 3 months 6 months 12 months
Social care resource use
Home care help 8 (3.36) 33 (13.87) 51 (21.43) 121 (50.84) 5 (2.12) 28 (11.86) 28 (11.86) 109 (46.19)
Meals on wheels 1 (0.42) 27 (11.34) 48 (20.17) 117 (49.16) 0 (0) 19 (8.05) 22 (9.32) 100 (42.37)
Day centre 2 (0.84) 28 (11.76) 48 (20.17) 117 (49.16) 0 (0) 19 (8.05) 23 (9.75) 100 (42.37)
Luncheon club 3 (1.26) 28 (11.76) 48 (20.17) 119 (50.00) 0 (0) 19 (8.05) 25 (10.59) 102 (43.22)
Sitting service 1 (0.42) 28 (11.76) 49 (20.59) 117 (49.16) 1 (0.42) 20 (8.47) 22 (9.32) 100 (42.37)
Night care 1 (0.42) 28 (11.76) 48 (20.17) 117 (49.16) 0 (0) 20 (8.47) 22 (9.32) 100 (42.37)
EQ-5D-3L
Mobility 1 (0.42) 27 (11.34) 49 (20.59) 117 (49.16) 0 (0) 18 (7.63) 22 (9.32) 100 (42.37)
Self-care 1 (0.42) 27 (11.34) 49 (20.59) 117 (49.16) 0 (0) 18 (7.63) 22 (9.32) 100 (42.37)
Usual activities 1 (0.42) 27 (11.34) 50 (21.01) 117 (49.16) 0 (0) 20 (8.47) 22 (9.32) 100 (42.37)
Pain and discomfort 1 (0.42) 27 (11.34) 48 (20.17) 117 (49.16) 0 (0) 18 (7.63) 23 (9.75) 100 (42.37)
Anxiety and depression 3 (1.26) 28 (11.76) 48 (20.17) 117 (49.16) 1 (0.42) 18 (7.63) 22 (9.32) 100 (42.37)
Visual analogue scale 6 (2.52) 28 (11.76) 50 (21.01) 117 (49.16) 3 (1.27) 19 (8.05) 23 (9.75) 100 (42.37)
D
O
I:10.3310/hta23360
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.36
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.
This
w
ork
w
as
produced
by
A
shburn
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
65
TABLE 19 NHS and social care resource use per patient over 6 months (complete case)
Resource use (number of visits)
Trial group
p-value
PDSAFE (N= 238) Control (N= 236)
n Mean SD Median
Minimum,
maximum n Mean SD Median
Minimum,
maximum
NHS
GP 144 2.72 2.47 2 0, 16 177 3.23 2.80 3 0, 15 0.09
Practice nurse 140 1.39 1.67 1 0, 9 170 2.09 4.67 1 0, 43 0.09
Parkinson’s nurse 138 1.21 1.45 1 0, 11 177 1.47 1.67 1 0, 11 0.15
Health visitor 138 0.11 0.54 0 0, 5 170 0.17 0.76 0 0, 8 0.42
Social worker 136 0.07 0.38 0 0, 3 170 0.17 0.72 0 0, 7 0.16
NHS physiotherapist 136 2.48 3.64 0 0, 16 170 1.34 2.42 0 0, 14 0.00
Occupational therapist 136 0.35 0.93 0 0, 6 169 0.50 1.44 0 0, 12 0.29
Speech therapist 135 0.89 2.09 0 0, 11 167 0.59 2.03 0 0, 21 0.22
Day hospital 137 0.93 1.89 0 0, 14 170 0.90 1.57 0 0, 10 0.89
Outpatient clinic 142 1.78 2.09 1 0, 13 173 1.78 1.79 1 0, 13 1.00
A&E by ambulance 137 0.14 0.42 0 0, 2 167 0.11 0.33 0 0, 2 0.48
Ambulance with paramedics only 131 0.26 0.83 0 0, 6 153 0.19 0.63 0 0, 5 0.42
A&E by own transport 135 0.16 0.45 0 0, 3 165 0.22 0.59 0 0, 4 0.31
Hospitalisation for treatment 187 0.30 2.51 0 0, 30 208 0.07 0.47 0 0, 5 0.19
Hospitalisation for respite care 187 0 0 0 0, 0 208 0 0 0 0, 0 –
ECO
N
O
M
IC
EVA
LU
A
TIO
N
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
66
Resource use (number of visits)
Trial group
p-value
PDSAFE (N= 238) Control (N= 236)
n Mean SD Median
Minimum,
maximum n Mean SD Median
Minimum,
maximum
Social care
Home care/home help 181 13.43 50.55 0 0, 390 192 29.99 103.30 0 0, 910 0.05
Meals on wheels 187 1.04 12.49 0 0, 169 207 1.00 12.77 0 0, 182 0.98
Day centre 186 0.49 4.35 0 0, 52 206 0.63 4.59 0 0, 52 0.75
Luncheon club 186 0.21 2.86 0 0, 39 204 0.51 6.43 0 0, 91 0.56
Sitting service 186 0.91 7.16 0 0, 65 206 1.33 7.75 0 0, 78 0.58
Night care 186 0.98 13.34 0 0, 182 206 0.06 0.91 0 0, 13 0.33
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TABLE 20 Cost of health-care and social care resources per patient over 6-months’ follow-up (complete-case analysis and after imputation)
Cost categories
Trial group (£)
p-valuePDSAFE (N= 238) Control (N= 236)
Unadjusted mean
(SE) 95% CI
Unadjusted mean
(SE) 95% CI OLS
Gamma,
log link
Gamma, log link,
adjusted for covariates
Complete-case analysis
NHS excluding hospitalisation 2639.92 (264.95) 2118.72 to 3161.12 2493.00 (202.81) 2094.05 to 2891.95 0.655 0.654 0.246
Hospitalisation 111.11 (67.97) –22.52 to 244.73 24.87 (11.95) 1.37 to 48.36 0.189 0.052 Did not converge
Social care 309.36 (81.21) 149.70 to 469.01 515.05 (120.15) 278.83 to 751.26 0.166 0.145 0.124
Total cost 2994.41 (303.44) 2397.48 to 3591.35 2871.02 (243.07) 2392.86 to 3349.18 0.748 0.748 0.167
Total baseline cost (3 months
pre baseline to baseline)
1827.02 (273.80) 1288.85 to 2365.20 1635.20 (200.00) 1242.08 to 2028.32 0.57 0.565 0.134
After imputation
NHS excluding hospitalisation 2653.81 (228.53) 2203.81 to 3103.80 2521.66 (188.09) 2151.88 to 2891.44 0.658 0.659 0.499
Hospitalisation 107.36 (63.96) –18.42 to 233.13 23.39 (11.17) 1.44 to 45.34 0.197 0.00 Did not converge
Social care 376.23 (85.26) 208.66 to 543.80 524.25 (113.39) 301.41 to 747.09 0.295 0.287 0.237
Total cost 3137.39 (272.08) 2602.18 to 3672.61 3069.30 (228.13) 2620.88 to 3517.72 0.849 0.849 Did not converge
Total baseline cost (3 months
prior to baseline)
1849.02 (266.16) 1325.82 to 2372.22 1659.16 (194.26) 1277.38 to 2040.95 0.565 0.56 Did not converge
OLS, ordinary least squares; SE, standard error.
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slightly higher in the intervention group than in the control group (but the difference was not statistically
significant); however, the total baseline cost (i.e. from 3 months pre baseline to baseline) was also higher
in the intervention group. The most commonly used NHS services were GP, NHS physiotherapist, practice
nurse, Parkinson’s nurse and outpatient clinic, with at least one visit per patient over the 6-month follow-up
period. The intervention group was found to have fewer GP visits, practice nurse visits and home care help
visits; none of the differences was statistically significant. The most frequently used social service was home
care, of which, over the 6-month follow-up period, each participant in the intervention group had an
average of 13 visits and each participant in the control group had an average of 30 visits. Medication was
not included in the total costs because of the large number of prescriptions identified, the frequent low cost
of medications, identified comparability across arms and poorly reported data.
Health-related quality of life
The EQ-5D-3L health utility values for each treatment group at baseline and at 3, 6 and 12 months are
shown in Table 21 (complete case), Table 22 (after imputation) and visualised in Figure 10 (after imputation),
assuming a linear change between each assessment point. The completeness of the EQ-5D-3L questionnaire
at the 6-month follow-up was 79% (188/238) for the intervention group and 90% (213/236) for the control
group. The utility values of the intervention group declined slightly less than the control group over the
6-month, as well as the 12-month, period. The differences in utility values between the arms were small
(i.e. 0.031 at 6 months and 0.017 at 12 months) given that the full range of the EQ-5D-3L index score was
–0.592 (worst) to 1 (full health), and not statistically significant.
Cost-effectiveness base-case analysis
The cost-effectiveness results for the PDSAFE home-based personalised physiotherapy intervention are
presented in Table 23. Overall, the PDSAFE intervention is more costly within the 6-month time horizon
but generates greater HRQoL than the control. The average cost per patient was £4020 (95% CI £3531
to £4510) in the intervention group and £3095 (95% CI £2694 to £3496) in the control group, an
incremental cost of £925 (95% CI £428 to £1422). The average QALY gain was 0.34 (95% CI 0.326 to
0.345) QALYs in the intervention group and 0.328 (95% CI 0.319 to 0.337) QALYs in the control group,
The intervention group had an incremental 0.008 (95% CI –0.006 to 0.021) QALY gain compared with
the control group.
The cost-effectiveness plane for the base-case analysis is shown in Figure 11. The dyads come from the 1000
bootstrap iterations. The x-axis represents the bootstrapped incremental QALYs between the randomisation
groups and the y-axis represents the incremental costs. All of the simulated cost–utility dyads were in the
north quadrant, indicating that the intervention was always more expensive than the control. Similarly, the
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FIGURE 9 Mean cost of NHS and social care resources use per patient over the 6-month follow-up period.
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TABLE 21 The EQ-5D-3L visual analogue scale and index value (complete case)
Time point
Trial group
p-value
PDSAFE (N= 238) Control (N= 236)
n Mean SD SE
Minimum,
maximum n Mean SD SE
Minimum,
maximum
Visual analogue scale
Baseline 232 60.685 23.595 1.549 3, 100 233 60.811 24.715 1.619 3, 100 0.96
3-month 210 62.486 22.841 1.576 4, 100 217 62.465 23.350 1.585 5, 95 0.99
6-month 188 63.750 21.808 1.590 5, 100 213 63.394 21.872 1.499 3, 100 0.87
12-month 121 64.322 17.209 1.564 25, 99 136 64.331 17.816 1.528 9, 100 1.00
Index score
Baseline 235 0.657 0.232 0.015 –0.181, 1 235 0.669 0.245 0.016 –0.115, 1 0.60
3-month 210 0.677 0.244 0.017 –0.086, 1 216 0.668 0.247 0.017 –0.077, 1 0.70
6-month 190 0.680 0.217 0.016 –0.016, 1 216 0.644 0.258 0.018 –0.126, 1 0.13
12-month 124 0.643 0.269 0.024 –0.016, 1 141 0.635 0.272 0.023 –0.115, 1 0.81
Utility change
6 month – baseline 188 0.008 0.239 0.017 –1, 0.795 215 –0.022 0.260 0.018 –0.795, 0.672 0.2266
12 month – baseline 123 –0.039 0.279 0.025 –1, 0.639 140 –0.053 0.295 0.025 –0.883, 0.743 0.7052
SE, standard error.
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TABLE 22 The EQ-5D-3L index value (after imputation)
Time point
Trial group
PDSAFE (N= 238) Control (N= 236)
Mean (SE) 95% CI Mean (SE) 95% CI
Baseline 0.657 (0.015) 0.628 to 0.687 0.669 (0.016) 0.637 to 0.700
3 months 0.672 (0.017) 0.638 to 0.705 0.664 (0.017) 0.630 to 0.697
6 months 0.672 (0.016) 0.640 to 0.704 0.641 (0.017) 0.607 to 0.676
12 months 0.644 (0.027) 0.590 to 0.697 0.626 (0.028) 0.571 to 0.681
SE, standard error.
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FIGURE 10 The EQ-5D-3L utility values at baseline and at 3, 6 and 12 months (after imputation).
TABLE 23 Cost-effectiveness results (after imputation) with 6-month follow-up
Trial group
Cost (£)a QALYb
Mean SE 95% CI Mean SE 95% CI
PDSAFE (n = 238) 4020.3 249.7 3530.7 to 4509.8 0.336 0.005 0.326 to 0.345
Control (n = 236) 3095.3 204.5 2694.3 to 3496.2 0.328 0.005 0.319 to 0.337
Difference (95% CI) 925.0 253.5 427.8 to 1422.2 0.008 0.007 –0.006 to 0.021
ICER 120,659 per QALY
95% CI for ICER (from bootstrap) –1,056,012.00 to 434,764.80
SE, standard error.
a Adjusted cost; per-participant intervention cost is included in the cost of the intervention group.
b Adjusted QALY.
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majority of the simulated cost–utility dyads were in the east quadrant, indicating that the intervention
was very likely to improve health outcomes compared with the control. The flat oval shape of the
cost-effectiveness plane indicates that there is a higher degree of uncertainty surrounding the estimates
of the incremental QALYs than the incremental cost, leading to a wide 95% CI for the estimate of ICER.
The CEAC for the base-case analysis is shown in Figure 12. The probability that the intervention was
cost-effective at the £30,000 per QALY threshold was 0.5%. This corresponds to the very few dyads
under the sand line in the cost-effectiveness plane in Figure 11.
Subgroup cost-effectiveness analysis
The results for the subgroups defined according to cognitive function, presence of freezing symptoms,
MDS-UPDRS and retrospective falls at baseline are presented in Table 24. The results indicated that the
ICER was lower in two subgroups (although still above NICE’s upper threshold of £30,000): (1) participants
who were cognitively impaired (MoCA score of ≤ 25) and (2) participants whose Parkinson’s was of
moderate severity (MDS-UPDRS score of between 22 and 39). Compared with the control group, those in
the cognitively impaired subgroup of the intervention arm (n = 184) consumed less resource (–£462.80,
excluding the intervention cost) and achieved a similar QALY gain to the control group; therefore, the ICER
for the PDSAFE intervention versus control was £39,486. In the subgroup including those participants with
Parkinson’s moderate severity of (n = 161), the PDSAFE intervention was associated with an incremental
cost of £500 and an incremental QALY (0.016) that was double the incremental QALY gain of the overall
group, leading to an ICER of £30,731.
Although still above the £30,000 per QALY threshold, compared with the base-case analysis the ICER is
lower in the following subgroups: participants with moderate cognitive function (£84,925 per QALY gained),
participants who had not experienced freezing symptoms (£61,687 per QALY gained) and participants
who had had at least two falls in the 12-month period prior to recruitment (£53,860 per QALY gained for
participants who had two or three falls and £82,532 per QALY gained for participants who had more than
three falls). In addition, the increase in QALYs gained in the PDSAFE intervention arm for the participants
who had not experienced freezing episodes was statistically significant [0.021 (95% CI 0.0007 to 0.041)
QALYs]. In contrast, the PDSAFE intervention was found to be less effective than usual care and more costly
in two subgroups, the subgroup with more severe Parkinson’s (i.e. those with a MDS-UPDRS score of ≥ 39)
and those who had experienced freezing episodes; therefore, usual care dominated PDSAFE in both of these
subgroups.
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FIGURE 12 Cost-effectiveness acceptability curve.
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Sensitivity analysis
The results of the sensitivity analysis are presented in Table 25. Although the PDSAFE intervention was
cost-ineffective compared with the control in all sensitivity analysis, the ICER decreased by more than half
when estimated over a 12-month time horizon with around half of the data imputed based on the
observed data. This was due to the linearly interpolated increase in QALYs over the 12-month period.
Discussion
The results showed that the PDSAFE home-based personalised physiotherapy intervention was not likely
to be cost-effective for the overall Parkinson’s population from the NHS and PSS perspective over the
6-month time horizon at a £20,000 to £30,000 threshold for the ICER estimated. There was little difference
in the mean cost of NHS and social service use between the treatment groups. The utility values declined
slightly less in the intervention group than in the control group over the trial period, but the difference was
minimal and not statistically significant.
A high degree of uncertainty over the QALYs gained was observed, leading to a wide CI for the estimate
of the ICER, which may be a result of the small mean QALY gained observed and large variation among
the participants. Another possible explanation might be related to the limitation of the EQ-5D-3L
questionnaire in capturing the impact of the PDSAFE physiotherapy intervention on QoL aspects, such as
TABLE 24 Subgroup analysis results (over 6 months)
Analysis
Incremental (PDSAFE – control) (95% CI)
ICER (cost per
QALY gained) (£)Cost (£) QALYs
Base-case analysis
Base-case 925.0 (427.8 to 1422.2) 0.008 (–0.006 to 0.021) 120,659
Subgroup by MoCA (cognitive function)
Impaired (MoCA score of ≤ 25) (n = 184) 292.9 (–890.4 to 1476.2) 0.007 (–0.014 to 0.029) 39,486
Not impaired (MoCA score of 26 or 27)
(n = 122)
1512.9 (206.9 to 2819.0) 0.018 (–0.008 to 0.043) 84,925
Good cognitive function (MoCA score of ≥ 28)
(n = 168)
1513.8 (329.4 to 2698.2) 0.0006 (–0.020 to 0.021) 2,613,629
Subgroup by the presence of freezing symptoms
No freezing (n = 182) 1284.8 (234.3 to 2335.3) 0.021 (0.0007 to 0.041) 61,687
Freezing (n = 291) 851.5 (–169.9 to 1872.8) –0.0006 (–0.018 to 0.017) Control dominates
Subgroup by MDS-UPDRS (Parkinson’s severity)
Lowest disease severity (MDS-UPDRS score of
≤ 22) (n = 153)
1956.2 (746.9 to 3165.6) 0.006 (–0.015 to 0.028) 301,605
Moderate disease severity (MDS-UPDRS score
of 23–38) (n = 161)
500.1 (–760.6 to 1760.8) 0.016 (–0.006 to 0.039) 30,731
Highest disease severity (MDS-UPDRS score of
≥ 39) (n = 158)
600.2 (–639.7 to 1840.0) –0.004 (–0.027 to 0.019) Control dominates
Subgroup by retrospective falls
One fall (n = 99) 1201.3 (–117.3 to 2519.8) 0.010 (–0.018 to 0.038) 197,810
Two or three falls (n = 198) 1121.1 (7.4 to 2234.8) 0.009 (–0.011 to 0.030) 53,860
More than three falls (n = 177) 724.8 (–531.5 to 1981.1) 0.007 (–0.014 to 0.029) 82,532
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improved falls efficacy and less fear of falling, as identified in the effectiveness results and qualitative study
in this report.
Subgroup analyses indicated that the PDSAFE intervention is more likely to be cost-effective in the
subgroup of participants who are cognitively impaired. This is due to the slightly lower (albeit non-
significant) NHS and social care service costs arising in this subgroup of the intervention arm compared
with the control group. The estimated NHS and social resource use costs in the cognitively impaired
subgroup were £3916.90 in the control group and £3454.20 in the intervention group, with a marginal
£462.70 lower resource use cost in the intervention group. In contrast, the intervention arm was associated
with higher resource use in the moderate cognitive function and good cognitive function subgroups
(marginal cost £709.20 and £664.20, respectively). In terms of individual service use, among the cognitively
impaired subgroup, the intervention group, in comparison with the control group, attended significantly
fewer outpatient clinic appointments (1.23 vs. 2.10; p = 0.02), received fewer social worker visits (0.02 vs.
0.14; p = 0.10). However, statistical significance for the differences between groups was not observed for
the other health-care resources. The details of the comparison of resource use between the intervention
and control groups among the cognitively impaired subpopulation are presented in Appendix 19. The
resource use savings arising in this subgroup may be attributed to the unusually high cost of the control
arm of this subgroup and the relatively lower cost of the intervention arm as a response to the improved
falls efficacy, reduced near-falls and improved balance; however, it could also be due to chance.
The intervention was also more likely to be cost-effective in the subgroup of participants who had a
Parkinson’s of moderate severity (MDS-UPDRS score of 23–38), owing to the cost savings arising in service
use and the larger magnitude of QALY gain. This is in line with the effectiveness results showing that the
PDSAFE intervention was associated with a statistically significantly lower risk of falling in this subgroup in
the FRR analysis. In addition, the ICER estimate of the PDSAFE intervention was lower than the overall
sample in the participants who had moderate cognitive function, those who had not experienced freezing
symptoms and those who had had at least two falls in the year prior to recruitment. In terms of the impact
on HRQoL, the PDSAFE intervention was shown to be statistically beneficial in participants who had not
experienced freezing episodes, whereas in participants who had experienced freezing episodes or had
severe Parkinson’s, it resulted in a lower mean QALY gain than in the control group.
TABLE 25 Sensitivity analysis: summary of results
Analysis
Incremental (PDSAFE – control) (95% CI)
ICER (cost per
QALY gained) (£)Cost (£) QALYs
Base-case analysis
Base case (6 months) 925.0 (427.8 to 1422.2) 0.008 (–0.006 to 0.021) 120,659
Time horizon
12 months 1176.2 (248.5 to 2103.9) 0.021 (–0.011 to 0.054) 55,176
Cost
10 sessions (actual number of sessions) 824.7 (327.7 to 1321.8) 0.008 (–0.005 to 0.021) 105,360
Number of sessions reduced to eight 719.2 (225.5 to 1212.9) 0.008 (–0.005 to 0.021) 91,876
Missing data
Complete-case analysis (n = 288) 1138.8 (588.4 to 1689.3) 0.010 (–0.006 to 0.025) 117,226
Routine use of physiotherapist
Routine physiotherapist visit not included
in the overall cost
903.1 (416.4 to 1389.8) 0.008 (–0.005 to 0.020) 120,086
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Sensitivity analyses indicated that the intervention was more likely to be cost-effective when a 12-month
time horizon was adopted, although only half of the data at the 12-month follow-up were directly
observed. This is because of the difference in HRQoL at the 6-month primary end point, as well as the
persistent benefit of the intervention beyond the 6-month intervention period. At 12 months, HRQoL in
the intervention group was still higher than in the control group with both observed-only data and
imputed data; therefore, it is likely that this difference would last beyond the 12-month follow-up point.
This means that the probability of the intervention being cost-effective might increase if the results were
extrapolated over a longer time horizon; although it would require a longer follow-up study to test the
long-term effect because of the large number (50%) of missing data at the 12-month follow-up.
It was found that there was a statistically significantly higher use of routine NHS physiotherapy in the
intervention group than in the control group over 0–3 months (1.3 vs. 0.7 times), 3–6 months (1.0 vs.
0.7 times) and 6–12 months (1.4 vs. 0.8), but not during the 3-month period prior to baseline (1.1 vs.
1.0 times). The intervention lasted for 6 months and the higher use of physiotherapists in the intervention
group over 0–6 months is likely to be because some participants included trial therapist visits in their health
and social care service use data, despite the distinction being made. Originally, the routine service use of
physiotherapists was designed to be collected through assessor interview in which the participants could
have had more guidance. However, a risk of unblinding the assessors was identified; therefore, the NHS
routine resource use questions were sent by post to the participants and filled in by participants themselves
at home. Even so, this does not explain the higher use of physiotherapists from 6 to 12 months. In this
situation, it is possible that some of the participants in the intervention group found the intervention effective
and therefore continued having physiotherapy visits provided by the routine services. Despite the possible
inaccuracy in the reported number of visits, the sensitivity analysis assuming no difference between the use of
this routine service found that this had little effect on the magnitude of ICER and, therefore, is not likely to
cause any bias.
Overall, the cost-effectiveness analysis results reflect the primary outcomes of the trial, in that there was no
difference in the risk of repeat falling, but the intervention was associated with a lower risk of near-falling, better
balance and an increased confidence in mobility. This mixed result may contribute to the small mean QALY gain
(0.008 years over the 6-month trial period) as well as the large degree of uncertainty surrounding the QALY
gain, which led to the wide CI of the ICER. The uncertainty analysis (see Figure 12) revealed that the probability
of the intervention being cost-effective is 0.5%, which suggested that the PDSAFE intervention was probably
not cost-effective from the NHS and PSS perspectives. The large magnitude of ICER was attributed primarily to
the very small QALY gains rather than the intervention cost. It was shown in the sensitivity analysis that, even
when the number of PDSAFE physiotherapy sessions was reduced from 12 to 8, the ICER (£91,876 per QALY)
was still much higher than the NICE threshold (£20,000–30,000 per QALY) because of the unchanged
incremental QALY gain. Therefore, cost reduction strategies only, such as changing home-based sessions to
group sessions, will not result in the intervention being cost-effective unless the effectiveness improves.
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Chapter 8 Discussion and conclusions
Main finding in context
To our knowledge, PDSAFE is the largest trial of physiotherapy for fall prevention among people with
Parkinson’s; it was novel, with an intervention that was personalised and conducted in the home. The
sample was more than double the size of any previous trial in the field. Despite this, the findings failed to
demonstrate that PDSAFE was effective in reducing falls in a heterogeneous sample of people with
Parkinson’s. The non-significant result is similar to that found by previous researchers of trials with > 100
participants.17,37,40,72,73 The exception is the trial by Morris et al.,72 who in 2015 reported a positive effect of
exercise training on fall reduction, largely conducted in an outpatient setting. Interestingly, they did not
replicate the finding in 2017 when training was delivered at home and at a lower frequency.73 Two other
research groups found a reduction in falls from interventions outside of normal physiotherapy delivery,
with virtual reality and treadmill training74 and tai chi.75 A mixed and very small response, with short- and
long-term effects, to various exercise interventions for fall reduction emerged from the meta-analysis by
Shen et al.76 This PDSAFE trial had a very heterogeneous sample; unlike other fall prevention trials, those
with high disease severity or those with more complex symptoms, such as freezing, were not excluded.
Wide spectrum of falling
The wide spectrum of falling experiences among participants in the sample may have contributed to the
non-significant finding. People with one fall were included, as were those with multiple falls and those
reporting falling every day in the year prior to commencing the trial. This inclusive approach was typical of
other trials and a reflection of a Parkinson’s population. The PDSAFE treatment was personalised; for this
reason, it was believed that the management of the range of profiles would have been addressed. However,
in hindsight, multiple falls are not just about the numbers of falls: the complex and varied nature of falling
among people with Parkinson’s may have been the challenge and the key contributing factor to the non-
significant treatment effect in this trial. Among this population, falls are indicative of a changing disease
process, the pathway from non-falling to near-falling, to falling and to repeat falling can differ, and falls
among established repeat fallers are different from the single-faller experience.77 People with Parkinson’s
who have an established pattern of falling will have more global features of decline that may be age-
and/or disease-related; Lord et al.77 suggest that these progressive features create additional challenges for
implementing appropriate management and research. Other researchers17,37,40 have previously suggested
that those with less severe Parkinson’s have responded positively to fall reduction programmes, but that
effect has been counterbalanced with the deterioration experienced among those with more severe disease,
leading to non-significant results. The analysis of our trial reflects a similar pattern.
Freezing of gait and worse Parkinson’s
As with any group of people with Parkinson’s, this sample included those with and without FoG. The motor
learning potential is reduced in people who freeze78,79 and there is increasing evidence that FoG is an important
risk factor of falls and associated with reduced balance22 and impaired cognition. The inclusion of people who
did or did not experience freezing illustrates the diverse range of motor problems present in a community
sample of people with Parkinson’s and the range of challenges faced when teaching and learning new skills.
Interestingly, all participants in the trial showed overall improvement in impairments such as balance, but no
overall significant reduction in falls in response to PDSAFE. The complexity of fall avoidance, it seems, resides
in the transition between these two features. More supervised therapy focused around the fall avoidance
strategies may have been required, even though a specific strategy for FoG was included in the training
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programme. As with those experiencing FoG, people with greater disease severity (more likely to have
additional cognitive impairment) may be more restricted in their ability to implement fall avoidance strategies
and may also have had greater difficulty in engaging in unsupervised sessions, thus limiting the intensity of
practice and the effects.
Cognitive impairment
Participants were screened for cognitive impairment, namely a score of ≥ 24 on the MMSE scale, to ensure
that understanding of and compliance with the exercise programme of the trial was not compromised.
In spite of this eligibility procedure, some participants were recruited to the trial with cognitive impairment
identified later through a low score on the MoCA. The MoCA is known to be more sensitive to specific
cognitive deficits linked to frontal and executive function associated with people who fall,80 but at the time
of designing this trial it was still a relatively new test and not widely used. To explore whether or not this
was a factor contributing to the lack of benefit overall, we looked at subgroups defined by tertiles of MoCA
score at baseline and found a pattern of association between decreasing MoCA score and decreasing
PDSAFE benefit with respect to the falling outcomes. As previously highlighted, all participants, even those
with cognitive impairments, showed improvements in their balance scores and fall efficacy scales. This is
interpreted as indicating that these participants were able to comply with exercise even when their MoCA
scores were low but were not able to benefit from the more demanding fall prevention programme, for
whatever reason. In future research, including MoCA81 as an eligibility criterion is recommended, although
researchers such as Domingos et al.82 have called for more studies into fall prevention with people with
impaired cognition.
Treatment of fall risk
The fall risk factors of participants in the trial (i.e. the secondary outcome measures of balance, falls
efficacy and functional strength) were targeted in the intervention; the analysis demonstrated a consistent
improvement across the whole PDSAFE group. A positive PDSAFE effect on near-falls, an indicator of
instability and reflective of the improvements in balance, was also reported. These results support those of
others,77 highlighting the benefits of exercise for balance and gait ability. Interventions in previous trials have
been delivered largely outside the home, but the results of this study demonstrate similar findings from
interventions within the home environment, which is important for those with fewer opportunities for
access, those who are unable to regularly travel for training or those who may suffer from fatigue or apathy.
Therapy
A strength of the trial was the evidence-based therapy programme delivered by skilled trained
physiotherapists. The training was structured and practice was rigorously tested for fidelity. Participants
received, on average, 11 or 12 face-to-face supervised sessions of 1–1.5 hours’ duration and were
encouraged to complete unsupervised daily practice, meeting the recommendations of Sherrington et al.83
of at least 50 hours of practice. Previous research has used a range of different interventions, often poorly
described, with a great deal of diversity of treatment protocols and dosage.76 This programme was
multidimensional, requiring individuals to progress their activities and to integrate their training into
everyday functional tasks; although this would have been manageable for those in the moderate to least
severe disease group, it may have been too challenging for those at the more severe end of the spectrum,
despite treatment being personalised. Active participation and cognitive reasoning were needed to comply
with PDSAFE and progress to self-management for falls avoidance. Participants at the severe end of the
disease spectrum with cognitive impairment and FoG may have needed more supervised sessions focused
on fall prevention strategy training.
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In the longitudinal qualitative inquiry into the expectations and experiences of people with Parkinson’s, the
first of its type, it was found that many of the participants receiving the treatment had realistic and well-
informed expectations about the PDSAFE intervention at the outset. Most had had previous experience of
physiotherapy and a variety of other rehabilitation interventions. Participants seemed well motivated to embark
on the programme for a variety of personal reasons, including anticipated benefits relating to improved
mobility and function, and more general improvements in confidence and independence. People also wanted
to participate for altruistic reasons, hoping that the research would benefit others with Parkinson’s. This variety
of potential motivations for participating in exercise by people with Parkinson’s, including the altruistic desire
to help others, was also found by O’Brien et al.84 in exploring views of people with Parkinson’s about
participation in an exercise group. PDSAFE was valued for its convenience, in being delivered at home, and
also for the input from specialist physiotherapists with experience and expertise in Parkinson’s.
Participants recalled the exercise programme well at the time of the second visit, and were able to
describe, in some detail, specific components. They recognised that the exercise programme was graded,
becoming more intense as it progressed, and acknowledged that their programmes were individually
tailored. Several also highlighted the strategies in describing the programme, and understood better the
process of discussion and negotiation whereby exercises and strategies were designed to meet individual
needs and expectations.
The mixed reactions to the equipment were affected by the value that participants placed on the increased
intensity that they afforded. The varied responses to the technology used within PDSAFE reflected a
continuum of familiarity and use among participants. However, some who were familiar with computers
and smartphones felt that the visual images should be offered in alternative formats (e.g. as an app),
which they could download and keep with them (e.g. on a tablet). These findings highlight a need to be
creative and flexible when using technology, in order that the means of delivery can likewise be tailored to
suit individual participants.
Most participants felt that the PDSAFE intervention had been of some benefit, when reflecting on its impact,
whether in mobility, balance, strength or freezing, more general functional activities or improved confidence
and independence. Similar views were expressed by people with Parkinson’s in Quinn et al.,85 who believed
that exercise would keep them ‘strong, functional and fit’. A significant minority of our participants mentioned
that they experienced fewer falls, or were more aware of triggers for falls. A wide variety of benefits were
highlighted, not all of which were captured by the outcome measures used within the main trial.
In terms of barriers to participation, lack of motivation was highlighted as a specific challenge. Participants
valued the encouragement, monitoring and feedback provided by the therapists, and missed this once
visits became less frequent and eventually stopped. Feedback from physiotherapists was also found
by O’Brien et al.86 to be important to people with Parkinson’s in making decisions about exercise
engagement. Another barrier was the time required to complete the individualised programmes; several
participants mentioned their other competing commitments and difficulties in carrying out the PDSAFE
intervention, either in full or at all. Many participants had busy lives including leisure activities, Parkinson’s
groups and family commitments, particularly those whose symptoms were not so severe.
The social support and encouragement provided by both the treating physiotherapists and others such as
spouses, carers and partners seemed to be the biggest facilitator for continued engagement with the
programme. Ravenek and Schneider,87 in the first study exploring factors influencing participation in
physical activity by people with Parkinson’s, highlighted the significance of social support, and described
three types: instrumental, information and emotional support. Participants mentioned that they found
written information about the PDSAFE intervention useful; this was offered in blue folders to which many
made reference.
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Fall recording
The most widely adopted and recommended process for recording fall events is the use of self-reported falls
diaries,88 as used in the trial. The process is dependent on recall but open to error, most likely under-reporting,
particularly when someone has multiple falls. For example, participants who did not receive any treatment
(i.e. the control group) had very little interaction with the trial team, and thus received fewer reminders to
complete falls diaries than the intervention group. It may be that those in the control group, particularly those
with cognitive impairment, were less likely to report falls. Conversely, those in the treatment group may
perhaps be more likely to report falls. Near-falls are open to similar errors of recording; they are events that
would result in a fall if protective moves such as reaching out or stepping were not taken.26 Near-falls among
people with Parkinson’s have been reported by a number of researchers, such Gazibara et al.89 and Ashburn
et al.;37 they are often related to stumbling or balance loss, and have been observed to predispose the general
older population to falling.90 Gazibara et al.89 describe near-falls as common among people with Parkinson’s
and particularly among people with FoG. In this trial, participants received guidance on recording fall events,
had a 3-month run-in period for recording falls and received reminders to keep records throughout the trial.
It is possible that participants in the intervention group were more aware of falling and kept more accurate
records. In the future, body-worn sensor technology could be adopted, although the feasibility of this in
clinical trials is not yet clear.
Beneficial effects on falls and stratification
As already stated in this discussion, previous researchers17,37,40 have suspected that those with less severe
Parkinson’s have responded to fall reduction programmes, whereas, in their trials, deterioration may
have occurred among people in the worse categories of Parkinson’s. For that reason, disease severity and
FoG were prespecified in a secondary subgroup analysis of PDSAFE; that analysis demonstrated a diverse
response to the intervention programme. Those with moderate disease severity benefited most from the
intervention, with a fall reduction of 30% over 6 months. Those at the severe end of the disease spectrum
and those with FoG experienced an increase in falls of between 43% and 50% over the same period.
The overall improvements in fall risks suggested that sufficient therapy for learning and responding to an
exercise programme was delivered but fall avoidance by those at the severe end of the disease spectrum
fell short. A greater understanding of the complexities of the transition from improved movements to fall
avoidance in people who are compromised by a progressive condition is needed. At a simplistic level,
PDSAFE may have made people more confident in their daily activities that exposed them to greater fall
risk, to which the more able could respond effectively, but the more severely affected were unable to
implement strategies for fall avoidance. People with more severe disease (i.e. more likely to have additional
cognitive impairment and possibly FoG) may be more restricted in their ability to choose how to respond
and may also have greater difficulty in engaging in unsupervised sessions, thus limiting the intensity of
practice and the effects of fall prevention. Falls management needs to be stratified with careful
consideration of the needs of those with multiple challenging issues that come with a progressive
condition. The benefits highlighted by the secondary analysis on those with moderate disease severity need
to be confirmed in a further trial.
Health economics
The results of the health economics analysis showed that the PDSAFE home-based personalised
physiotherapy intervention was not likely to be cost-effective for the overall Parkinson’s population from
the NHS and PSS perspectives over the 6-month time horizon at a £20,000- to £30,000-per-QALY threshold
for the ICER estimated. There was little difference in the mean cost of NHS and social service use between
the treatment groups. The utility values of the intervention group declined slightly less than in the control
group over the trial period, but the difference was minimal and not statistically significant.
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Although not cost-effective in the overall population, subgroup analyses indicated that the PDSAFE
intervention appears to be cost-effective in the subgroup of participants with more severe disease. This is
because of the substantial saving of NHS and social care services arising in this subgroup of the intervention
arm. The intervention was also cost-effective in the subgroup of participants who had Parkinson’s of
moderate severity (i.e. a MDS-UPDRS score of 23–38), because of the reduction in service use and the larger
magnitude of QALY gain. In terms of the impact on HRQoL, the PDSAFE intervention was shown to be
statistically significantly beneficial in participants who had not experienced freezing episodes whereas,
among participants with severe Parkinson’s, it resulted in a lower mean QALY gain than the control group.
Sensitivity analyses indicated that the intervention was more likely to be cost-effective when a 12-month
time horizon was adopted; although only half of the data for participants at the 12-month follow-up were
directly observed. This is because of the difference in HRQoL at the 6-month primary end point, as well as
the persistent benefit of the intervention beyond the 6-month intervention period. At 12 months, HRQoL
in the intervention group was still higher than in the control group, with both observed-only data and
imputed data; therefore, it is likely that this difference would last beyond the 12-month follow-up point.
This means that the probability of the intervention being cost-effective might increase if extrapolating the
results to a longer term.
Limitations
Most participants in the trial were followed to 12 months, with the primary outcome measured at 6 months
post randomisation; however, the last 132 participants to be recruited could be followed only to the primary
outcome point (i.e. 6 months) because of restricted funding. This meant that the numbers of participants
in the trial reduced during the period between 6 and 12 months, creating a limitation in the analysis and
interpretation of the long-term outcome of the intervention and the health economic sensitivity analysis.
Participants were asked to complete a number of self-recorded diaries. The most important was the falls
diaries for the primary outcome. The trial team invested a great deal in facilitating the completion of the
falls diaries. Self-recorded data on unsupervised practice of the intervention was incomplete. The demand
on the participant meant that recording of unsupervised practice was not always completed and was less
of a priority than the falls record.
Implications for practice
l The PDSAFE intervention did not reduce falls in a heterogeneous sample of people with Parkinson’s.
l Secondary analysis supported previous research findings that exercise had a positive effect on fall risk.
Future research
l Future fall prevention trials should not target heterogeneous samples but specific groups of people
with Parkinson’s.
l Primary trials of fall prevention for disease-specific groups are recommended.
l Secondary analysis demonstrated that the PDSAFE intervention did have a positive effect on balance,
functional strength, falls efficacy and near-falls.
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Conclusion
The PDSAFE intervention did not reduce falls in a heterogeneous sample of people with Parkinson’s. There
was evidence of improvement in balance, functional strength and falls efficacy, with a reduction in near-falls.
Secondary analysis showed diverse responses to the intervention in accordance with disease severity and
FoG. Further trials of falls prevention on targeted groups of people with Parkinson’s are recommended.
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Appendix 1 Participant invitation letter
<Printed on local headed paper 
with address and telephone number> 
 
PARTICIPANT INVITATION LETTER 
 
A randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people with 
Parkinson’s: Main Trial 
 
 
Dear 
 
I am writing on behalf of Dr, to invite you to take part in a research trial, ‘A randomised controlled trial of the 
effectiveness of PDSAFE to prevent falls among people with Parkinson’s.  This research is being led by 
Professor Ann Ashburn, Professor of Rehabilitation at the University of Southampton.  We are considering new 
ways of helping people with Parkinson’s to maintain safe balance and walking and we have chosen to do this by 
studying the benefits of exercises and strategies designed to help people to improve the way they move about.  I 
enclose an Information Sheet that explains more about the trial.  If you have any questions that are not answered 
in the Information Sheet please feel free to contact me using the details above.  
 
If you are interested in taking part in this trial and would like further information, I would be most grateful if 
you would complete the ‘reply slip’ enclosed and return it in the pre-addressed Freepost envelope provided.  
This will not commit you to taking part in the trial.  
 
Thank you. 
 
Yours sincerely, 
 
 
<Contact details for Local Assessor for the PDSAFE Trial> 
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Appendix 2 Participant information sheet
PARTICIPANT INFORMATION SHEET 
A randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people 
with Parkinson’s:  Main Trial
We would like to invite you to take part in our research trial. Before you decide whether or not to take 
part, we would like you to understand why the research is being carried out and what it would involve 
for you. Please take time to read the following information carefully and discuss it with friends, relatives,
and your GP if you wish. A member of our research team will go through this Information Sheet with
you and answer any questions you may have. If you would like further information, please do not 
hesitate to telephone the number above.
What is the purpose of this trial?
Parkinson's is a common, progressive condition that affects the body's nervous system. Over time
people with Parkinson’s are likely to become less steady, less able to move around within their homes 
and outside and more prone to falls. Although drugs are available to treat the symptoms of Parkinson’s,
reduced balance control and falls do not respond to drugs. There is some evidence that physiotherapy
can help, though to date there are insufficient research findings to quantify the benefits for people 
with Parkinson’s. A new exercise and strategy-based intervention for people with Parkinson’s, called
PDSAFE, has been developed by a research team led by Professor Ann Ashburn in Southampton.
PDSAFE is a personalised physiotherapy programme that is aimed to help with balance and movement. 
The purpose of this trial is to see if the PDSAFE intervention helps people with Parkinson’s to fall less
often and to assess whether it is cost-effective.  More specifically, our main question is: do people with
Parkinson’s who follow PDSAFE fall less than those who do not follow it? 
Why have I been invited?
We are planning to recruit 600 people with Parkinson’s to this trial. You have been identified as
someone who has been diagnosed with Parkinson’s and might be interested in taking part in this
research trial. You have been told about this trial either a) by a health professional who is known to
you, b) by your Parkinson’s support group, or c) because you have previously agreed that we could 
inform you of further research taking place at the University of Southampton or with the local research
network. 
Do I have to take part?
It is up to you to decide if you wish to join the trial. By returning the reply slip accompanying this
Information Sheet you are only agreeing to be contacted by a researcher at this point. He/she will
describe the trial and go through this Information Sheet with you. If you agree to take part, we will then
ask you to sign a consent form. You are free to withdraw at any time without giving a reason. Deciding 
not to take part or withdrawing from the trial at any point will not affect the standard of care you receive. 
What will happen to me if I take part? 
How long will I be involved with the research? 
You will be involved in the research over a period of approximately 15 months. 
How many times will I meet the researcher for assessments?
You will meet the researcher on five separate occasions for assessments. The first assessments will 
take place in the three months before the trial formally starts (a screening visit to obtain your written 
consent).  At the baseline assessment visit (three months later) you will be randomly allocated either to 
the exercise group, who will receive the PDSAFE intervention, or the control group. The researcher will
see you again for assessments at 3, 6 and 12 months after your random group allocation. 
Where will I meet the researcher? 
The assessments will take place in your own home. 
How long will these visits for assessments be? 
The assessments will take up to 90 minutes.
What happens during these assessment visits? 
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During the screening visit, the researcher will talk to you about the research trial and ask you to sign a 
consent form. The researcher will then ask you to complete two assessments to confirm your eligibility 
to join the trial. Should you be unable to complete these, the researcher will advise you that, 
unfortunately, you are not suitable to be included in the trial. If you complete the assessments the
researcher will proceed to ask you questions about your balance, ability to move about, stamina, vision, 
any falls you have had, ability to remember instructions and any medical and/or surgical condition you 
feel may affect the way you move. They will also ask you whether you have a carer whom we could 
approach to take part in the trial.  Having a carer is not a requirement for you to take part in the trial.
During the assessment visits (at baseline, 3, 6 and 12 months), you will be asked to complete a 
questionnaire on your quality of life, mood, fear of falling and an ability to complete everyday tasks. You 
only have to answer the questions you feel comfortable with and if you are unhappy with any of the
questions you may stop at any time. The researcher will also ask you questions about your usual leisure
activities and ask you to complete tests of your balance, posture, turning and walking. The assessment
of turning involves you turning round and may require video recording.  The balance tests involve you 
completing a series of exercises like standing up, reaching forward and attempting to stand on one leg.
You may also be asked to complete a hand grip test. You will not be asked to complete any tests you 
feel you cannot manage. You will be allowed to rest during and between tests. The tests can be 
stopped at any time if you become tired. 
Throughout the duration of the trial, you will be asked to record any falls you may have in a diary, which 
we will provide. We will explain the falls diary to you during the screening visit and give you a contact 
number to call if you have any queries about completing the falls diary.
Which group will I be put into? 
To date there are insufficient research findings to quantify the benefits of exercise on fall risk for people
with Parkinson’s. We do not know if taking part in these exercises will reduce your fall risk and how big 
the benefits of exercising are on other aspects of your wellbeing e.g. your balance. To find out, we
need to compare different treatments. We will allocate people to two groups; one group will have the
PDSAFE exercises and their usual care, while the other group will only have their usual care. The 
results are compared to see if one is better.  To try to make sure the groups are the same to start with,
each patient is put into a group by chance (randomly). 
If you are allocated to the PDSAFE exercise group: you will be asked to continue with your usual 
care and normal day to day life and you will be asked to follow the PDSAFE programme which will be
personalised to your needs and ability by a physiotherapist. If you are happy to do so the physiotherapist 
will ask you to comply with an exercise agreement, but only if you feel that this will encourage you to
practice the agreed exercises. The programme includes exercises for balance (such as standing still 
and reaching forwards and back and standing on foam and stepping sideways) muscle strengthening
(such as standing up from sitting, stepping up and down from a step, these may be progressed by
wearing a weighted vest adjusted to your ability) and strategies for improving walking, freezing (unable 
to move), steadiness and avoiding falls, as well as identifying fall hazards in and around your home. 
The physiotherapist will discuss the exercise treatment with you, teach you the exercises and together
you will identify how often you would practice the exercises during the week. The physiotherapist will
come to your house to practice the exercises with you.  The frequency of his/her visits will be reduced 
over a six month period; starting with one hour twice a week for two or three weeks, then once a week
for four to six weeks, followed by a visit at three months and a final visit at five months. 
In each treatment session, the physiotherapist will illustrate ways of improving means of moving around
by showing videos of demonstrations and s/he may video the treatment session, then transfer the film
onto DVD and return it to you, so that you can replay it at home. You will be provided with all of the 
necessary equipment (including lending you a DVD player if you do not have one at home) to allow you 
to take part in the intervention.  The DVD will enable multiple replays of a session as required and act 
as a reminder of the activity, instructions, information and feedback. PDSAFE will be delivered by
physiotherapists in your own home over a period of up to five months. As part of the intervention, the 
physiotherapist will identify fall hazards in and around your home. If the physiotherapist identifies any 
fall hazards, we will discuss these issues with you and try to find possible solutions. However, if the
hazards cannot be easily rectified by the research team, the physiotherapist will ask you for your 
permission to contact relevant authorities to address these hazards. You will be asked not to share the 
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treatment with other Parkinson’s friends as it is important that the exercises and videos are only
available to those under supervision in the treatment group of this trial.  
If you are in the control group: you will be asked to continue with your usual care and normal day to
day life. A physiotherapist will visit you to give you a DVD with information about Parkinson’s and visit 
again at the end of the trial to advise about safe mobility and leave a booklet containing general tips on
fall prevention and general advice about physical activities and strategies for balance and safety. 
Participants in the control group play an important role in the success of the trial.
Quality assurance 
In order to check the quality of assessments being performed on all participants and the delivery of
physiotherapy, advice and information, an additional member of the PDSAFE team may join the 
assessor and/or physiotherapist on an occasional visit. This will only apply to a very small number of 
participants. 
Personal views interviews:
A small group of trial participants (40 in total) will be invited to take part in interviews to talk about your
personal views of the treatment. If you agree to take part in this aspect of the trial, the first interview 
will be conducted soon after the baseline assessments are completed and prior to the start of the
intervention. The second interview will be six months later. The researcher will visit you at home to
discuss your experience. Interview visits will last approximately 60 minutes. 
What are the possible benefits of taking part?
There will be no direct benefit to you from taking part in the trial although you might enjoy completing
the exercises and being more active.  However it is hoped that the data collected will allow us to define
the benefits of PDSAFE, in terms of reducing falls and improving balance of people with Parkinson’s.
The cost of PDSAFE will be assessed using information about the treatment delivery costs. This
information will be used to further develop the treatment and enhance clinical services. 
Are there any risks involved?
Answering questions from questionnaires can sometimes cause distress but we do not anticipate any 
disadvantage or risks. You do not have to answer any questions or participate in activities you don’t 
wish to and can stop at any point. It is possible that taking part in exercises and/or assessments 
can cause instability and put you off balance. You do not have to practice any exercises or do any 
assessments you feel unsure about. A researcher will be present during the assessments to help
ensure your safety. 
Can you practice the exercises on your own?
Only after you have practiced with the physiotherapist and you both agree that you are happy and safe
to do so with the help of your strategy DVD.  
What if there is a problem or I have a complaint? 
If you feel you have any concerns or complaints about this trial you should contact Professor Ann 
Ashburn (
). If you remain unhappy 
and wish to complain, Ann will provide you with details of the University of Southampton and 
University Hospital Southampton NHS Foundation Trust Complaints Procedure. Alternatively, you 
may wish to speak to the local Patient Support Services, PALS on  < contact details for local Patient 
Support Services>.
Who is organizing the research & reviewing the trial?
The research is being led by Professor Ann Ashburn, Professor of Rehabilitation at the University
of Southampton. It has been reviewed by the National Ethics Research Service Committee South
Central – Hampshire B Research Ethics Committee and University Hospital Southampton are the 
sponsors. 
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Will my participation be kept confidential?
All information which is collected about you during the course of the research will be kept strictly
confidential. Each person will be allocated an ID number by which any documentation will be identifiable
to the researchers only.  All information will be kept in a locked filing cabinet in accordance with storage 
of medical records. The results from the trial will be entered into a University computer, accessible only
to the researchers. Any information about you which is used in research reports or publications will have
your name and address removed so that you cannot be identified.  Nevertheless, the research team is
required by law to break confidentiality where cases of malpractice, abuse, or risk to self or others are
disclosed.  Such cases will be referred to the appropriate authority.  
What happens when the research trial stops? 
When the research trial stops, the PDSAFE exercises as delivered by a physiotherapist will come to an
end and participants will continue to receive their usual care. The group who took part in the PDSAFE
exercises can choose to continue the exercises and will be able to keep their personalised PDSAFE
exercise DVD. The group who did not take part in the exercises will be able to keep the Parkinson’s 
information DVD and falls prevention booklet. We will disseminate our findings after the completion of
the study.
What will happen to the results of the research?
At the end of the research, the data collected will be securely stored at the University of Southampton 
for 10 years. The results will be presented at conferences and may be published in research papers
for scientific journals. If you would like a copy of the published results at the end of the trial please let 
us know. 
Contact for further information:
If you would like any further information please contact: 
< LOCAL CONTACT DETAILS> 
Or
Dr Kim Chivers Seymour (Trial Manager)
Thank you for taking the time to read this information. 
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Appendix 3 Participant reply slip
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Appendix 4 Falls diaries
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Appendix 5 Recruitment and randomisation
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FIGURE 13 PDSAFE recruitment against target.
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FIGURE 14 PDSAFE randomisation against target (90% of those recruited).
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Appendix 6 Power calculations
TABLE 26 Power calculations for primary and secondary falling outcomes: risk of repeat falling
Risk of repeat fallinga
Trial group (%) Required in analysis (n) Needed at (n)
Control PDSAFE Per group Total Recruitmentb Randomisationc
0–6 months (5% loss to follow-up)
13% difference 63 50 228 456 534 480
15% difference 70 55 163 326 382 344
15% difference 60 45 173 346 408 366
13% difference 63 50 228 456 534 480
6–12 months (10% loss to follow-up)
13% difference 63 50 228 456 564 508
15% difference 70 55 163 326 404 364
15% difference 60 45 173 346 430 386
a In EXSART,37 risks of repeat falling from 0 to 6 months were 68% for the control group and 56% for the
intervention group.
b Numbers needed at recruitment allow for 10% of those agreeing to enter the pre-randomisation falls collection period
not to participate in the main trial, and a further loss of 5% of falls information by 6 months and 10% by 12 months.
This is conservative in the case of the falls rate models, as participants dropping out during a period will contribute some
exposure time to the analysis.
c Numbers needed at randomisation allow for 5% loss of falls information by 6 months and 10% by 12 months.
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TABLE 27 Power calculations for secondary falling outcomes: fall rates
Fall ratesa Baseline rate per 3 months
Required in analysis (n) Needed at (n)
Per group Total Recruitmentb Randomisationc
FRR 0–6 months (5% loss to follow-up)
0.75 3 100 200 236 212
0.8 3 164 328 386 346
0.75 2.5 120 240 278 254
0.8 2.5 197 394 464 416
0.75 2 150 300 352 316
0.8 2 246 492 576 518
FRR 6–12 months (10% loss to follow-up)
0.75 3 100 200 250 224
0.8 3 164 328 408 366
0.75 2.5 120 240 298 268
0.8 2.5 197 394 488 438
0.75 2 150 300 372 334
0.8 2 246 492 610 548
a In EXSART, the FRR over the 6-month follow-up was 0.833; the control group had a rate of falls of 3 over 3 months of
follow-up.
b Numbers needed at recruitment allow for 10% of those agreeing to enter the pre-randomisation falls collection period
not to participate in the main trial, and a further loss of 5% of falls information by 6 months and 10% by 12 months.
This is conservative in the case of the falls rate models, as participants dropping out during a period will contribute some
exposure time to the analysis.
c Numbers needed at randomisation allow for 5% loss of falls information by 6 months and 10% by 12 months.
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Appendix 7 Sensitivity analysis
TABLE 28 Sensitivity analysis for ITT OR for repeat falling from 0 to 6 months and from 6 to 12 months, whole
group, based on three methods: restricted to those with 50% diary completion or more, restricted to full diary and
unrestricted to diary completion
Period
Trial group, n/N (%)
PDSAFE/controla OR (95% CI) p-valueaPDSAFE Control
Repeat falling restricted to ≥ 50% diaries
0–6 months 125/203 (62) 116/211 (55) 1.21 (0.74 to 1.98) 0.447
6–12 months 57/114 (50) 71/132 (54) 0.86 (0.45 to 1.65) 0.657
Repeat fallers restricted to full diary completion
0–6 months 79/130 (61) 83/158 (53) 1.31 (0.72 to 2.39) 0.374
6–12 months 34/64 (53) 37/76 (49) 1.28 (0.47 to 3.52) 0.627
Repeat fallers unrestricted to diary completion
0–6 months 134/237(57) 127/236 (54) 1.07 (0.69 to 1.66) 0.759
6–12 months 63/137 (46) 78/150 (52) 0.68 (0.38 to 1.22) 0.200
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period, and H&Y scale stage.
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Appendix 8 Repeat falling
TABLE 29 The ITT OR for repeat falling from 0 to 6 months and from 6 to 12 months, whole group and subgroups,
restricted to those with 50% diary completion or more
Participant
group
Period
(months)
Trial group, n/N (%)
PDSAFE/control
OR (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
All participants 0 to 6 125/203 (62) 116/211 (55) 1.21 (0.74 to 1.98) 0.447
6 to 12 57/114 (50) 71/132 (54) 0.86 (0.45 to 1.65) 0.657
MDS-UPDRS
score of ≤ 58
0 to 6 115/192 (60) 106/195 (54) 1.18 (0.71 to 1.95) 0.521
6 to 12 55/111 (50) 66/125 (53) 0.90 (0.47 to 1.74) 0.758
H&Y scale
stage ≤ 3
0 to 6 104/180 (58) 92/179 (51) 1.13 (0.68 to 1.87) 0.651
6 to 12 50/106 (47) 54/113 (48) 0.91 (47 to 1.76) 0.785
MoCA score
≤ 25 0 to 6 49/74 (66) 45/80 (56) 2.03 (0.91 to 4.54) 0.083 0.111
≥ 26 0 to 6 76/129 (59) 71/131 (54) 0.91 (0.49 to 1.67) 0.754
≤ 25 6 to 12 20/43 (47) 33/56 (59) 0.71 (0.25 to 2.02) 0.525 0.606
≥ 26 6 to 12 37/71 (52) 38/76 (50) 1.01 (0.44 to 2.29) 0.987
FoG
No 0 to 6 27/76 (36) 38/93 (41) 0.66 (0.32 to 1.38) 0.269 0.025
Yes 0 to 6 98/126 (78) 78/118 (66) 2.04 (1.03 to 4.06) 0.042
No 6 to 12 12/43 (28) 22/58 (38) 0.58 (0.21 to 1.57) 0.282 0.309
Yes 6 to 12 45/70 (64) 49/74 (66) 1.14 (0.48 to 2.70) 0.772
MoCA score
≤ 25 0 to 6 49/74 (66) 45/80 (56) 2.04 (0.91 to 4.55) 0.083 0.238
26 or 27 0 to 6 32/55 (58) 27/53 (51) 1.07 (0.42 to 2.79) 0.863
≥ 28 0 to 6 44/74 (59) 44/78 (56) 0.78 (0.35 to 1.75) 0.352
≤ 25 6 to 12 20/43 (47) 33/56 (59) 0.71 (0.25 to 2.01) 0.248 0.751
26 or 27 6 to 12 16/32 (50) 14/31 (45) 1.30 (0.38 to 4.43) 0.680
≥ 28 6 to 12 21/39 (54) 24/45 (53) 0.82 (0.27 to 2.45) 0.720
MDS-UPDRS score
≥ 39 0 to 6 44/61 (72) 41/74 (55) 2.55 (1.03 to 6.33) 0.044 0.140
23–38 0 to 6 48/77 (62) 35/60 (58) 0.80 (0.35 to 1.86) 0.609
≤ 22 0 to 6 33/65 (51) 39/76 (51) 0.97 (0.43 to 2.17) 0.942
≥ 39 6 to 12 16/29 (55) 29/46 (63) 0.80 (0.23 to 2.80) 0.727 0.943
23–38 6 to 12 24/49 (50) 18/38 (47) 1.02 (0.35 to 2.98) 0.976
≤ 22 6 to 12 17/36 (47) 23/47 (49) 1.02 (0.35 to 2.98) 0.936
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TABLE 29 The ITT OR for repeat falling from 0 to 6 months and from 6 to 12 months, whole group and subgroups,
restricted to those with 50% diary completion or more (continued )
Participant
group
Period
(months)
Trial group, n/N (%)
PDSAFE/control
OR (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
Retrospective falls
> 3 0 to 6 75/88 (85) 49/63 (78) 1.45 (0.57 to 3.67) 0.436 0.407
2 or 3 0 to 6 35/71 (49) 58/104 (56) 0.79 (0.39 to 1.61) 0.523
1 0 to 6 15/44 (34) 9/44 (20) 1.68 (0.59 to 4.77) 0.331
> 3 6 to 12 34/45 (76) 31/41 (76) 1.18 (0.36 to 3.88) 0.780 0.501
2 or 3 6 to 12 17/43 (40) 35/62 (56) 0.57 (0.22 to 1.49) 0.251
1 6 to 12 6/26 (23) 5/29 (17) 1.36 (0.32 to 5.73) 0.672
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period, H&Y scale stage, and the interaction term
where this is listed.
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Appendix 9 Falls rate ratio
TABLE 30 The ITT FRRs from 0 to 6 months and from 6 to 12 months: whole group and subgroups
Participant
group
Period
(months)
Participants
contributing
diaries, n
PDSAFE/control
FRR (95% CI)a
p-valuea
PDSAFE within
participant group Interaction
All participants 0–6 461 0.98 (0.80 to 1.19) 0.824
6–12 274 0.83 (0.62 to 1.11) 0.200
MDS-UPDRS
score of ≤ 58
0–6 429 0.95 (0.77 to 1.18) 0.648
6–12 256 0.79 (0.58 to 1.08) 0.142
H&Y scale
stage ≤ 3
0–6 395 0.99 (0.78 to 1.25) 0.915
6–12 240 0.80 (0.57 to 1.12) 0.191
MoCA score
≤ 25 0–6 178 1.19 (0.88 to 1.61) 0.255 0.088
≥ 26 0–6 283 0.85 (0.66 to 1.09) 0.208
≤ 25 6–12 112 1.06 (0.67 to 1.66) 0.810 0.154
≥ 26 6–12 162 0.69 (0.48 to 1.00) 0.050
FoG
No 0–6 181 0.89 (0.61 to 1.29) 0.527 0.566
Yes 0–6 279 1.01 (0.80 to 1.26) 0.964
No 6–12 112 0.81 (0.47 to 1.38) 0.766 0.956
Yes 6–12 161 0.82 (0.58 to 1.15) 0.251
MoCA score
≤ 25 0–6 178 1.12 (0.89 to 1.61) 0.246 0.089
26 or 27 0–6 119 1.06 (0.71 to 1.58) 0.778
≥ 28 0–6 164 0.75 (0.55 to 1.02) 0.055
≤ 25 6–12 112 1.06 (0.67 to 1.67) 0.800 0.361
26 or 27 6–12 70 0.66 (0.37 to 1.16) 0.148
≥ 28 6–12 92 0.72 (0.45 to 1.17) 0.191
MDS-UPDRS score
≥ 39 0–6 152 1.43 (1.04 to 1.95) 0.028 0.009
23–38 0–6 155 0.70 (0.50 to 0.98) 0.038
≤ 22 0–6 152 0.97 (0.69 to 1.37) 0.866
≥ 39 6–12 87 1.07 (0.67 to 1.72) 0.773 0.231
23–38 6–12 95 0.60 (0.36 to 1.01) 0.057
≤ 22 6–12 91 1.00 (0.59 to 1.70) 0.992
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TABLE 30 The ITT FRRs from 0 to 6 months and from 6 to 12 months: whole group and subgroups (continued )
Participant
group
Period
(months)
Participants
contributing
diaries, n
PDSAFE/control
FRR (95% CI)a
p-valuea
PDSAFE within
participant group Interaction
Retrospective falls
> 3 0–6 168 1.16 (0.88 to 1.52) 0.286 0.050
2 or 3 0–6 196 0.70 (0.50 to 0.96) 0.026
1 0–6 97 1.03 (0.59 to 1.80) 0.916
> 3 6–12 96 0.98 (0.64 to 1.49) 0.925 0.402
2 or 3 6–12 119 0.64 (0.40 to 1.04) 0.072
1 6–12 59 0.69 (0.31 to 1.54) 0.364
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling in the pre-randomisation falls collection period, H&Y scale stage, and the interaction term
where this is listed.
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Appendix 10 Near-falls rate ratio
TABLE 31 The ITT near-falls rate ratio from 0 to 6 months and from 6 to 12 months: whole group and subgroups
Participant
group
Period
(months)
Participants
contributing
diaries, n
PDSAFE/control
FRR (95% CI)a
p-valuea
PDSAFE within
participant group Interaction
All participants 0–6 447 0.67 (0.53 to 0.86) 0.001
6–12 280 1.01 (0.67 to 1.52) 0.968
MDS-UPDRS
score of ≤ 58
0–6 415 0.63 (0.49 to 0.80) 0.000
6–12 262 0.97 (0.64 to 1.46) 0.881
H&Y scale
stage ≤ 3
0–6 386 0.65 (0.51 to 0.83) 0.001
6–12 243 0.92 (0.60 to 1.41) 0.701
MoCA score
≤ 25 0–6 169 0.64 (0.43 to 0.96) 0.032 0.755
≥ 26 0–6 281 0.69 (0.51 to 0.93) 0.015
≤ 25 6–12 113 1.00 (0.53 to 1.88) 0.992 0.981
≥ 26 6–12 168 0.99 (0.59 to 1.68) 0.980
FoG
No 0–6 178 0.55 (0.37 to 0.84) 0.005 0.277
Yes 0–6 271 0.74 (0.54 to 0.99) 0.048
No 6–12 116 1.04 (0.54 to 2.03) 0.899 0.903
Yes 6–12 165 0.99 (0.59 to 1.66) 0.976
MoCA score
≤ 25 0–6 169 0.64 (0.43 to 0.96) 0.033 0.885
26 or 27 0–6 119 0.74 (0.47 to 1.17) 0.199
≥ 28 0–6 162 0.66 (0.45 to 0.98) 0.039
≤ 25 6–12 113 0.97 (0.52 to 1.81) 0.930 0.407
26 or 27 6–12 71 1.33 (0.63 to 2.82) 0.452
≥ 28 6–12 97 0.67 (0.33 to 1.35) 0.266
MDS-UPDRS score
≥ 39 0–6 148 0.74 (0.49 to 1.12) 0.152 0.364
23–38 0–6 150 0.56 (0.37 to 0.85) 0.007
≤ 22 0–6 150 0.85 (0.56 to 1.28) 0.429
≥ 39 6–12 90 1.32 (0.65 to 2.70) 0.446 0.567
23–38 6–12 97 0.77 (0.38 to 1.58) 0.483
≤ 22 6–12 93 1.11 (0.56 to 2.21) 0.763
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TABLE 31 The ITT near-falls rate ratio from 0 to 6 months and from 6 to 12 months: whole group and subgroups
(continued )
Participant
group
Period
(months)
Participants
contributing
diaries, n
PDSAFE/control
FRR (95% CI)a
p-valuea
PDSAFE within
participant group Interaction
Retrospective falls
> 3 0–6 166 0.74 (0.51 to 1.07) 0.113 0.652
2 or 3 0–6 187 0.70 (0.47 to 1.03) 0.073
1 0–6 97 0.54 (0.31 to 0.95) 0.032
> 3 6–12 98 1.17 (0.61 to 2.26) 0.630 0.358
2 or 3 6–12 124 1.21 (0.65 to 2.27) 0.545
1 6–12 59 0.54 (0.20 to 1.43) 0.215
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior
to screening, log rate of falling and log rate of near-falling in the pre-randomisation falls collection period, H&Y scale
stage, and the interaction term where this is listed.
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Appendix 11 Mini-Balance Evaluation Systems
Test
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TABLE 32 The ITT Mini-BESTest analysis (0–28, lower values worse) measured at 6 and 12 months: whole group and subgroups
Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
All participants 6 394 1.1 (3.8) 0.2 (3.8) 0.95 (0.24 to 1.67) 0.009
12 241 –0.7 (4.5) –0.2 (3.8) –0.41 (–1.48 to 0.66) 0.449
MDS-UPDRS score of ≤ 58 6 369 1.1 (3.8) 0.1 (3.6) 1.04 (0.32 to 1.77) 0.005
12 227 –0.8 (4.4) –0.1 (3.8) –0.52 (–1.62 to 0.58) 0.353
H&Y scale stage ≤ 3 6 345 1.1 (3.7) 0.0 (3.6) 1.01 (0.35 to 1.82) 0.004
12 216 –0.7 (4.4) –0.5 (3.8) –0.30 (–1.43 to 0.84) 0.607
MoCA score
≤ 25 6 140 0.9 (4.0) 0.2 (4.5) 0.73 (–0.46 to 1.91) 0.228 0.654
≥ 26 6 254 1.2 (3.7) 0.2 (3.3) 1.06 (0.18 to 1.95) 0.019
≤ 25 12 91 –1.2 (5.0) 0 (4.1) –0.76 (–2.47 to 0.95) 0.384 0.570
≥ 26 12 150 –0.3 (4.1) –0.2 (4.1) –0.13 (–1.49 to 1.23) 0.851
FoG
No 6 157 0.7 (3.7) –0.1 (3.5) 0.71 (–0.42 to 1.83) 0.220 0.570
Yes 6 236 1.4 (3.6) 0.5 (4.0) 1.12 (0.20 to 2.04) 0.017
No 12 101 –0.6 (3.8) –0.4 (4.1) 0.05 (–1.59 to 1.69) 0.950 0.464
Yes 12 139 –0.8 (4.9) 0.1 (3.7) –0.74 (–2.13 to 0.66) 0.299
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Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
MoCA score
≤ 25 6 140 0.9 (4.0) 0.2 (4.5) 0.74 (–0.45 to1.92) 0.225 0.892
12 91 –1.2 (5.0) 0 (3.4) –0.75 (–2.47 to 0.97) 0.391 0.786
26 or 27 6 106 1.2 (4.4) 0.1 (3.4) 1.16 (–0.21 to 2.53) 0.096
12 63 –0.3 (4.6) –0.6 (5.0) 0.24 (–1.84 to 2.31) 0.822
≥ 28 6 148 1.2 (3.2) 0.3 (3.2) 1.01 (–0.14 to 2.16) 0.086
12 87 –0.4 (3.8) 0 (3.5) –0.35 (–2.12 to 1.43) 0.701
MDS-UPDRS score
≥ 39 6 126 1.28 (4.2) 0.6 (4.4) 0.77 (–0.49 to 2.04) 0.231 0.255
12 73 0.1 (4.9) 1.5 (3.5) –1.49 (–3.44 to 0.45) 0.132 0.493
23–38 6 126 1.9 (3.9) 0.4 (3.3) 1.64 (0.40 to 2.87) 0.010
12 80 –0.5 (4.6) –0.6 (3.4) 0.07 (–1.74 to 1.88) 0.939
≤ 22 6 139 0 (3.2) –0.3 (3.4) 0.21 (–0.98 to 1.40) 0.729
12 85 –1.46 (3.8) –1.2 (4.0) –0.41 (–2.14 to 1.33) 0.647
Retrospective falls
> 3 6 147 1.1 (3.8) 0.6 (3.5) 0.70 (–0.46 to 1.86) 0.236 0.162
12 85 –1.1 (5.2) 0.1 (3.7) –1.31 (–3.09 to 0.47) 0.149 0.195
2 or 3 6 168 1.2 (4.1) 0 (4.1) 1.78 (0.66 to 2.90) 0.002
12 104 –0.4 (3.9) –0.6 (4.2) 0.78 (–0.90 to 2.46) 0.360
1 6 79 0.9 (3.3) 0.1 (3.4) 0 (–1.58 to 1.58) 0.998
12 52 –0.2 (4.0) 0.5 (3.0) –1.14 (–3.44 to 1.16) 0.330
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 12 Falls Efficacy Scale – International
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TABLE 33 The ITT FES-I analysis (16–64, higher values worse) measured at 6 and 12 months: whole group and subgroups
Participants group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
All participants 6 400 –0.7 (7.9) 1.1 (7.2) –1.60 (–3.0 to –0.19) 0.026
12 354 1.3 (8.2) 3.5 (9.3) –1.40 (–3.41 to 0.66) 0.184
MDS-UPDRS score of ≤ 58 6 376 –0.8 (7.9) 1.1 (7.0) –1.44 (–2.85 to –0.02) 0.047
12 241 1.3 (8.3) 3.1 (8.8) –0.93 (–2.97 to 1.12) 0.372
H&Y scale stage ≤ 3 6 352 –0.9 (7.9) 1.2 (6.7) –1.5 (–2.97 to 0.04) 0.045
12 228 0.9 (8.1) 3.7 (9.1) –1.50 (–3.63 to 0.65) 0.170
MoCA score
≤ 25 6 145 –0.4 (7.7) 1.8 (8.3) –1.89 (–4.16 to 0.37) 0.101 0.724
≥ 26 6 255 –0.9 (8.0) 0.6 (6.3) –1.39 (–3.11 to 0.34) 0.115
≤ 25 12 99 1.9 (8.1) 4.3 (10.3) –2.20 (–5.41 to 1.02) 0.180 0.534
≥ 26 12 155 1.0 (8.2) 2.9 (8.6) –0.91 (–3.49 to 1.67) 0.489
FoG
No 6 159 0.1 (6.5) 0.3 (5.8) –0.18 (–2.33 to 1.98) 0.872 0.085
Yes 6 240 –1.2 (8.6) 1.7 (8.0) –2.60 (–4.37 to –0.82) 0.004
No 12 105 1.1 (6.5) 2.6 (7.6) –0.89 (–3.96 to 2.18) 0.569 0.580
Yes 12 148 1.5 (9.1) 4.2 (8.6) –2.01 (–4.63 to 0.61) 0.132
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Participants group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
MoCA score
≤ 25 6 145 –0.4 (7.7) 1.8 (8.3) –1.92 (–4.18 to 0.33) 0.095 0.448
12 99 1.9 (8.1) 4.3 (10.3) –2.23 (–5.43 to 0.97) 0.170 0.112
26 or 27 6 107 0.2 (9.4) 0.6 (6.9) –0.21 (–2.83 to 2.41) 0.873
12 67 2.9 (8.6) 1.9 (7.4) 1.93 (–1.92 to 5.77) 0.325
≥ 28 6 148 –1.7 (6.6) 0.7 (6.0) –2.33 (–4.56 to -0.09) 0.041
12 88 –0.6 (7.6) 3.6 (9.4) –3.26 (–6.66 to 0.13) 0.060
MDS-UPDRS score
≥ 39 6 140 –0.5 (9.3) 1.5 (5.9) –1.68 (–3.97 to 0.60) 0.149 0.929
12 86 3.4 (7.2) 2.7 (8.6) –1.89 (–5.22 to 1.44) 0.256 0.507
23–38 6 132 –0.3 (7.6) 0.4 (6.5) –1.12 (–3.47 to 1.23) 0.349
12 88 0.6 (8.7) 2.4 (9.3) 0.07 (–3.24 to 3.38) 0.967
≤ 22 6 124 –1.6 (6.4) 0.7 (6.4) –1.67 (–4.14 to 0.80) 0.185
12 77 0.7 (9.3) 4.8 (11.4) –2.72 (–6.44 to 1.00) 0.151
Retrospective falls
> 3 6 146 –1.7 (8.5) 0.4 (6.5) –2.15 (–4.44 to 0.14) 0.065 0.834
12 87 0.6 (8.7) 2.4 (9.3) –1.58 (–5.00 to 1.84) 0.364 0.994
2 or 3 6 170 –0.3 (6.4) 1.1 (8.2) –1.32 (–3.51 to 0.87) 0.238
12 110 1.17 (7.2) 3.3 (9.8) –1.33 (–4.54 to 1.88) 0.415
1 6 84 0.6 (8.1) 1.9 (5.4) –1.21 (–4.20 to 1.78) 0.426
12 58 2.8 (8.6) 5.2 (8.3) –1.43 (–5.67 to 2.82) 0.509
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 13 Repeat falling
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TABLE 34 The ITT and per-protocol OR for the primary outcome, repeat falling, from 0 to 6 months and from 6 to 12 months, restricted to those with 50% diary completion
or more: whole group and subgroups
Participant group
Period
(months)
ITT Per protocol
PDSAFE/control
OR (95% CI)a
PDSAFE within
participant
group p-valuea
Interaction
p-valuea
PDSAFE/control
OR (95% CI)a
PDSAFE within
participant
group p-valuea
Interaction
p-valuea
All participants 0–6 1.21 (0.74 to 1.98) 0.447 1.16 (0.71 to 1.92) 0.538
6–12 0.86 (0.45 to 1.65) 0.657 0.92 (0.47 to 1.77) 0.793
MDS-UPDRS score of
≤ 58
0–6 1.18 (0.71 to 1.95) 0.521 1.14 (0.69 to 1.89) 0.616
6–12 0.90 (0.47 to 1.74) 0.758 0.96 (0.49 to 1.86) 0.896
H&Y scale stage ≤ 3 0–6 1.13 (0.68 to 1.87) 0.651 1.10 (0.66 to 1.83) 0.723
6–12 0.91 (47 to 1.76) 0.785 0.97 (47 to 1.76) 0.918
MoCA score
≤ 25 0–6 2.03 (0.91 to 4.54) 0.083 0.111 1.96 (0.88 to 4.41) 0.101 0.113
≥ 26 0–6 0.91 (0.49 to 1.67) 0.754 0.87 (0.47 to 1.63) 0.672
≤ 25 6–12 0.71 (0.25 to 2.02) 0.525 0.606 0.75 (0.26 to 2.12) 0.583 0.561
≥ 26 6–12 1.01 (0.44 to 2.29) 0.987 1.10 (0.48 to 2.55) 0.819
FoG
No 0–6 0.66 (0.32 to 1.38) 0.269 0.025 0.66 (0.32 to 1.39) 0.280 0.039
Yes 0–6 2.04 (1.03 to 4.06) 0.042 1.90 (0.95 to 3.81) 0.068
No 6–12 0.58 (0.21 to 1.57) 0.282 0.309 0.59 (0.22 to 1.63) 0.311 0.304
Yes 6–12 1.14 (0.48 to 2.70) 0.772 1.25 (0.52 to 2.83) 0.620
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Participant group
Period
(months)
ITT Per protocol
PDSAFE/control
OR (95% CI)a
PDSAFE within
participant
group p-valuea
Interaction
p-valuea
PDSAFE/control
OR (95% CI)a
PDSAFE within
participant
group p-valuea
Interaction
p-valuea
MoCA score
≤ 25 0–6 2.04 (0.91 to 4.55) 0.083 0.238 1.96 (0.88 to 4.41) 0.101 0.264
26 or 27 0–6 1.07 (0.42 to 2.79) 0.863 0.94 (0.36 to 2.45) 0.902
≥ 28 0–6 0.78 (0.35 to 1.75) 0.352 0.81 (0.36 to 1.81) 0.608
≤ 25 6–12 0.71 (0.25 to 2.01) 0.248 0.751 0.74 (0.25 to 2.01) 0.575 0.820
26 or 27 6–12 1.30 (0.38 to 4.43) 0.680 1.23 (0.38 to 4.43) 0.745
≥ 28 6–12 0.82 (0.27 to 2.45) 0.720 1.00 (0.27 to 2.45) 0.994
MDS-UPDRS
≥ 39 0–6 2.55 (1.03 to 6.33) 0.044 0.140 2.45 (0.98 to 6.18) 0.055 0.149
23–38 0–6 0.80 (0.35 to 1.86) 0.609 0.79 (0.33 to 1.84) 0.588
≤ 22 0–6 0.97 (0.43 to 2.17) 0.942 0.92 (0.41 to 2.08) 0.839
≥ 39 6–12 0.80 (0.23 to 2.80) 0.727 0.943 0.95 (0.26 to 3.43) 0.940 0.989
23–38 6–12 1.02 (0.35 to 2.98) 0.976 1.08 (0.37 to 3.16) 0.895
≤ 22 6–12 1.02 (0.35 to 2.98) 0.936 1.01 (0.33 to 3.05) 0.989
Retrospective falls
> 3 0–6 1.45 (0.57 to 3.67) 0.436 0.407 1.38 (0.54 to 3.52) 0.497 0.453
2 or 3 0–6 0.79 (0.39 to 1.61) 0.523 0.79 (0.39 to 1.61) 0.511
1 0–6 1.68 (0.59 to 4.77) 0.331 1.61 (0.56 to 4.66) 0.379
> 3 6–12 1.18 (0.36 to 3.88) 0.780 0.501 1.12 (0.34 to 3.71) 0.853 0.575
2 or 3 6–12 0.57 (0.22 to 1.49) 0.251 0.64 (0.24 to 1.68) 0.365
1 6–12 1.36 (0.32 to 5.73) 0.672 1.53 (0.36 to 6.50) 0.568
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, and the interaction term where this is listed.
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Appendix 14 Falls rate ratio
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TABLE 35 The ITT and per-protocol FRRs from 0 to 6 months and from 6 to 12 months: whole group and subgroups
Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
All participants 6 402 1.9 (10.7) 1.0 (11.7) 0.16 (–1.83 to 2.15) 0.876
12 254 7.2 (13.5) 3.3 (13.4) 3.86 (0.99 to 6.73) 0.009
MDS-UPDRS score of ≤ 58 6 378 2.4 (10.3) 2.2 (10.6) –0.08 (–2.08 to 1.93) 0.938
12 241 7.6 (13.2) 4.3 (12.8) 3.86 (0.94 to 6.78) 0.010
H&Y scale stage ≤ 3 6 352 2.4 (10.4) 1.7 (10.8) 0.25 (–1.77 to 2.27) 0.809
12 227 7.3 (13.2) 3.9 (14.5) 3.67 (0.76 to 6.58) 0.014
MoCA score
≤ 25 6 145 2.1 (10.6) 1.2 (12.5) –0.06 (–3.32 to 3.20) 0.968 0.860
≥ 26 6 257 1.8 (10.8) 0.9 (11.2) 0.29 (–2.17 to 2.75) 0.812
≤ 25 12 98 5.3 (13.6) 3.6 (12.8) 1.45 (–3.09 to 6.00) 0.529 0.186
≥ 26 12 156 8.2 (13.4) 3.1 (13.9) 5.32 (1.69 to 8.94) 0.004
FoG
No 6 160 2.9 (11.2) 2.0 (10.6) 0.42 (–2.69 to 3.53) 0.791 0.844
Yes 6 241 1.4 (10.3) 0.4 (12.4) 0.02 (–2.53 to 2.58) 0.987
No 12 102 6.5 (14.7) 3.2 (13.0) 3.34 (–1.03 to 7.72) 0.133 0.846
Yes 12 148 7.6 (12.8) 3.4 (13.8) 3.90 (0.19 to 7.61) 0.039
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Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
MoCA score
≤ 25 6 145 2.0 (10.5) 1.1 (12.5) –0.06 (–3.32 to 3.20) 0.970 0.401
12 98 5.2 (13.6) 3.6 (12.7) 1.40 (–3.10 to 5.90) 0.540 0.448
26 or 27 6 107 3.4 (10.7) 0.1 (11.5) 2.22 (–1.56 to 5.99) 0.249
12 67 12.1 (12.6) 6.2 (14.2) 5.66 (0.27 to 11.05) 0.040
≥ 28 6 150 0.5 (10.7) 1.4 (11.0) –1.13 (–4.32 to 2.07) 0.488
12 89 4.9 (13.1) 0.9 (13.3) 4.37 (–0.38 to 9.11) 0.071
MDS-UPDRS score
≥ 39 6 128 –1.2 (10.5) –6.2 (12.5) 4.20 (0.71 to 7.69) 0.018 0.007
12 79 –0.6 (13.5) –6.2 (13.2) 6.89 (1.70 to 12.09) 0.009 0.295
23–38 6 132 –0.3 (9.7) 3.1 (9.1) –3.47 (–6.83 to –0.11) 0.043
12 87 6.5 (13.1) 5.7 (9.7) 1.36 (–3.4 to 6.12) 0.574
≤ 22 6 140 7.1 (10.2) 6.3 (9.2) 0.12 (–3.15 to 3.40) 0.941
12 86 14.1 (10.2) 11.1 (10.3) 4.07 (–0.69 to 8.82) 0.093
Retrospective falls
> 3 6 148 2.2 (11.9) –0.9 (12.6) 1.90 (–1.34 to 5.14) 0.249 0.403
12 87 7.3 (14.0) 0 (16.1) 7.00 (2.21 to 11.79) 0.004 0.277
2 or 3 6 171 2.6 (10.2) 1.5 (12.1) –0.68 (–3.80 to 2.44) 0.668
12 109 9.4 (10.5) 4.8 (13.5) 3.07 (–1.41 to 7.54) 0.179
1 6 83 –0.1 (8.6) 2.9 (8.6) –1.18 (–5.49 to 3.14) 0.592
12 58 3.2 (16.2) 4.3 (7.9) 1.29 (–4.64 to 7.22) 0.668
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 15 Physical Activity Scale for the
Elderly
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TABLE 36 The PASE analysis (0–400, lower values worse) measured at 6 and 12 months: whole group and subgroups
Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
All participants 6 331 2.6 (51.0) 1.3 (49.5) 1.27 (–9.0 to 11.5) 0.808 –
12 253 –8.7 (53.0) –11.0 (48.5) 0.52 (–12.8 to 13.8) 0.939 –
MDS-UPDRS score of ≤ 58 6 312 2.4 (52.0) 0.9 (50.0) 1.19 (–9.52 to 11.89) 0.828 –
12 200 –8.1 (54.3) –10.6 (48.8) 0.78 (–13.28 to 14.82) 0.914 –
H&Y scale stage ≤ 3 6 292 2.4 (52.0) 3.2 (51.3) 3.50 (–7.85 to 14.84) 0.545 –
12 189 –7.1 (53.7) –9.3 (50.3) 0.36 (–13.94 to 14.64) 0.961 –
MoCA score
≤ 25 6 111 5 (46.5) 5.9 (45.8) –1.94 (–19.39 to 15.52) 0.827 0.904
≥ 26 6 219 1.2 (52.9) –2.5 (50.1) –0.64 (–13.12 to 11.84) 0.920
≤ 25 12 79 –7.6 (44.1) –2.7 (38.5) –9.26 (–31.10 to 12.59) 0.404 0.347
≥ 26 12 134 –9.3 (57.8) –16.2 (53.4) 3.73 (–12.99 to 20.46) 0.660
FoG
No 6 139 3.1 (55.7) 5.7 (48.9) –2.34 (–17.85 to 13.16) 0.766 0.799
Yes 6 190 1.7 (47.8) –3.5 (48.1) 0.28 (–13.13 to 13.68) 0.968
No 12 96 –14.6 (61.2) –11.2 (53.7) –3.05 (–22.81 to 16.72) 0.761 0.732
Yes 12 116 –4.4 (46.8) –10.9 (43.7) 1.52 (–16.44 to 19.48) 0.867
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Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a
p-valuea
PDSAFE Control
PDSAFE within
participant group Interaction
MoCA score
≤ 25 6 111 5 (46.5) 5.9 (45.8) –1.90 (–19.39 to 15.58) 0.831 0.881
12 79 –7.6 (44.1) –2.7 (38.5) –9.26 (–31.1 to 12.59) 0.404 0.501
26 or 27 6 90 –3.8 (52.9) 9.3 (45.3) –5.27 (–24.90 to 14.35) 0.597
12 55 –12.1 (45.1) –30 (49.5) 9.29 (–17.0 to 35.18) 0.480
≥ 28 6 129 4.9 (53) 1.9 (52.8) 1.20 (–15.0 to 17.39) 0.885
12 79 –7.3 (66.2) –7.2 (54.5) 1.27 (–20.54 to 23.1) 0.908
MDS-UPDRS score
≥ 39 6 104 7.1 (35.6) –6.6 (46.2) 2.31 (–16.16 to 20.71) 0.809 0.387
12 60 0.4 (47.8) –18.1 (51.5) 4.93 (–21.17 to 30.02) 0.710 0.881
23–38 6 109 –6.4 (53.6) 9.6 (55.3) –10.63 (–28.25 to 7.30) 0.247
12 74 –17.5 (60.9) –5.3 (56.7) –3.83 (–15.99 to 20.61) 0.804
≤ 22 6 104 7.9 (59.5) –0.3 (45.5) 5.82 (–12.86 to 21.98) 0.607
12 77 –4.5 (45.6) –10.8 (39.4) 0.30 (–22.12 to 22.71) 0.979
Retrospective falls
> 3 6 118 6.1 (50.7) –6.6 (42) 10.48 (–6.32 to 27.28) 0.221 0.194
12 72 –2.4 (47.5) –11.3 (49.8) 9.95 (–12.47 to 32.37) 0.382 0.423
2 or 3 6 142 –0.8 (54.1) 3.9 (46.8) –8.48 (–24.43 to 7.47) 0.296
12 95 –10.5 (50.7) –7 (46.3) –10.99 (–31.58 to 9.59) 0.293
1 6 70 2.4 (50.8) 0.5 (48.6) –3.99 (–25.84 to 17.84) 0.719
12 46 –18.1 (68.1) –19 (52.0) 3.21 (–25.80 to 32.21) 0.830
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 16 Parkinson’s Disease Questionnaire
DOI: 10.3310/hta23360 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 36
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ashburn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
137
TABLE 37 The ITT PDQ-39 analysis (0–100, higher values worse) measured at 6 and 12 months: whole group and subgroups
Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a p-valuea Participant groupPDSAFE Control
All participants 6 279 0.8 (8.3) 0.9 (9.0) –0.12 (–2.28 to 2.0) 0.911 –
12 177 2.0 (8.6) 2.8 (11.2) –0.48 (–3.49 to 2.53) 0.754 –
MDS-UPDRS score of ≤ 58 6 268 0.9 (8.4) 0.9 (9.0) –0.07 (–2.28 to 2.14) 0.952 –
12 166 1.8 (8.5) 2.9 (11.5) –0.4 (–3.55 to 2.74) 0.800 –
H&Y scale stage ≤ 3 6 251 1.2 (8.0) 0.2 (8.9.0) 0.91 (–1.32 to 3.14) 0.423
12 159 1.7 (8.6) 2.1 (11.0) –0.35 (–3.4 to 2.7) 0.820
MoCA score
≤ 25 6 90 0.7 (9.6) 0.3 (9.6) 0.69 (–3.02 to 4.40) 0.715 0.594
≥ 26 6 189 0.9 (7.7) 1.1 (8.7) –0.51 (–3.11 to 2.07) 0.697
≤ 25 12 61 2.2 (10.8) 4.2 (11.2) –0.86 (–5.87 to 4.15) 0.734 0.947
≥ 26 12 116 1.8 (7.3) 2.0 (11.2) –0.65 (–4.39 to 3.09) 0.732
FoG
No 6 124 1.2 (7.5) 1.4 (8.7) –0.77 (–4.0 to 2.46) 0.639 0.710
Yes 6 154 0.6 (8.9) 0.3 (9.2) 0.25 (–2.59 to 3.1) 0.864
No 12 79 2.8 (8.1) 4.5 (12.7) –0.91 (–5.43 to 3.60) 0.689 0.732
Yes 12 97 1.3 (9.0) 1.3 (9.5) 0.12 (–3.85 to 3.48) 0.952
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Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a p-valuea Participant groupPDSAFE Control
MoCA score
≤ 25 6 90 0.7 (9.6) 0.3 (9.6) 0.67 (–3.02 to 4.36) 0.721 0.441
12 61 2.2 (10.8) 4.2 (11.2) –0.84 (–5.86 to 4.18) 0.742 0.532
26 or 27 6 76 2.3 (7.1) 1.7 (8) 1.04 (–3.0 to 5.11) 0.611
12 47 2 (5.5) 1 (10.3) 1.74 (–3.92 to 7.39) 0.546
≥ 28 6 103 –0.2 (8.1) 0.8 (9.1) –1.93 (–5.24 to 1.39) 0.254
12 69 1.7 (8.6) 2.6 (11.8) –2.47 (–7.42 to 2.48) 0.326
MDS-UPDRS score
≥ 39 6 75 1.9 (10.5) 0.9 (9.8) –0.85 (–4.32 to 2.62) 0.631 0.492
12 46 0.7 (11) 6 (12.2) 0.91 (–4.19 to 5.98) 0.723 0.270
23–38 6 95 –0.1 (7.7) 0.6 (8.7) –1.11 (–4.72 to 2.52) 0.548
12 63 3 (8.1) 1.3 (11.9) 1.03 (–3.81 to 5.87) 0.674
≤ 22 6 107 1.1 (7.3) 1.3 (8.7) 2.00 (–2.22 to 6.24) 0.352
12 65 1.4 (7.4) 1.6 (10) –4.73 (–10.76 to 1.29) 0.123
Retrospective falls
> 3 6 99 0.3 (8) 2 (11.5) –1.49 (–4.99 to 2.01) 0.403 0.512
12 65 0.6 (7.9) 5.3 (12.5) –4.77 (–9.50 to –0.37) 0.048 0.090
2 or 3 6 122 1 (8) –0.7 (6.4) 1.09 (–2.17 to 4.36) 0.511
12 75 3.7 (9.3) 1.3 (8.7) 2.33 (–2.40 to 7.06) 0.333
1 6 58 1.6 (9.8) 2.5 (9.1) –1.23 (–5.84 to 3.39) 0.601
12 37 1.4 (8.4) 2.3 (13.6) 1.10 (–5.3 to 7.52) 0.736
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 17 Geriatric Depression Scale
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TABLE 38 The ITT GDS analysis (0–15, higher values worse) measured at 6 and 12 months: whole group and subgroups
Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a p-valuea Participant groupPDSAFE Control
All participants 6 337 0.3 (1.8) 0.2 (1.9) –0.02 (–0.42 to 0.39) 0.942 –
12 214 0.2 (2.0) 0.4 (1.7) –0.21 (–0.72 to 0.31) 0.421 –
MDS-UPDRS score of ≤ 58 6 318 0.2 (1.8) 0.3 (1.9) –0.10 (–0.52 to 0.32) 0.636 –
12 200 0.2 (2.1) 0.4 (1.8) –0.26 (–0.79 to 0.28) 0.354 –
H&Y scale stage ≤ 3 6 301 0.3 (2.2) 0.2 (1.9) –0.02 (–0.47 to 0.40) 0.923 –
12 192 0.2 (2.0) 0.5 (1.7) –0.26 (–0.79 to 0.30) 0.344 –
MoCA score
≤ 25 6 115 0 (1.5) 0.4 (2.0) –0.42 (–1.10 to 0.26) 0.229 0.151
≥ 26 6 222 0.4 (1.9) 0.1 (1.8) 0.19 (–0.30 to 0.68) 0.456
≤ 25 12 79 0.2 (2.2) 0.2 (2.0) 0.16 (–0.69 to 1.01) 0.713 0.302
≥ 26 12 135 0.2 (2.0) 0.6 (1.6) –0.40 (–1.05 to 0.25) 0.231
FoG
No 6 145 0.4 (1.9) 0.2 (1.7) 0.19 (–0.41 to 0.80) 0.528 0.379
Yes 6 192 0.2 (2.2) 0.3 (2.0) –0.16 (–0.69 to 0.37) 0.552
No 12 99 0.7 (2.1) 0.5 (2.0) 0.24 (–0.62 to 1.08) 0.526 0.105
Yes 12 113 –0.2 (1.9) 0.3 (1.6) –0.59 (–1.38 to 0.04) 0.100
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Participant group Visit (months) Participants (n)
Trial group: change from
baseline, mean (SD)
PDSAFE – control mean
change (95% CI)a p-valuea Participant groupPDSAFE Control
MoCA score
≤ 25 6 115 0 (1.5) 0.4 (2.0) –0.41 (–1.08 to 0.27) 0.237 0.009
12 79 0.2 (2.2) 0.2 (2.0) 0.16 (–0.70 to 1.02) 0.715 0.450
26 or 27 6 93 0.8 (2.1) –0.2 (2.0) 0.97 (0.22 to 1.72) 0.011
12 56 0.2 (2.4) 0.4 (1.6) –0.12 (–1.10 to 0.87) 0.814
≥ 28 6 130 0.1 (1.8) 0.3 (1.7) –0.38 (–1.01 to 0.25) 0.241
12 78 0.2 (1.5) 0.7 (1.6) –0.61 (–1.47 to 0.26) 0.168
MDS-UPDRS score
≥ 39 6 106 0.3 (1.7) 0.4 (1.9) –0.06 (–0.74 to 0.63) 0.868 0.841
12 64 –0.1 (1.8) 0.4 (1.7) –0.23 (–1.30 to 0.68) 0.605 0.944
23–38 6 112 0.1 (1.4) 0.1 (1.7) –0.14 (–0.83 to 0.55) 0.691
12 72 0.2 (1.9) 0.2 (1.5) –0.09 (–0.96 to 0.78) 0.837
≤ 22 6 125 0.2 (2.2) 0.1 (1.9) 0.15 (–0.58 to 0.88) 0.684
12 77 0.2 (2.2) 0.5 (0.5 –0.31 (–1.30 to 0.68) 0.537
Retrospective falls
> 3 6 62 0.3 (2.0) 0.7 (2.2) –0.06 (–0.92 to 0.79) 0.889 0.441
12 71 –0.3 (2.3) 0.8 (1.6) –0.01 (–1.10 to 1.08) 0.987 0.019
2 or 3 6 147 0.2 (1.8) –0.1 (1.5) 0.23 (–0.36 to 1.23) 0.471
12 97 0.4 (2.0) 0 (1.6) 0.44 (–0.65 to 1.48) 0.278
1 6 71 1.8 (1.8) 0.3 (1.9) –0.36 (–1.02 to 0.31) 0.293
12 46 0.5 (1.2) 0.8 (1.9) –1.21 (–2.07 to -0.35) 0.006
a Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the pre-randomisation falls
collection period, H&Y scale stage, covariate value at baseline and the interaction term where this is listed.
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Appendix 18 Secondary outcomes
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PASE (95% CI) p-valuea PDQ-39 (95% CI) p-valuea GDS (95% CI) p-valuea MDS-UPDRS (95% CI) p-valuea
30 20 10 0 – 10 – 20 – 30 – 7 – 5 – 3 – 1.5 – 1.0 – 6 – 4 – 2 0 2 4 6 8– 0.5 0 0.5 1.0 1.5 2.0– 1 1 3 5 7
All participants
MoCA
Freezer
≤ 25 impaired
≥ 26 not impaired
≥ 28
≥ 39 most severe
≤ 25 impaired
≤ 22 least severe
26, 27
23 – 28
> 3 falls
2 or 3 falls
1 fall
Non-freezer
Freezing of gait
MoCA
MDS-UPDRS
Restrospective falls
Favours PDSAFE Favours control Favours PDSAFE Favours control Favours PDSAFE Favours control Favours PDSAFE Favours control
0.904
0.799
0.881
0.387
0.194
0.594
0.710
0.441
0.492
0.512
0.151
0.379
0.009
0.841
0.441
0.864
0.844
0.401
0.007
0.403
Subgroups
FIGURE 15 Overall and subgroup analysis of the secondary outcomes measured at 6 months (PASE, PDQ-39, GDS and MDS-UPDRS). a, Test for interaction of PDSAFE contrast
differing across subgroups controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of
falling in the pre-randomisation falls collection period, H&Y scale stage, and the outcome in question assessed at baseline.
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Appendix 19 Further exploration
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TABLE 39 Subgroup analysis further exploration: resource use of the intervention and control groups in the cognitively impaired group
Resource p-value
Trial group
PDSAFE (N= 91) Control (N= 93)
Mean Median Minimum, maximum SD n Mean Median Minimum, maximum SD n
GP 0.44 3.02 2.5 0, 11 2.61 44 3.45 3 0, 12 2.96 62
Practice nurse 0.23 1.73 1 0, 9 2.05 44 3.11 1 0, 43 7.44 61
Parkinson’s nurse 0.33 1.30 1 0, 11 1.87 43 1.69 1 0, 11 2.11 64
Health visitor 0.56 0.20 0 0, 5 0.81 45 0.13 0 0, 2 0.42 62
Social worker 0.10 0.02 0 0, 1 0.15 44 0.14 0 0, 2 0.47 63
NHS physiotherapist 0.48 1.86 0 0, 12 3.52 43 1.45 0 0, 9 2.32 60
Occupational therapist 0.41 0.37 0 0, 5 0.98 43 0.64 0 0, 12 1.95 61
Speech therapist 0.13 0.95 0 0, 11 2.33 43 0.42 0 0, 7 1.27 62
Day hospital 0.25 0.82 0 0, 14 2.31 44 1.28 0.5 0, 8 1.77 60
Outpatient clinic 0.02 1.23 1 0, 6 1.38 44 2.10 2 0, 13 2.16 62
A&E by ambulance 0.84 0.11 0 0, 2 0.44 44 0.10 0 0, 2 0.35 61
Ambulance with paramedics only 0.58 0.26 0 0, 5 0.94 42 0.37 0 0, 5 0.94 54
A&E by own transport 0.18 0.18 0 0, 3 0.54 44 0.37 0 0, 4 0.81 62
Home care/home help 0.11 23.58 0 0, 390 66.44 59 52.00 0 0, 728 122.76 73
Meals on wheels 0.82 3.10 0 0, 169 21.49 63 2.30 0 0, 182 20.48 79
Day centre 0.54 1.44 0 0, 52 7.42 63 0.83 0 0, 26 4.36 78
Luncheon club 0.37 0.00 0 0, 0 0.00 63 0.17 0 0, 13 1.48 77
Sitting service 0.77 1.68 0 0, 52 9.26 62 2.17 0 0, 78 10.35 78
Night care 0.29 2.94 0 0, 182 23.11 62 0.17 0 0, 13 1.47 78
Hospitalisation for treatmenta 0.14 0.71 0 0, 30 4.20 63 0.03 0 0, 2 0.22 80
Hospitalisation for respite carea / 0 0 0, 0 0 63 0 0 0, 0 0 80
a The table can be visualised in the bar graph, as in Figure 16.
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A&E by own transport
Meals on wheels
Luncheon club
Night care
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FIGURE 16 Six months’ resource use of the intervention (n= 91) and control (n= 93) groups in the cognitively
impaired group.
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